

# Dietary Advanced Glycation End Products and Their Potential Role in Disease in Children

Hormone Research in Paediatrics

85, 291-300

DOI: [10.1159/000444053](https://doi.org/10.1159/000444053)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Subcellular localization of guanylate cyclase. Life Sciences, 1975, 17, 837-843.	2.0	63
2	Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk. BMJ: British Medical Journal, 1998, 317, 1202-1208.	2.4	389
3	Diabetes: a time for excitement--and concern. BMJ: British Medical Journal, 1998, 317, 691-692.	2.4	19
4	Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ: British Medical Journal, 1998, 317, 693-694.	2.4	72
5	Treatment of type 2 diabetes in youth: An argument for randomized controlled studies. Paediatrics and Child Health, 1999, 4, 265-269.	0.3	8
6	The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British Journal of Clinical Pharmacology, 1999, 48, 643-648.	1.1	436
7	Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca <sup>2+</sup> regulation prevail over changes in insulin content. British Journal of Pharmacology, 1999, 127, 1883-1891.	2.7	47
8	Patient education to users of oral hypoglycemic agents: the perspective of Dutch community pharmacists. International Journal of Clinical Pharmacy, 1999, 21, 200-204.	1.4	8
9	The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease. Herz, 1999, 24, 544-547.	0.4	37
10	Does social medicine still matter in an era of molecular medicine?. Journal of Urban Health, 1999, 76, 164-175.	1.8	23
11	The Use of Sulphonylureas in the Elderly. Drugs and Aging, 1999, 15, 471-481.	1.3	33
12	Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ: British Medical Journal, 1999, 319, 83-86.	2.4	241
13	A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus. Drug Safety, 1999, 20, 489-503.	1.4	164
14	Benefits and Risks of Transfer from Oral Agents to Insulin in Type 2 Diabetes Mellitus. Drug Safety, 1999, 21, 7-22.	1.4	27
15	Drug Therapy of Postprandial Hyperglycaemia. Drugs, 1999, 57, 19-29.	4.9	141
16	Troglitazone. Drugs, 1999, 57, 409-438.	4.9	89
17	Prevention of Type 2 Diabetes. Drugs, 1999, 58, 71-73.	4.9	12
18	Randomised controlled trials in primary care: case study. BMJ: British Medical Journal, 2000, 321, 24-27.	2.4	91

#	ARTICLE	IF	CITATIONS
19	Perceived access problems among patients with diabetes in two public systems of care. <i>Journal of General Internal Medicine</i> , 2000, 15, 797-804.	1.3	19
20	Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 223-230.	1.1	65
21	Effects of peroxisome proliferator-activated receptor- $\alpha$ and - $\beta$ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. <i>British Journal of Pharmacology</i> , 2000, 130, 495-504.	2.7	82
22	Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. <i>Journal of General Internal Medicine</i> , 2000, 15, 220-228.	1.3	55
23	Interpreting diabetes mellitus: differences between patient and provider models of disease and their implications for clinical practice. , 2000, 24, 379-401.		63
24	Issues and challenges with antithrombotic therapy in diabetic patients with acute coronary syndromes. <i>Current Cardiology Reports</i> , 2000, 2, 411-418.	1.3	2
25	Insulin and the vasculature. <i>Current Hypertension Reports</i> , 2000, 2, 148-153.	1.5	33
27	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 412-419.	2.4	1,737
28	Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. <i>BMJ: British Medical Journal</i> , 2000, 320, 1720-1723.	2.4	133
29	Thiazolidinediones for type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2000, 321, 252-253.	2.4	60
30	Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). <i>BMJ: British Medical Journal</i> , 2000, 320, 1373-1378.	2.4	269
31	Transforming growth factor beta contributes to progressive diabetic nephropathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 7667-7669.	3.3	214
32	Insulin resistance and cardiovascular disease. <i>Journal of Clinical Investigation</i> , 2000, 106, 453-458.	3.9	997
33	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. <i>BMJ: British Medical Journal</i> , 2000, 321, 405-412.	2.4	7,060
34	Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. <i>The Cochrane Library</i> , 2000, , CD001481.	1.5	282
35	Glipizide. <i>Pharmacoeconomics</i> , 2000, 18, 289-306.	1.7	32
36	Beneficial and Detrimental Effects of Intensive Glycaemic Control, with Emphasis on Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 463-476.	1.3	12
37	Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 411-425.	1.3	71

#	ARTICLE	IF	CITATIONS
38	Optimising Therapy for Insulin-Treated Type 2 Diabetes Mellitus. <i>Drugs and Aging</i> , 2000, 17, 283-294.	1.3	8
39	Implications of the UK Prospective Diabetes Study. <i>Drugs and Aging</i> , 2000, 16, 159-164.	1.3	18
42	Is it possible to predict diabetic kidney disease?. <i>Journal of Endocrinological Investigation</i> , 2000, 23, 44-53.	1.8	1
45	Comparative Tolerability of Sulphonylureas in Diabetes Mellitus. <i>Drug Safety</i> , 2000, 22, 313-320.	1.4	79
46	Miglitol. <i>Drugs</i> , 2000, 59, 521-549.	4.9	371
47	A Rational Approach to Drug Therapy of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2000, 60, 95-113.	4.9	101
48	Management of Type 2 Diabetes Mellitus and Cardiovascular Risk. <i>Drugs</i> , 2000, 60, 975-983.	4.9	41
49	Antidiabetic Drugs Present and Future. <i>Drugs</i> , 2000, 60, 1017-1028.	4.9	46
50	Insulin Glargine. <i>Drugs</i> , 2001, 61, 1599-1624.	4.9	69
51	Repaglinide. <i>Drugs</i> , 2001, 61, 1625-1660.	4.9	129
53	Management of Painful Diabetic Neuropathy. <i>Drugs and Aging</i> , 2001, 18, 737-749.	1.3	37
54	Management of Type 2 Diabetes Mellitus in the Elderly. <i>Drugs and Aging</i> , 2001, 18, 31-44.	1.3	88
55	Randomised controlled trial of structured personal care of type 2 diabetes mellitus. <i>BMJ: British Medical Journal</i> , 2001, 323, 970-970.	2.4	252
61	Complexity science: Complexity, leadership, and management in healthcare organisations. <i>BMJ: British Medical Journal</i> , 2001, 323, 746-749.	2.4	542
62	Management of Diabetic Nephropathy. <i>Journal of the Royal Society of Medicine</i> , 2001, 94, 210-217.	1.1	21
63	The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study Commentary: UKPDS is well designed and clinically important. <i>BMJ: British Medical Journal</i> , 2001, 323, 854-858.	2.4	32
64	Regular review: Point of care testing. <i>BMJ: British Medical Journal</i> , 2001, 322, 1285-1288.	2.4	276
65	Science, medicine, and the future: Islet and stem cell transplantation for treating diabetes. <i>BMJ: British Medical Journal</i> , 2001, 322, 29-32.	2.4	72

#	ARTICLE	IF	CITATIONS
66	"Normal" blood glucose and coronary risk. <i>BMJ: British Medical Journal</i> , 2001, 322, 5-6.	2.4	28
67	Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. <i>BMJ: British Medical Journal</i> , 2001, 322, 986-988.	2.4	120
68	Management of diabetes: are doctors framing the benefits from the wrong perspective?. <i>BMJ: British Medical Journal</i> , 2001, 323, 994-996.	2.4	99
69	Diabetes: Statins, fibrates, or both?. <i>Current Atherosclerosis Reports</i> , 2001, 3, 19-28.	2.0	19
70	Type 2 diabetes in children. <i>Current Diabetes Reports</i> , 2001, 1, 19-27.	1.7	43
71	Combination oral agent and insulin therapy for type 2 diabetes mellitus. <i>Current Diabetes Reports</i> , 2001, 1, 106-111.	1.7	0
72	New aspects of insulin therapy in type 1 and type 2 diabetes. <i>Current Diabetes Reports</i> , 2001, 1, 112-118.	1.7	4
73	Treatments for diabetic neuropathy. <i>Current Diabetes Reports</i> , 2001, 1, 127-132.	1.7	15
74	Risk factors for diabetic neuropathy and foot ulceration. <i>Current Diabetes Reports</i> , 2001, 1, 202-207.	1.7	13
75	Measurement of somatic neuropathy for clinical practice and clinical trials. <i>Current Diabetes Reports</i> , 2001, 1, 208-215.	1.7	8
76	Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low". <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001, 2, 8.	1.5	6
77	The genetics of type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 195-199.	1.1	24
78	Oral antidiabetic treatment in patients with coronary disease: Timeâ€related increased mortality on combined glyburide/metformin therapy over a 7.7â€year followâ€up. <i>Clinical Cardiology</i> , 2001, 24, 151-158.	0.7	103
79	Pycnogenol for diabetic retinopathy. A review. <i>International Ophthalmology</i> , 2001, 24, 161-171.	0.6	39
80	Diagnosis and treatment of type 2 diabetes in three Belgian regions. Registration via a network of sentinel general practices. <i>European Journal of Epidemiology</i> , 2001, 17, 743-750.	2.5	15
81	Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 177-184.	1.0	28
82	Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na <sup>+</sup> -glucose cotransporter inhibitor T-1095. <i>British Journal of Pharmacology</i> , 2001, 132, 578-586.	2.7	138
83	Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. <i>British Journal of Pharmacology</i> , 2001, 132, 1542-1548.	2.7	65

#	ARTICLE	IF	CITATIONS
84	Glimepiride block of cloned $\hat{I}^2$ -cell, cardiac and smooth muscle KATP channels. British Journal of Pharmacology, 2001, 133, 193-199.	2.7	66
85	Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ: British Medical Journal, 2001, 322, 15-15.	2.4	832
86	Synthesis of an organoinsulin molecule that can be activated by antibody catalysis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13514-13518.	3.3	11
87	Culturally Competent Diabetes Self-Management Education for Mexican Americans: The Starr County Border Health Initiative. Diabetes Care, 2002, 25, 259-268.	4.3	380
88	Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. BMJ: British Medical Journal, 2002, 324, 459-464.	2.4	58
89	Nonlinear partial differential equations and applications: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15596-15601.	3.3	604
90	Blood pressure control and diabetic retinopathy. British Journal of Ophthalmology, 2002, 86, 365-367.	2.1	51
91	The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study. British Journal of Ophthalmology, 2002, 86, 84-90.	2.1	117
92	Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease. British Heart Journal, 2002, 87, 54-60.	2.2	6
93	Atherosclerotic cardiovascular disease and diabetic retinopathy. British Journal of Ophthalmology, 2002, 86, 3-4.	2.1	4
94	Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ: British Medical Journal, 2002, 325, 860-860.	2.4	72
95	Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design. Journal of the American Medical Informatics Association: JAMIA, 2002, 9, 49-62.	2.2	162
96	A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke. Drug Safety, 2002, 25, 943-963.	1.4	8
97	Treatment of Heart Failure in Patients with Diabetes Mellitus. Drugs, 2002, 62, 285-307.	4.9	7
98	Rosiglitazone. Drugs, 2002, 62, 1805-1837.	4.9	156
99	Insulin Aspart. Drugs, 2002, 62, 1945-1981.	4.9	58
100	A Real-World Analysis of Persistence on and Adherence to Glipizide GITS, Glipizide IR and Glibenclamide in Managed Care among Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2002, 22, 575-584.	1.1	5
102	Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine, 2002, 346, 393-403.	13.9	16,031

#	ARTICLE	IF	CITATIONS
103	A Guideline for the Use of Pharmacoeconomic Models of Diabetes Treatment in the US Managed-Care Environment. <i>Pharmacoeconomics</i> , 2002, 20, 21-30.	1.7	7
104	Insulin Lispro. <i>Pharmacoeconomics</i> , 2002, 20, 989-1025.	1.7	9
105	Increasing Incidence of Type 2 Diabetes in Children and Adolescents. <i>Paediatric Drugs</i> , 2002, 4, 209-221.	1.3	55
106	MANAGEMENT OF TYPE 2 DIABETES (NIDDM). <i>Medical Journal Armed Forces India</i> , 2002, 58, 53-59.	0.3	1
107	Effective diabetes care: a need for realistic targets. <i>BMJ: British Medical Journal</i> , 2002, 324, 1577-1580.	2.4	84
108	A randomised controlled trial of a patient based Diabetes recall and Management system: the DREAM trial: A study protocol [ISRCTN32042030]. <i>BMC Health Services Research</i> , 2002, 2, 5.	0.9	21
109	Endocrine heart disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2002, 4, 181-192.	0.4	0
110	Atherosclerotic risk factors in patients with ischemic cerebrovascular disease. <i>Current Treatment Options in Neurology</i> , 2002, 4, 445-453.	0.7	10
111	Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: Insights into the pathogenesis of macrovascular complications in diabetes. <i>Current Atherosclerosis Reports</i> , 2002, 4, 228-237.	2.0	167
112	Prevention of heart failure. <i>Current Cardiology Reports</i> , 2002, 4, 194-199.	1.3	7
113	Insulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions. <i>Current Cardiology Reports</i> , 2002, 4, 514-521.	1.3	29
114	The role of PCI and CABG in the management of coronary artery disease in patients with diabetes. <i>Current Diabetes Reports</i> , 2002, 2, 16-20.	1.7	1
115	Glucose and insulin management in the post-MI setting. <i>Current Diabetes Reports</i> , 2002, 2, 37-44.	1.7	2
116	Patient-centered diabetes self-management education. <i>Current Diabetes Reports</i> , 2002, 2, 145-152.	1.7	23
117	Reaching underserved populations and cultural competence in diabetes education. <i>Current Diabetes Reports</i> , 2002, 2, 166-176.	1.7	28
118	Is hepatic glucose production increased in type 2 diabetes mellitus?. <i>Current Diabetes Reports</i> , 2002, 2, 231-236.	1.7	32
119	Insulin analogues: New therapies for type 2 diabetes mellitus. <i>Current Diabetes Reports</i> , 2002, 2, 403-408.	1.7	7
120	Preventing diabetes by treating aspects of the metabolic syndrome. <i>Current Diabetes Reports</i> , 2002, 2, 416-422.	1.7	14

#	ARTICLE	IF	CITATIONS
121	Diagnosis and management of diabetic neuropathy. <i>Current Diabetes Reports</i> , 2002, 2, 495-500.	1.7	32
122	The relationship between glucose control and the development and progression of diabetic nephropathy. <i>Current Diabetes Reports</i> , 2002, 2, 523-529.	1.7	26
123	Blood pressure controlâ€™Effects on diabetic nephropathy progression: How low does blood pressure have to be?. <i>Current Diabetes Reports</i> , 2002, 2, 530-538.	1.7	5
124	Screening for diabetes in an outpatient clinic population. <i>Journal of General Internal Medicine</i> , 2002, 17, 23-28.	1.3	38
125	Impoverished diabetic patients whose doctors facilitate their participation in medical decision making are more satisfied with their care. <i>Journal of General Internal Medicine</i> , 2002, 17, 866-875.	1.3	96
126	Identifying older diabetic patients at risk of poor glycemic control. <i>BMC Geriatrics</i> , 2002, 2, 4.	1.1	3
127	What should we measure in the diabetic patient and how does this respond to therapy?. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 81-86.	1.1	0
128	Revealing the cost of Type II diabetes in Europe. <i>Diabetologia</i> , 2002, 45, S5-S12.	2.9	342
129	The Cost of Diabetes Type II in Europe The CODE-2 Study. <i>Diabetologia</i> , 2002, 45, S1-S4.	2.9	97
130	Evaluation of risk factors for development of complications in Type II diabetes in Europe. <i>Diabetologia</i> , 2002, 45, S23-S28.	2.9	182
131	Understanding variation in chronic disease outcomes. <i>Health Care Management Science</i> , 2002, 5, 175-189.	1.5	37
132	Effect of Metformin and Sulfonylurea on C-Reactive Protein Level in Well-Controlled Type 2 Diabetics with Metabolic Syndrome. <i>Endocrine</i> , 2003, 20, 215-218.	2.2	53
133	The Relationship Between Red Blood Cell Na/K-ATPase Activities and Diabetic Complications in Patients with Type 2 Diabetes Mellitus. <i>Endocrine</i> , 2003, 21, 273-278.	2.2	24
134	The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study. <i>Quality of Life Research</i> , 2003, 12, 413-425.	1.5	39
135	Unexpected yes- and no-answering behaviour in the discrete choice approach to elicit willingness to pay: a methodological comparison with payment cards. <i>International Journal of Health Care Finance and Economics</i> , 2003, 3, 147-166.	1.2	6
136	Type 2 diabetes in children and youth. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2003, 4, 33-42.	2.6	30
137	The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. <i>Diabetologia</i> , 2003, 46, 3-19.	2.9	1,767
138	Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. <i>Diabetologia</i> , 2003, 46, 394-400.	2.9	134



#	ARTICLE	IF	CITATIONS
139	Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. <i>Diabetologia</i> , 2003, 46, 843-851.	2.9	87
140	Variations in process and outcomes of diabetes care by socio-economic status in Salford, UK. <i>Diabetologia</i> , 2003, 46, 750-759.	2.9	27
141	Microalbuminuria and diabetic cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2003, 5, 350-357.	2.0	9
142	Cardiovascular risk in diabetic women. <i>Current Atherosclerosis Reports</i> , 2003, 5, 79-81.	2.0	2
143	Optimal medical management of angina. <i>Current Cardiology Reports</i> , 2003, 5, 259-265.	1.3	2
144	Diabetic neuropathy and microcirculation. <i>Current Diabetes Reports</i> , 2003, 3, 446-451.	1.7	61
145	New treatments for diabetic neuropathy: Symptomatic treatments. <i>Current Diabetes Reports</i> , 2003, 3, 459-467.	1.7	9
146	The role of renal proximal tubular cells in diabetic nephropathy. <i>Current Diabetes Reports</i> , 2003, 3, 491-496.	1.7	61
147	Proteinuria in diabetic nephropathy: Treatment and evolution. <i>Current Diabetes Reports</i> , 2003, 3, 497-504.	1.7	28
148	Heart disease in diabetic patients. <i>Current Diabetes Reports</i> , 2003, 3, 223-229.	1.7	71
149	Prevention of type 2 diabetes. <i>Current Diabetes Reports</i> , 2003, 3, 235-241.	1.7	32
150	Reducing CVD risk in type 2 DM. <i>Current Diabetes Reports</i> , 2003, 3, 363-364.	1.7	0
151	Insulin therapy for type 2 diabetes. <i>Current Diabetes Reports</i> , 2003, 3, 378-385.	1.7	10
152	Nutrition therapy for diabetic nephropathy. <i>Current Diabetes Reports</i> , 2003, 3, 412-417.	1.7	12
153	Nutrition therapy for diabetic gastroparesis. <i>Current Diabetes Reports</i> , 2003, 3, 418-426.	1.7	27
154	Fibromyalgia in diabetes mellitus. <i>Rheumatology International</i> , 2003, 23, 171-173.	1.5	43
157	Sulphonylurea action revisited: the post-cloning era. <i>Diabetologia</i> , 2003, 46, 875-891.	2.9	270
158	Diabetes-induced activation of protein kinase C inhibits store-operated Ca <sup>2+</sup> uptake in rat retinal microvascular smooth muscle. <i>Diabetologia</i> , 2003, 46, 1252-1259.	2.9	39

#	ARTICLE	IF	CITATIONS
159	Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. <i>Diabetologia</i> , 2003, 46, 1611-1617.	2.9	38
160	Under-prescribing of cardiovascular therapies for diabetes in primary care. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 835-841.	0.8	26
161	Spatial visual filtering in diabetes mellitus. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2003, 241, 489-496.	1.0	1
162	Cost of managing complications resulting from type 2 diabetes mellitus in Canada. <i>BMC Health Services Research</i> , 2003, 3, 7.	0.9	93
163	Variation in diabetes care by age: opportunities for customization of care. <i>BMC Family Practice</i> , 2003, 4, 16.	2.9	28
164	Usefulness of electronic databases for the detection of unrecognized diabetic patients. <i>Cardiovascular Diabetology</i> , 2003, 2, 13.	2.7	14
165	Diabetes control improved when inner-city patients received graphic feedback about glycosylated hemoglobin levels. <i>Journal of General Internal Medicine</i> , 2003, 18, 120-124.	1.3	26
166	Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 246-251.	1.1	30
167	Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 147-157.	1.1	50
168	The pharmacokinetics of pioglitazone in patients with impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 368-374.	1.1	125
169	An autosome-wide search using longitudinal data for loci linked to type 2 diabetes progression. <i>BMC Genetics</i> , 2003, 4, S8.	2.7	8
170	Ragaglitazar: a novel PPAR $\alpha$ & PPAR $\gamma$ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. <i>British Journal of Pharmacology</i> , 2003, 140, 527-537.	2.7	77
173	Not-only-a-title. <i>Health and Quality of Life Outcomes</i> , 2003, 1, 1.	1.0	487
174	Clinical Potential of Insulin Therapy in Critically Ill Patients. <i>Drugs</i> , 2003, 63, 625-636.	4.9	60
175	Pharmacological Treatment of Patients with Peripheral Arterial Disease. <i>Drugs</i> , 2003, 63, 637-647.	4.9	10
176	Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. <i>Drugs</i> , 2003, 63, 1165-1184.	4.9	76
177	Insulin Glargine. <i>Drugs</i> , 2003, 63, 1743-1778.	4.9	91
178	Long-Term Improvement of Metabolic Control by Acarbose in Type 2 Diabetes Patients Poorly Controlled with Maximum Sulfonylurea Therapy. <i>Clinical Drug Investigation</i> , 2003, 23, 679-686.	1.1	12

#	ARTICLE	IF	CITATIONS
179	Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice. <i>Clinical Drug Investigation</i> , 2003, 23, 725-734.	1.1	8
180	Localization of a Susceptibility Gene for Type 2 Diabetes to Chromosome 5q34-q35.2. <i>American Journal of Human Genetics</i> , 2003, 73, 323-335.	2.6	177
182	The burden of type 2 diabetes: are we doing enough?. <i>Diabetes and Metabolism</i> , 2003, 29, 6S9-6S18.	1.4	190
183	Novel Drug Delivery Systems for Insulin. <i>Drugs and Aging</i> , 2003, 20, 303-312.	1.3	20
184	Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2003, 21, 501-512.	1.7	37
185	The Economics of Screening and Treatment in Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2003, 21, 543-564.	1.7	28
186	Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach. <i>Clinical Medicine and Research</i> , 2003, 1, 189-200.	0.4	75
187	The Diabetes Prevention Program and Its Global Implications. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S103-S107.	3.0	46
188	Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2003, 348, 2294-2303.	13.9	761
189	Effectiveness of diabetes mellitus screening recommendations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10574-10579.	3.3	34
190	Extracts from "Concise Clinical Evidence": Diabetic retinopathy * Commentary: Treatment of diabetic retinopathy. <i>BMJ: British Medical Journal</i> , 2003, 326, 1023-1025.	2.4	15
191	What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. <i>BMJ: British Medical Journal</i> , 2003, 327, 266-0.	2.4	63
192	Poor glycaemic control caused by insulin induced lipohypertrophy. <i>BMJ: British Medical Journal</i> , 2003, 327, 383-384.	2.4	82
193	Intensive education for lifestyle change in diabetes. <i>BMJ: British Medical Journal</i> , 2003, 327, 1120-1121.	2.4	17
194	Type 2 diabetes is cardiovascular disease. <i>Journal of the Royal Society of Medicine</i> , 2003, 96, 371-372.	1.1	1
195	Diabetes and Hypertension in Severe Obesity and Effects of Gastric Bypass-Induced Weight Loss. <i>Annals of Surgery</i> , 2003, 237, 751-758.	2.1	383
196	Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. <i>Journal of Clinical Investigation</i> , 2003, 112, 1049-1057.	3.9	622
197	Type 2 Diabetes is Cardiovascular Disease. <i>Journal of the Royal Society of Medicine</i> , 2003, 96, 371-372.	1.1	1

#	ARTICLE	IF	CITATIONS
198	Clinical Outcomes in Patients with Type 2 Diabetes Managed by a Diabetes Resource Nurse in a Primary Care Practice. Baylor University Medical Center Proceedings, 2003, 16, 336-340.	0.2	12
200	Wandering Hemiparesis. Journal of the Royal Society of Medicine, 2004, 97, 26-27.	1.1	2
201	GLP-1: Target for a New Class of Antidiabetic Agents?. Journal of the Royal Society of Medicine, 2004, 97, 270-274.	1.1	4
202	Lack of insurance coverage for testing supplies is associated with poorer glycemic control in patients with type 2 diabetes. Cmaj, 2004, 171, 39-43.	0.9	34
203	View 1: Should this patient receive laser treatment?. British Journal of Ophthalmology, 2004, 88, 433-a-435.	2.1	0
204	Multi-vessel coronary disease and percutaneous coronary intervention. Heart, 2004, 90, 341-346.	1.2	10
205	Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. British Journal of Ophthalmology, 2004, 88, 145-151.	2.1	47
206	Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. British Heart Journal, 2004, 90, 732-738.	2.2	58
207	Overview. British Journal of Ophthalmology, 2004, 88, 436-437.	2.1	0
208	HbA1c measurement. Journal of Clinical Pathology, 2004, 57, 344-345.	1.0	24
209	Diabetes and atherogenesis. Heart, 2004, 90, 336-340.	1.2	34
210	Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. British Heart Journal, 2004, 90, 9-12.	2.2	96
211	The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clinical Trials, 2004, 1, 532-544.	0.7	54
212	Diabetic Patients Who Smoke: Are They Different?. Annals of Family Medicine, 2004, 2, 26-32.	0.9	93
213	Utility of hemoglobin A1c in predicting diabetes risk. Journal of General Internal Medicine, 2004, 19, 1175-1180.	1.3	167
214	Strategies to curb the epidemic of diabetes and obesity in primary care settings. Journal of General Internal Medicine, 2004, 19, 1242-1243.	1.3	4
215	Prandial Glucose Regulation in the Glucose Triad: Emerging Evidence and Insights. Endocrine, 2004, 25, 195-202.	2.2	24
216	Boronic Acid Based Modular Fluorescent Sensors for Glucose. Journal of Fluorescence, 2004, 14, 549-559.	1.3	70

#	ARTICLE	IF	CITATIONS
217	A Comparison of Diabetes Care in Rural and Urban Medical Clinics in Alabama. <i>Journal of Community Health</i> , 2004, 29, 29-44.	1.9	58
218	PPAR- $\gamma$ receptor agonists—a review of their role in diabetic management in Trinidad and Tobago. <i>Molecular and Cellular Biochemistry</i> , 2004, 263, 189-210.	1.4	3
219	Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team—a pilot study. <i>International Journal of Clinical Pharmacy</i> , 2004, 26, 18-25.	1.4	60
220	Molecular Defects in Insulin Secretion in Type-2 Diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 135-142.	2.6	54
221	Glycooxidation and Diabetic Complications: Modern Lessons and a Warning?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 181-188.	2.6	81
222	The effects of a combined strength and aerobic exercise program on glucose control and insulin action in women with type 2 diabetes. <i>European Journal of Applied Physiology</i> , 2004, 92, 437-42.	1.2	93
223	Surgical treatment of diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2004, 242, 704-709.	1.0	14
224	Direct medical costs unequivocally related to diabetes in Italian specialized centers. <i>European Journal of Health Economics</i> , 2004, 5, 15-21.	1.4	16
227	The effect of post prandial glucose changes on oscillatory potentials in subjects with type 2 diabetes mellitus. <i>Documenta Ophthalmologica</i> , 2004, 109, 35-42.	1.0	6
228	Characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions. <i>International Urology and Nephrology</i> , 2004, 36, 611-616.	0.6	5
235	Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?. <i>Diabetologia</i> , 2004, 47, 157-169.	2.9	177
236	Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. <i>Diabetologia</i> , 2004, 47, 575-580.	2.9	58
237	Neointimal proliferation within carotid stents is more pronounced in diabetic patients with initial poor glycaemic state. <i>Diabetologia</i> , 2004, 47, 400-406.	2.9	30
238	Effects of a 12-month physical activity counselling intervention on glycaemic control and on the status of cardiovascular risk factors in people with Type 2 diabetes. <i>Diabetologia</i> , 2004, 47, 821-832.	2.9	123
239	Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. <i>Diabetologia</i> , 2004, 47, 1245-1256.	2.9	150
240	Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. <i>Diabetologia</i> , 2004, 47, 1257-1265.	2.9	107
241	Towards worldwide standardisation of HbA1c determination. <i>Diabetologia</i> , 2004, 47, 1143-1148.	2.9	61
242	Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. <i>Diabetologia</i> , 2004, 47, 1535-1540.	2.9	26

#	ARTICLE	IF	CITATIONS
243	Albuminuria is a marker of increasing intracranial and extracranial vascular involvement in Type 2 diabetic Chinese patients. <i>Diabetologia</i> , 2004, 47, 1528-1534.	2.9	23
244	Spirolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes. <i>Diabetologia</i> , 2004, 47, 1687-1694.	2.9	102
245	A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). <i>Diabetologia</i> , 2004, 47, 1747-1759.	2.9	516
246	Glycemic control in the ICU: a multicenter survey. <i>Intensive Care Medicine</i> , 2004, 30, 798-803.	3.9	63
247	Treatment of lipids and type 2 diabetes. <i>Current Cardiology Reports</i> , 2004, 6, 443-450.	1.3	4
248	The role of advanced glycation end products in the development of atherosclerosis. <i>Current Diabetes Reports</i> , 2004, 4, 31-36.	1.7	89
249	Waiting to inhale: Noninjectable insulin, are we there yet?. <i>Current Diabetes Reports</i> , 2004, 4, 335-341.	1.7	8
250	Basal insulin therapy. <i>Current Diabetes Reports</i> , 2004, 4, 342-345.	1.7	8
251	Women, type 2 diabetes, and fracture risk. <i>Current Diabetes Reports</i> , 2004, 4, 364-369.	1.7	31
252	Diabetic nephropathy in African-American patients. <i>Current Diabetes Reports</i> , 2004, 4, 455-461.	1.7	33
253	Gene expression in diabetic nephropathy. <i>Current Diabetes Reports</i> , 2004, 4, 462-469.	1.7	10
254	Oxidative stress and diabetic vascular complications. <i>Current Diabetes Reports</i> , 2004, 4, 247-252.	1.7	81
255	Hypertension management in patients with diabetic nephropathy. <i>Current Hypertension Reports</i> , 2004, 6, 272-279.	1.5	2
256	Cost-effectiveness in preventive cardiology. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 279-290.	0.4	0
257	When there is too much to do. <i>Journal of General Internal Medicine</i> , 2004, 19, 646-653.	1.3	56
258	The association of patient trust and self-care among patients with diabetes mellitus. <i>BMC Family Practice</i> , 2004, 5, 26.	2.9	106
259	Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K. <i>Cost Effectiveness and Resource Allocation</i> , 2004, 2, 2.	0.6	14
260	Cost-Effective Strategies in the Prevention of Diabetic Nephropathy. <i>Pharmacoeconomics</i> , 2004, 22, 9-28.	1.7	24

#	ARTICLE	IF	CITATIONS
261	Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective. <i>Pharmacoeconomics</i> , 2004, 22, 321-341.	1.7	25
262	Repaglinide. <i>Pharmacoeconomics</i> , 2004, 22, 389-411.	1.7	34
263	Managing comorbidities in patients at the end of life. <i>BMJ: British Medical Journal</i> , 2004, 329, 909-912.	2.4	116
264	Reduction of cardiovascular morbidity and mortality in Type 2 diabetes. A rational approach to hypoglycemic therapy. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 485-495.	1.8	5
265	Hemoglobin A1c levels in non-diabetic patients with end-stage renal disease (ESRD) receiving hemodialysis. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 733-735.	1.8	11
266	Erectile dysfunction: symptom or disease?. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 80-95.	1.8	23
268	Clinical Pharmacokinetics of Nateglinide. <i>Clinical Pharmacokinetics</i> , 2004, 43, 97-120.	1.6	88
269	Insulin Disposition in the Lung Following Oral Inhalation in Humans. <i>Clinical Pharmacokinetics</i> , 2004, 43, 539-552.	1.6	43
270	Clinical Pharmacokinetics and Pharmacodynamics of Inhaled Insulin. <i>Clinical Pharmacokinetics</i> , 2004, 43, 781-801.	1.6	156
271	Evolving Strategies for Insulin Delivery and Therapy. <i>Drugs</i> , 2004, 64, 1149-1161.	4.9	21
272	The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2004, 64, 1339-1358.	4.9	251
273	Pramlintide for the Treatment of Insulin-Requiring Diabetes Mellitus. <i>Drugs</i> , 2004, 64, 1419-1432.	4.9	61
274	Insulin Aspart. <i>Drugs</i> , 2004, 64, 1957-1974.	4.9	38
275	Slowing the Progression of Adult Chronic Kidney Disease. <i>Drugs</i> , 2004, 64, 2273-2289.	4.9	27
276	Insulin Detemir. <i>Drugs</i> , 2004, 64, 2577-2595.	4.9	80
277	Orlistat. <i>Drugs</i> , 2004, 64, 2845-2864.	4.9	39
278	Insulin Aspart. <i>Clinical Drug Investigation</i> , 2004, 24, 695-717.	1.1	7
279	Hypoglycaemia in Elderly Patients with Diabetes Mellitus. <i>Drugs and Aging</i> , 2004, 21, 511-530.	1.3	137

#	ARTICLE	IF	CITATIONS
280	Tolerability Profile of Metformin/Glibenclamide Combination Tablets (Glucovance?). Drug Safety, 2004, 27, 1205-1216.	1.4	15
281	Measuring the Quality of Diabetes Care for Older American Indians and Alaska Natives. American Journal of Public Health, 2004, 94, 60-65.	1.5	21
282	Pounds Off With Empowerment (POWER): A Clinical Trial of Weight Management Strategies for Black and White Adults With Diabetes Who Live in Medically Underserved Rural Communities. American Journal of Public Health, 2004, 94, 1736-1742.	1.5	166
283	Wandering hemiparesis. Journal of the Royal Society of Medicine, 2004, 97, 26-27.	1.1	7
284	GLP-1: target for a new class of antidiabetic agents?. Journal of the Royal Society of Medicine, 2004, 97, 270-274.	1.1	7
285	Effect of Duodenal Jejunum Exclusion in a Non-obese Animal Model of Type 2 Diabetes. Annals of Surgery, 2004, 239, 1-11.	2.1	581
286	Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. The Cochrane Library, 2004, , CD003418.	1.5	70
287	Diabetes Outcomes in the Indian Health System During the Era of the Special Diabetes Program for Indians and the Government Performance and Results Act. American Journal of Public Health, 2005, 95, 1518-1522.	1.5	44
288	Racial/Ethnic Disparities in Potentially Preventable Readmissions: The Case of Diabetes. American Journal of Public Health, 2005, 95, 1561-1567.	1.5	129
289	Racial and Ethnic Approaches to Community Health (REACH) Detroit Partnership: Improving Diabetes-Related Outcomes Among African American and Latino Adults. American Journal of Public Health, 2005, 95, 1552-1560.	1.5	208
290	The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance. Annals of Internal Medicine, 2005, 142, 323.	2.0	578
291	Time for "drilling down". Journal of General Internal Medicine, 2005, 20, 483-484.	1.3	0
292	Self-Reported Goals of Older Patients with Type 2 Diabetes Mellitus. Journal of the American Geriatrics Society, 2005, 53, 306-311.	1.3	119
293	Developing a Quality Measure for Clinical Inertia in Diabetes Care. Health Services Research, 2005, 40, 1836-1853.	1.0	93
294	Improving Diabetes Care by Combating Clinical Inertia. Health Services Research, 2005, 40, 1854-1861.	1.0	38
295	Assessing Quality of Diabetes Care by Measuring Longitudinal Changes in Hemoglobin A1c in the Veterans Health Administration. Health Services Research, 2005, 40, 1818-1835.	1.0	30
296	Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERxR insulin Diabetes Management System. British Journal of Clinical Pharmacology, 2005, 59, 546-551.	1.1	37
297	Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study. BMC Public Health, 2005, 5, 36.	1.2	157



#	ARTICLE	IF	CITATIONS
298	Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 893-897.	0.8	31
300	An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. <i>Diabetologia</i> , 2005, 48, 17-26.	2.9	192
301	Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. <i>Diabetologia</i> , 2005, 48, 282-289.	2.9	322
302	Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. <i>Diabetologia</i> , 2005, 48, 553-560.	2.9	29
303	Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. <i>Diabetologia</i> , 2005, 48, 2667-2674.	2.9	77
304	Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). <i>Diabetologia</i> , 2005, 48, 695-702.	2.9	101
305	IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). <i>Diabetologia</i> , 2005, 48, 703-708.	2.9	83
306	Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). <i>Diabetologia</i> , 2005, 48, 868-877.	2.9	147
307	Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice. <i>Diabetologia</i> , 2005, 48, 1614-1620.	2.9	26
308	The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. <i>Diabetologia</i> , 2005, 48, 1749-1755.	2.9	233
309	Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. <i>Diabetologia</i> , 2005, 48, 1726-1735.	2.9	143
310	Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. <i>Diabetologia</i> , 2005, 48, 1898-1905.	2.9	39
311	Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. <i>Diabetologia</i> , 2005, 48, 1988-1995.	2.9	109
315	Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis. <i>Clinical and Experimental Nephrology</i> , 2005, 9, 164-169.	0.7	23
316	The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. <i>Journal of Human Genetics</i> , 2005, 50, 267-275.	1.1	74
317	Comparison of diets high in monounsaturated versus polyunsaturated fatty acid on postprandial lipoproteins in diabetes. <i>Irish Journal of Medical Science</i> , 2005, 174, 8-20.	0.8	15
318	Prevention of coronary heart disease in diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 259-271.	0.4	3
319	The impact of antidiabetic therapies on cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2005, 7, 50-57.	2.0	19

#	ARTICLE	IF	CITATIONS
320	The impact of evidence-based medicine on diabetes therapy. <i>Current Diabetes Reports</i> , 2005, 5, 157-159.	1.7	1
321	Challenges in the diagnosis and management of new-onset diabetes after transplantation. <i>Current Diabetes Reports</i> , 2005, 5, 194-199.	1.7	8
322	Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications. <i>Current Diabetes Reports</i> , 2005, 5, 91-97.	1.7	38
323	Atherosclerosis and restenosis: Is there a role for rage?. <i>Current Diabetes Reports</i> , 2005, 5, 11-16.	1.7	34
324	Rational drug design and PPAR Agonists. <i>Current Diabetes Reports</i> , 2005, 5, 340-345.	1.7	11
325	Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. <i>Current HIV/AIDS Reports</i> , 2005, 2, 132-139.	1.1	15
326	Advanced-glycation end products in insulin-resistant states. <i>Current Hypertension Reports</i> , 2005, 7, 96-102.	1.5	31
327	Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents. <i>Current Hypertension Reports</i> , 2005, 7, 110-116.	1.5	13
328	Prevention of Nephropathy in Patients with type 2 Diabetes Mellitus. <i>International Urology and Nephrology</i> , 2005, 37, 655-663.	0.6	8
329	Transforming growth factor- $\beta$ 1 regulation of laminin $\beta$ 1 and fibronectin expression and survival of mouse mesangial cells. <i>Molecular and Cellular Biochemistry</i> , 2005, 278, 165-175.	1.4	12
330	Antidiabetic Drug Utilization in Hungary. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 263-265.	1.4	5
331	GPs' perspectives of type 2 diabetes patients' adherence to treatment: A qualitative analysis of barriers and solutions. <i>BMC Family Practice</i> , 2005, 6, 20.	2.9	137
332	The DiGEM trial protocol – a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes [ISRCTN47464659]. <i>BMC Family Practice</i> , 2005, 6, 25.	2.9	34
333	Community Diabetes: An East London Perspective. <i>Journal of the Royal Society of Medicine</i> , 2005, 98, 96-100.	1.1	4
334	Impact of an Electronic Medical Record on Diabetes Quality of Care. <i>Annals of Family Medicine</i> , 2005, 3, 300-306.	0.9	115
335	Case-Based Study: From Prediabetes to Complications – Opportunities for Prevention. <i>PLoS Medicine</i> , 2005, 2, e40.	3.9	1
336	Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. <i>Cmaj</i> , 2005, 173, 1457-1466.	0.9	54
337	Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 289, H1744-H1751.	1.5	109

#	ARTICLE	IF	CITATIONS
338	Portal 5-hydroxytryptophan infusion enhances glucose disposal in conscious dogs. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E225-E231.	1.8	23
339	Longitudinal Research and Data Collection in Primary Care. Annals of Family Medicine, 2005, 3, S46-S51.	0.9	50
340	Post-challenge hyperinsulinaemia rather than hyperglycaemia is associated with the severity of coronary artery disease in patients without a previous diagnosis of diabetes mellitus. Heart, 2005, 91, 731-736.	1.2	17
341	Is There Time for Management of Patients With Chronic Diseases in Primary Care?. Annals of Family Medicine, 2005, 3, 209-214.	0.9	606
342	Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications. Diabetes, 2005, 54, 234-242.	0.3	165
343	Measuring Diabetes Self-Care: A psychometric analysis of the Self-Care Inventory-revised with adults. Diabetes Care, 2005, 28, 1346-1352.	4.3	267
344	Strategies to Identify Adults at High Risk for Type 2 Diabetes: The Diabetes Prevention Program. Diabetes Care, 2005, 28, 138-144.	4.3	75
345	Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine, 2005, 353, 2643-2653.	13.9	4,433
346	Can diabetes management programs create sustained improvements in disease outcomes?. Cmaj, 2005, 173, 1467-1468.	0.9	5
347	Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. Cmaj, 2005, 172, 177-180.	0.9	34
348	Metformin's contraindications should be contraindicated. Cmaj, 2005, 173, 502-504.	0.9	66
349	Diabetes and cardiovascular disease: the road to cardioprotection. Heart, 2005, 91, 1621-1625.	1.2	24
350	Quality of Diabetes Care in U.S. Academic Medical Centers: Low rates of medical regimen change. Diabetes Care, 2005, 28, 337-442.	4.3	289
351	Intensive Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants With Impaired Glucose Tolerance. Diabetes, 2005, 54, 1566-1572.	0.3	306
352	QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart, 2005, 91, 44-50.	1.2	71
353	Secondary prevention of coronary heart disease in the elderly. Heart, 2005, 91, 396-400.	1.2	15
354	Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose. British Journal of Ophthalmology, 2005, 89, 1638-1642.	2.1	36
355	MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7970-7975.	3.3	144

#	ARTICLE	IF	CITATIONS
356	Community diabetes: an East London perspective. <i>Journal of the Royal Society of Medicine</i> , 2005, 98, 96-100.	1.1	5
357	Hemoglobin A1c Measurements over Nearly Two Decades: Sustaining Comparable Values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. <i>Clinical Chemistry</i> , 2005, 51, 753-758.	1.5	103
359	Continuous quality improvement in rural health clinics. <i>Journal of General Internal Medicine</i> , 2005, 20, 862-865.	1.3	6
360	Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2005, , CD004096.	1.5	54
361	Willingness to Pay for Inhaled Insulin. <i>Pharmacoeconomics</i> , 2005, 23, 1215-1227.	1.7	33
364	The case for low carbohydrate diets in diabetes management. <i>Nutrition and Metabolism</i> , 2005, 2, 16.	1.3	75
365	A low-carbohydrate, ketogenic diet to treat type 2 diabetes. <i>Nutrition and Metabolism</i> , 2005, 2, 34.	1.3	192
366	Potential Role of Oral Thiazolidinedione Therapy in Preserving $\beta$ -Cell Function in Type 2 Diabetes Mellitus. <i>Drugs</i> , 2005, 65, 1-13.	4.9	72
367	A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus. <i>Drugs</i> , 2005, 65, 325-340.	4.9	57
368	Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus. <i>Drugs</i> , 2005, 65, 433-445.	4.9	8
369	Exenatide. <i>Drugs</i> , 2005, 65, 1681-1692.	4.9	59
370	Effects of Pioglitazone and Insulin on $\beta$ -Tight Glycaemic Control Assessed by the Continuous Glucose Monitoring System. <i>Clinical Drug Investigation</i> , 2005, 25, 347-352.	1.1	3
371	Long-Term Efficacy and Tolerability of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2005, 25, 589-595.	1.1	21
372	Oral antihyperglycemic therapy for type 2 diabetes mellitus. <i>Cmaj</i> , 2005, 172, 213-226.	0.9	354
373	Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2005, , CD003638.	1.5	175
374	A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies. <i>Pharmacoeconomics</i> , 2006, 24, 5-19.	1.7	15
375	Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK. <i>Pharmacoeconomics</i> , 2006, 24, 21-34.	1.7	167
376	Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2006, 24, 425-441.	1.7	42

#	ARTICLE	IF	CITATIONS
377	NICE Says No to Inhaled Insulin: What Lessons Should We Learn?. <i>Pharmacoeconomics</i> , 2006, 24, 627-629.	1.7	2
378	Reduced Acute Vascular Injury and Atherosclerosis in Hyperlipidemic Mice Transgenic for Lysozyme. <i>American Journal of Pathology</i> , 2006, 169, 303-313.	1.9	22
379	Bioavailability of Immediate- and Extended-Release Formulations of Glipizide in Healthy Male Volunteers. <i>Clinical Pharmacokinetics</i> , 2006, 45, 317-324.	1.6	5
380	Premixed Insulin Analogues for the Treatment of Diabetes Mellitus. <i>Drugs</i> , 2006, 66, 31-49.	4.9	85
381	Pioglitazone. <i>Drugs</i> , 2006, 66, 85-109.	4.9	146
382	Should Postprandial Hyperglycaemia in Prediabetic and Type 2 Diabetic Patients be Treated?. <i>Drugs</i> , 2006, 66, 273-286.	4.9	12
383	Insulin Glulisine. <i>Drugs</i> , 2006, 66, 861-869.	4.9	15
384	Inhaled Human Insulin (Exubera?). <i>Drugs</i> , 2006, 66, 1013-1032.	4.9	28
385	Orlistat. <i>Drugs</i> , 2006, 66, 1625-1656.	4.9	83
386	New Potential Agents in Treating Diabetic Kidney Disease. <i>Drugs</i> , 2006, 66, 2287-2298.	4.9	26
387	A Review of 20??Years??? Experience with the Novopen?? Family of Insulin Injection Devices. <i>Clinical Drug Investigation</i> , 2006, 26, 367-401.	1.1	49
389	A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 17.	1.0	39
390	Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 80.	1.0	66
391	Low-carbohydrate diet in type 2 diabetes. Stable improvement of bodyweight and glycemic control during 22 months follow-up. <i>Nutrition and Metabolism</i> , 2006, 3, 22.	1.3	49
392	Growth Factor Midkine Is Involved in the Pathogenesis of Diabetic Nephropathy. <i>American Journal of Pathology</i> , 2006, 168, 9-19.	1.9	53
393	Diabetic Retinopathy in a Multi-ethnic Cohort in the United States. <i>American Journal of Ophthalmology</i> , 2006, 141, 446-455.e1.	1.7	548
394	Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2653-2658.	3.3	988
395	Can Stevioside in Combination with a Soy-Based Dietary Supplement Be a New Useful Treatment of Type 2 Diabetes? - An in vivo Study in the Diabetic Goto-Kakizaki Rat. <i>Review of Diabetic Studies</i> , 2006, 3, 189-189.	0.5	36

#	ARTICLE	IF	CITATIONS
396	Can the Glycemic Index (GI) be Used as a Tool in the Prevention and Management of Type 2 Diabetes?. Review of Diabetic Studies, 2006, 3, 61-61.	0.5	17
397	Oral Adsorbent AST-120 Decreases Serum Levels of AGEs in Patients with Chronic Renal Failure. Molecular Medicine, 2006, 12, 180-184.	1.9	54
398	Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes. PLoS Medicine, 2006, 3, e215.	3.9	59
399	Causes and Characteristics of Diabetic Cardiomyopathy. Review of Diabetic Studies, 2006, 3, 108-108.	0.5	116
400	Pioglitazone for type 2 diabetes mellitus. The Cochrane Library, 2006, , CD006060.	1.5	49
401	Implications of New Geriatric Diabetes Care Guidelines for the Assessment of Quality of Care in Older Patients. Medical Care, 2006, 44, 373-377.	1.1	20
402	Prognostic value of physicians' assessment of compliance regarding all-cause mortality in patients with type 2 diabetes: primary care follow-up study. BMC Family Practice, 2006, 7, 42.	2.9	13
403	Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovascular Diabetology, 2006, 5, 15.	2.7	62
404	Will availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes? The design of the Real World trial. Trials, 2006, 7, 25.	0.7	12
405	Assessment of diabetes screening by general practitioners in France: the EPIDIA Study. Diabetic Medicine, 2006, 23, 803-807.	1.2	13
406	The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus. British Journal of Clinical Pharmacology, 2006, 62, 660-665.	1.1	20
407	A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 313-343.	0.8	129
408	Prospective Assessment of Proliferative Diabetic Retinopathy with Observations of Posterior Vitreous Detachment. International Ophthalmology, 2006, 26, 15-19.	0.6	45
409	Long-term effect of Trigonella foenum graecum and its combination with sodium orthovanadate in preventing histopathological and biochemical abnormalities in diabetic rat ocular tissues. Molecular and Cellular Biochemistry, 2006, 289, 137-147.	1.4	33
410	Population-Based Study of Nonproliferative Diabetic Retinopathy Among Type 2 Diabetic Patients in Kinmen, Taiwan. Japanese Journal of Ophthalmology, 2006, 50, 44-52.	0.9	14
411	High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography. Clinical Research in Cardiology, 2006, 95, 80-87.	1.5	33
414	High glucose and N <sup>ε</sup> -(carboxymethyl) lysine bovine serum albumin modulate release of matrix metalloproteinases in cultured human endothelial cells. European Journal of Nutrition, 2006, 45, 283-290.	1.8	10
416	Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia, 2006, 49, 49-55.	2.9	94

#	ARTICLE	IF	CITATIONS
417	How should HbA1c measurements be reported?. <i>Diabetologia</i> , 2006, 49, 7-10.	2.9	36
418	Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. <i>Diabetologia</i> , 2006, 49, 271-278.	2.9	257
419	Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. <i>Diabetologia</i> , 2006, 49, 405-420.	2.9	78
420	To: Gerstein HC, Pogue J, Mann JFE, Lonn E, Dagenais GR, McQueen M, Yusuf S, for the HOPE investigators (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. <i>Diabetologia</i> 48:1749-1755. <i>Diabetologia</i> , 2006, 49, 611-612.	2.9	14
421	Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. <i>Diabetologia</i> , 2006, 49, 775-783.	2.9	42
422	The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. <i>Diabetologia</i> , 2006, 49, 1064-1070.	2.9	14
423	Effect of R-(+)- $\alpha$ -lipoic acid on experimental diabetic retinopathy. <i>Diabetologia</i> , 2006, 49, 1089-1096.	2.9	92
424	Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. <i>Diabetologia</i> , 2006, 49, 930-936.	2.9	283
425	Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. <i>Diabetologia</i> , 2006, 49, 1071-1080.	2.9	163
426	Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2006, 49, 846-854.	2.9	130
427	Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. <i>Diabetologia</i> , 2006, 49, 872-880.	2.9	39
428	Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. <i>Diabetologia</i> , 2006, 49, 1163-1168.	2.9	61
429	Understanding of diabetes prevention studies: questionnaire survey of professionals in diabetes care. <i>Diabetologia</i> , 2006, 49, 1742-1746.	2.9	58
430	Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. <i>Diabetologia</i> , 2006, 49, 1777-1784.	2.9	50
431	Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). <i>Diabetologia</i> , 2006, 49, 1761-1769.	2.9	303
432	Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular KATP channels. <i>Diabetologia</i> , 2006, 49, 2039-2048.	2.9	52
433	Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2006, 49, 1711-1721.	2.9	373
434	Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. <i>Diabetologia</i> , 2006, 49, 2058-2067.	2.9	28

#	ARTICLE	IF	CITATIONS
435	Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. <i>Diabetologia</i> , 2006, 49, 2024-2029.	2.9	36
436	Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4. <i>Diabetologia</i> , 2006, 49, 2437-2448.	2.9	52
437	Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling. <i>Diabetologia</i> , 2006, 49, 2572-2579.	2.9	30
438	The $\gamma$ 374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. <i>Diabetologia</i> , 2006, 49, 2745-2755.	2.9	63
439	Evidence for the homeostatic regulation of induced beta cell mass expansion. <i>Diabetologia</i> , 2006, 49, 2910-2919.	2.9	20
440	Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: The Fremantle Diabetes Study. <i>Diabetologia</i> , 2006, 49, 2634-2641.	2.9	135
441	Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76. <i>Diabetologia</i> , 2006, 49, 2892-2899.	2.9	17
442	Diabetes and stroke: Part one—Risk factors and pathophysiology. <i>Current Cardiology Reports</i> , 2006, 8, 23-28.	1.3	27
443	Is glycemic variability important to assessing antidiabetes therapies?. <i>Current Diabetes Reports</i> , 2006, 6, 350-356.	1.7	11
444	Is the metabolic syndrome a real clinical entity and should it receive drug treatment?. <i>Current Diabetes Reports</i> , 2006, 6, 357-364.	1.7	7
445	Are sulfonylureas passÃ©?. <i>Current Diabetes Reports</i> , 2006, 6, 373-377.	1.7	20
446	A public health approach to the diabetes epidemic: New York city's diabetes registry. <i>Current Diabetes Reports</i> , 2006, 6, 169-171.	1.7	2
447	Advanced glycation end products and vascular structure and function. <i>Current Hypertension Reports</i> , 2006, 8, 472-478.	1.5	27
448	Microdialysis as a tool in local pharmacodynamics. <i>AAPS Journal</i> , 2006, 8, E222-E235.	2.2	32
449	Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes. <i>Irish Journal of Medical Science</i> , 2006, 175, 36-41.	0.8	1
450	Structuring diabetes care in general practices: Many improvements, remaining challenges. <i>Irish Journal of Medical Science</i> , 2006, 175, 42-47.	0.8	11
451	Effects of insulin treatment on intracellular lipid metabolism in liver of diabetic rats. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2006, 26, 284-287.	1.0	1
452	Association of socio-economic status with diabetes prevalence and utilization of diabetes care services. <i>BMC Health Services Research</i> , 2006, 6, 124.	0.9	185



#	ARTICLE	IF	CITATIONS
453	Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Medicine, 2006, 4, 34.	2.3	87
454	Prevention and early detection of vascular complications of diabetes. BMJ: British Medical Journal, 2006, 333, 475-480.	2.4	164
455	Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?. BMJ: British Medical Journal, 2006, 333, 1200-1204.	2.4	53
456	The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients. Current Medical Research and Opinion, 2006, 22, 2301-2311.	0.9	3
457	Do sulfonylurea drugs increase the risk of cardiac events?. Cmaj, 2006, 174, 185-186.	0.9	54
458	Utilization and outcomes of HbA1c testing: a population-based study. Cmaj, 2006, 174, 327-329.	0.9	13
459	Multitherapy for diabetes. Cmaj, 2006, 175, 1247-1248.	0.9	0
460	Evaluation of Tumour Necrosis Factor Alpha, Interleukin-2 Soluble Receptor, Nitric Oxide Metabolites, and Lipids as Inflammatory Markers in Type 2 Diabetes Mellitus. Mediators of Inflammation, 2006, 2006, 1-7.	1.4	40
461	Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Cmaj, 2006, 174, 169-174.	0.9	186
462	Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart, 2006, 93, 1577-1583.	1.2	131
463	Evidence-Based Prescribing of Statins: A Developing World Perspective. PLoS Medicine, 2006, 3, e50.	3.9	10
464	Measuring Continuity of Care in Diabetes Mellitus: An Experience-Based Measure. Annals of Family Medicine, 2006, 4, 548-555.	0.9	48
465	Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgraduate Medical Journal, 2006, 82, 280-284.	0.9	240
466	Prevalence and Risk Factors for Urinary Incontinence in Women With Type 2 Diabetes and Impaired Fasting Glucose: Findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002. Diabetes Care, 2006, 29, 1307-1312.	4.3	114
467	From Bedside to Bench and Back Again: Research Issues in Animal Models of Human Disease. Biological Research for Nursing, 2006, 8, 78-88.	1.0	26
468	Contribution of Aldose Reductase to Diabetic Hyperproliferation of Vascular Smooth Muscle Cells. Diabetes, 2006, 55, 901-910.	0.3	59
469	Diabetes: How Are We Diagnosing and Initially Managing It?. Annals of Family Medicine, 2006, 4, 15-22.	0.9	27
470	Glycated haemoglobin (HbA 1c ) monitoring. BMJ: British Medical Journal, 2006, 333, 586-588.	2.4	34

#	ARTICLE	IF	CITATIONS
471	Management of Type 2 Diabetes in the Primary Care Setting: A Practice-Based Research Network Study. <i>Annals of Family Medicine</i> , 2006, 4, 23-31.	0.9	120
472	The Impact of Patient Preferences on the Cost-Effectiveness of Intensive Glucose Control in Older Patients With New-Onset Diabetes. <i>Diabetes Care</i> , 2006, 29, 259-264.	4.3	56
473	Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1006-1011.	3.3	806
474	Cognitive Dysfunction Is Associated With Poor Diabetes Control in Older Adults. <i>Diabetes Care</i> , 2006, 29, 1794-1799.	4.3	308
475	Disparities in HbA1c Levels Between African-American and Non-Hispanic White Adults With Diabetes: A meta-analysis. <i>Diabetes Care</i> , 2006, 29, 2130-2136.	4.3	296
476	Effect of crew resource management on diabetes care and patient outcomes in an inner-city primary care clinic. <i>Quality and Safety in Health Care</i> , 2007, 16, 244-247.	2.5	49
477	Patient Perceptions of Quality of Life With Diabetes-Related Complications and Treatments. <i>Diabetes Care</i> , 2007, 30, 2478-2483.	4.3	223
478	Pharmacotherapies for Diabetic Retinopathy: Present and Future. <i>Experimental Diabetes Research</i> , 2007, 2007, 1-8.	3.8	18
479	The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. <i>Bulletin of the World Health Organization</i> , 2007, 85, 279-288.	1.5	380
480	Use of Chronic Care Model Elements Is Associated With Higher-Quality Care for Diabetes. <i>Annals of Family Medicine</i> , 2007, 5, 14-20.	0.9	143
481	Glycaemic control is a myth. <i>BMJ: British Medical Journal</i> , 2007, 334, 1236.2-1236.	2.4	0
482	Circulating Glycotoxins and Dietary Advanced Glycation Endproducts: Two Links to Inflammatory Response, Oxidative Stress, and Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2007, 62, 427-433.	1.7	450
483	Screening for diabetes in women with polycystic ovary syndrome. <i>Cmaj</i> , 2007, 176, 951-952.	0.9	1
484	Diabetes and Arterial Extracellular Matrix Changes in a Porcine Model of Atherosclerosis. <i>Journal of Histochemistry and Cytochemistry</i> , 2007, 55, 1149-1157.	1.3	52
485	The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. <i>Current Medical Research and Opinion</i> , 2007, 23, 1423-1430.	0.9	20
486	Competing Demands or Clinical Inertia: The Case of Elevated Glycosylated Hemoglobin. <i>Annals of Family Medicine</i> , 2007, 5, 196-201.	0.9	184
487	Specialists versus generalists in the era of pay for performance: "A plague o' both your houses!". <i>Quality and Safety in Health Care</i> , 2007, 16, 3-5.	2.5	8
488	Diabetes Downregulates Large-Conductance Ca <sup>2+</sup> -Activated Potassium $\hat{1}$ 1 Channel Subunit in Retinal Arteriolar Smooth Muscle. <i>Circulation Research</i> , 2007, 100, 703-711.	2.0	129

#	ARTICLE	IF	CITATIONS
489	Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. American Journal of Pathology, 2007, 171, 438-451.	1.9	235
490	Reduced Oxidant Stress and Extended Lifespan in Mice Exposed to a Low Glycotoxin Diet. American Journal of Pathology, 2007, 170, 1893-1902.	1.9	157
491	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Canadian Journal of Cardiology, 2007, 23, 21-45.	0.8	131
492	Insulin Therapy in Diabetes Mellitus. Drugs, 2007, 67, 1813-1827.	4.9	20
493	Quality of care: assessment. Lipids in Health and Disease, 2007, 6, 12.	1.2	6
494	Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada. Pharmacoeconomics, 2007, 25, 253-266.	1.7	41
495	Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin. Pharmacoeconomics, 2007, 25, 881-897.	1.7	34
496	Acetyl-L-Carnitine in Diabetic Polyneuropathy. CNS Drugs, 2007, 21, 13-23.	2.7	31
497	Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Scandinavian Journal of Primary Health Care, 2007, 25, 147-153.	0.6	11
498	Self-monitoring of blood glucose and glycaemic control in type 2 diabetes. Scandinavian Journal of Primary Health Care, 2007, 25, 140-146.	0.6	18
499	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 fgBT /Overlock 10 T	1.0	2,331
500	Smooth muscle cell signal transduction: Implications of vascular biology for vascular surgeons. Journal of Vascular Surgery, 2007, 45, A15-A24.	0.6	95
501	Dietary advice for treatment of type 2 diabetes mellitus in adults. The Cochrane Library, 2010, 2010, CD004097.	1.5	83
503	Studying the Hurdles of Insulin Prescription (SHIPÂ©): development, scoring and initial validation of a new self-administered questionnaire. Health and Quality of Life Outcomes, 2007, 5, 53.	1.0	30
504	Drug-Induced Endocrine and Metabolic Disorders. Drug Safety, 2007, 30, 215-245.	1.4	42
505	Insulin Lispro. Drugs, 2007, 67, 407-434.	4.9	34
506	Exenatide. Drugs, 2007, 67, 935-954.	4.9	89
507	Pathophysiology and Management of Diabetic Gastropathy. Drugs, 2007, 67, 1671-1687.	4.9	29

#	ARTICLE	IF	CITATIONS
508	Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index. Clinical Drug Investigation, 2007, 27, 279-285.	1.1	60
509	Biphasic Insulin Aspart in Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2007, 27, 299-324.	1.1	12
510	Rosiglitazone for type 2 diabetes mellitus. The Cochrane Library, 2007, , CD006063.	1.5	67
511	Independent Associations of Fasting Insulin, Glucose, and Glycated Haemoglobin with Stroke and Coronary Heart Disease in Older Women. PLoS Medicine, 2007, 4, e263.	3.9	48
512	Achieving American Diabetes Association Goals in Hiv-Seropositive Patients with Diabetes Mellitus. Baylor University Medical Center Proceedings, 2007, 20, 118-123.	0.2	22
513	Clinical Experience of an Iontophoresis Based Glucose Measuring System. Journal of Korean Medical Science, 2007, 22, 70.	1.1	20
514	Epidemiology, Clinical and Complications Profile of Diabetes in Saudi Arabia: A Review. Annals of Saudi Medicine, 2007, 27, 241-250.	0.5	109
515	Patient Engagement and Coaching for Health: The PEACH study – a cluster randomised controlled trial using the telephone to coach people with type 2 diabetes to engage with their GPs to improve diabetes care: a study protocol. BMC Family Practice, 2007, 8, 20.	2.9	36
516	Changing illness perceptions in patients with poorly controlled type 2 diabetes, a randomised controlled trial of a family-based intervention: protocol and pilot study. BMC Family Practice, 2007, 8, 36.	2.9	40
517	Walking behaviour and glycemic control in type 2 diabetes: seasonal and gender differences--study design and methods. Cardiovascular Diabetology, 2007, 6, 1.	2.7	64
518	Clinical and medication profiles stratified by household income in patients referred for diabetes care. Cardiovascular Diabetology, 2007, 6, 11.	2.7	19
519	Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovascular Diabetology, 2007, 6, 20.	2.7	72
520	Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes. Cardiovascular Ultrasound, 2007, 5, 32.	0.5	36
521	A pragmatic cluster randomised controlled trial of a Diabetes REcall And Management system: the DREAM trial. Implementation Science, 2007, 2, 6.	2.5	23
522	A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopathic Medicine and Primary Care, 2007, 1, 9.	0.5	15
523	Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine, 2007, 24, 626-634.	1.2	77
524	Diabetic periodontitis: a model for activated innate immunity and impaired resolution of inflammation. Periodontology 2000, 2007, 43, 233-244.	6.3	112
525	Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. International Journal of Clinical Practice, 2007, 61, 20-27.	0.8	39

#	ARTICLE	IF	CITATIONS
530	Accumulation of dietary glycotoxins in the reproductive system of normal female rats. <i>Journal of Molecular Medicine</i> , 2007, 85, 1413-1420.	1.7	84
531	Increased expression of CCAAT/enhancer binding protein- $\beta$ and $\gamma$ and monocyte chemoattractant protein-1 genes in aortas from hyperinsulinaemic rats. <i>Diabetologia</i> , 2007, 50, 481-489.	2.9	31
532	A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> , 2007, 50, 259-267.	2.9	422
533	Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. <i>Diabetologia</i> , 2007, 50, 452-460.	2.9	65
534	Comment on: Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> 49:1711-1721. <i>Diabetologia</i> , 2007, 50, 693-694.	2.9	1
535	The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. <i>Diabetologia</i> , 2007, 50, 643-653.	2.9	122
536	Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. <i>Diabetologia</i> , 2007, 50, 1140-1147.	2.9	803
537	Improved survival rate in patients with diabetes and end-stage renal disease in Denmark. <i>Diabetologia</i> , 2007, 50, 922-929.	2.9	45
538	Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. <i>Diabetologia</i> , 2007, 50, 1170-1177.	2.9	69
539	Glucose tolerance is negatively associated with circulating progenitor cell levels. <i>Diabetologia</i> , 2007, 50, 2156-2163.	2.9	92
540	GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. <i>Diabetologia</i> , 2007, 50, 2052-2060.	2.9	54
541	Relationship between glycated haemoglobin levels and mean glucose levels over time. <i>Diabetologia</i> , 2007, 50, 2239-2244.	2.9	371
542	Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. <i>Diabetologia</i> , 2007, 50, 2553-2561.	2.9	193
543	Quality of life, health status and clinical outcomes in Type 2 diabetes patients. <i>Quality of Life Research</i> , 2007, 16, 165-177.	1.5	132
544	Maximizing the value of validation findings to better understand treatment satisfaction issues for diabetes. <i>Quality of Life Research</i> , 2007, 16, 1053-1063.	1.5	24
545	Utilities and disutilities for type 2 diabetes treatment-related attributes. <i>Quality of Life Research</i> , 2007, 16, 1251-1265.	1.5	102
546	Cardiovascular disease risk in youth with diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 7, 197-204.	2.6	28
547	A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort. <i>European Journal of Epidemiology</i> , 2007, 22, 151-157.	2.5	13

#	ARTICLE	IF	CITATIONS
548	The role of glucose as an independent cardiovascular risk factor. <i>Current Diabetes Reports</i> , 2007, 7, 43-49.	1.7	13
549	Gene discovery in diabetic nephropathy. <i>Current Diabetes Reports</i> , 2007, 7, 139-145.	1.7	9
550	ADOPT: Lessons from Comparison of Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. <i>Current Diabetes Reports</i> , 2007, 7, 173-174.	1.7	8
551	Glycotoxins in the diet promote diabetes and diabetic complications. <i>Current Diabetes Reports</i> , 2007, 7, 235-241.	1.7	66
552	Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers. <i>Current Diabetes Reports</i> , 2007, 7, 329-332.	1.7	0
553	Who should benefit from the use of alpha-glucosidase inhibitors?. <i>Current Diabetes Reports</i> , 2007, 7, 333-339.	1.7	41
554	Which basal insulin should be used in patients with type 2 diabetes mellitus?. <i>Current Diabetes Reports</i> , 2007, 7, 348-352.	1.7	3
555	Exenatide and rimonabant: New treatments that may be useful in the management of diabetes and obesity. <i>Current Diabetes Reports</i> , 2007, 7, 369-375.	1.7	6
556	Atherosclerotic renovascular disease and renal impairment: Can we predict the effect of intervention?. <i>Current Hypertension Reports</i> , 2007, 9, 140-147.	1.5	3
557	Chronic hyperglycemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications. <i>Genes and Nutrition</i> , 2007, 2, 195-208.	1.2	47
558	Can a Chronic Care Model Collaborative Reduce Heart Disease Risk in Patients with Diabetes?. <i>Journal of General Internal Medicine</i> , 2007, 22, 215-222.	1.3	89
559	Sources of Variation in Physician Adherence with Clinical Guidelines: Results from a Factorial Experiment. <i>Journal of General Internal Medicine</i> , 2007, 22, 289-296.	1.3	88
560	Racial/Ethnic Differences in Multiple Self-Care Behaviors in Adults with Diabetes. <i>Journal of General Internal Medicine</i> , 2007, 22, 115-120.	1.3	82
561	Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic Control. <i>Journal of General Internal Medicine</i> , 2007, 22, 453-458.	1.3	125
562	Racial Differences in Long-Term Self-Monitoring Practice Among Newly Drug-Treated Diabetes Patients in an HMO. <i>Journal of General Internal Medicine</i> , 2007, 22, 1506-1513.	1.3	16
563	The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 531-538.	0.8	85
564	Effect of Laparoscopic Mini-Gastric Bypass for Type 2 Diabetes Mellitus: Comparison of BMI $\geq 35$ and $< 35$ kg/m <sup>2</sup> . <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 945-952.	0.9	197
565	Diabetic nephropathy in American Indians, with a special emphasis on the pima Indians. <i>Current Diabetes Reports</i> , 2008, 8, 486-493.	1.7	18

#	ARTICLE	IF	CITATIONS
566	The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. <i>Cardiovascular Diabetology</i> , 2008, 7, 29.	2.7	141
567	Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: A follow up study. <i>BMC Health Services Research</i> , 2008, 8, 189.	0.9	25
568	A cost effectiveness study of integrated care in health services delivery: a diabetes program in Australia. <i>BMC Health Services Research</i> , 2008, 8, 205.	0.9	31
569	Diabetes experts' reasoning about diabetes prevention studies: a questionnaire survey. <i>BMC Research Notes</i> , 2008, 1, 90.	0.6	8
570	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2010, 2010, CD006739.	1.5	175
571	New Drugs for Type 2 Diabetes Mellitus. <i>Drugs</i> , 2008, 68, 2131-2162.	4.9	105
572	Deleterious Outcomes after Abrupt Transition from InsulinÂGlargine toÂInsulin Detemir in Patients with TypeÂ1ÂDiabetesÂMellitus. <i>Clinical Drug Investigation</i> , 2008, 28, 697-701.	1.1	14
573	Weight Change in Diabetes and Glycemic and Blood Pressure Control. <i>Diabetes Care</i> , 2008, 31, 1960-1965.	4.3	118
574	A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2198-2202.	4.3	377
575	Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. <i>Cmaj</i> , 2008, 179, 920-926.	0.9	37
576	Comparison of Combined Aerobic and High-Force Eccentric Resistance Exercise With Aerobic Exercise Only for People With Type 2 Diabetes Mellitus. <i>Physical Therapy</i> , 2008, 88, 1345-1354.	1.1	106
577	Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. <i>Diabetes Care</i> , 2008, 31, 2086-2091.	4.3	380
578	Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. <i>Physical Therapy</i> , 2008, 88, 1322-1335.	1.1	727
579	Additive Interaction of Hyperglycemia and Albuminuria on Risk of Ischemic Stroke in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2294-2300.	4.3	27
580	Cardiovascular Outcomes in Trials of Oral Diabetes Medications. <i>Archives of Internal Medicine</i> , 2008, 168, 2070.	4.3	266
581	An Appreciation of Robert Turner. <i>Diabetes</i> , 2008, 57, 2918-2921.	0.3	2
582	Improved Survival of Diabetic Foot Ulcer Patients 1995â€“2008. <i>Diabetes Care</i> , 2008, 31, 2143-2147.	4.3	129
583	Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence. <i>Clinical Medicine and Research</i> , 2008, 6, 54-67.	0.4	107

#	ARTICLE	IF	CITATIONS
584	Effect of Acute and Recurrent Hypoglycemia on Changes in Brain Glycogen Concentration. <i>Endocrinology</i> , 2008, 149, 1499-1504.	1.4	82
585	Linkage analysis of glomerular filtration rate in American Indians. <i>Kidney International</i> , 2008, 74, 1185-1191.	2.6	22
586	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2008, 168, 1867.	4.3	98
587	Self-Monitoring of Blood Glucose Before and After Medicare Expansion Among Medicare Beneficiaries With Diabetes Who Do Not Use Insulin. <i>American Journal of Public Health</i> , 2008, 98, 358-364.	1.5	7
588	Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 575-596.	1.0	230
589	Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 561-574.	1.0	30
590	Therapeutic interventions and oxidative stress in diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 192.	3.0	24
591	Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage. <i>Diabetes</i> , 2009, 58, 215-226.	0.3	188
592	Multifaceted Determinants for Achieving Glycemic Control. <i>Diabetes Care</i> , 2009, 32, 227-233.	4.3	248
593	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. <i>Diabetes Care</i> , 2009, 32, 187-192.	4.3	624
594	Rates of Progression in Diabetic Retinopathy During Different Time Periods. <i>Diabetes Care</i> , 2009, 32, 2307-2313.	4.3	171
595	Factors Associated With Intensification of Oral Diabetes Medications in Primary Care Provider-Patient Dyads: A Cohort Study. <i>Diabetes Care</i> , 2009, 32, 25-31.	4.3	50
596	Changes in Albumin Excretion in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2009, 32, 720-725.	4.3	22
597	The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2009, 121, 94-107.	0.9	80
598	Green tea ( <i>Camellia sinensis</i> ) Attenuates Nephropathy by Downregulating Nox4 NADPH Oxidase in Diabetic Spontaneously Hypertensive Rats. <i>Journal of Nutrition</i> , 2009, 139, 96-100.	1.3	59
599	How Our Current Medical Care System Fails People With Diabetes: Lack of timely, appropriate clinical decisions. <i>Diabetes Care</i> , 2009, 32, 370-372.	4.3	65
600	Secular Trends in Diabetes-Related Preventable Hospitalizations in the United States, 1998-2006. <i>Diabetes Care</i> , 2009, 32, 1213-1217.	4.3	53
601	Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2009, 23, 1313-1320.	1.3	107



#	ARTICLE	IF	CITATIONS
602	Ablation of NF- $\kappa$ B expression by small interference RNA prevents the dysfunction of human umbilical vein endothelial cells induced by high glucose. <i>Endocrine</i> , 2009, 35, 63-74.	1.1	14
603	Blood Glucose Monitoring is Associated with Better Glycemic Control in Type 2 Diabetes: A Database Study. <i>Journal of General Internal Medicine</i> , 2009, 24, 48-52.	1.3	12
604	Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. <i>Diabetologia</i> , 2009, 52, 38-41.	2.9	49
605	Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. <i>Diabetologia</i> , 2009, 52, 17-30.	2.9	635
606	INVEST: Results of combined strategies to control blood pressure. <i>Clinical Cardiology</i> , 2001, 24, V-12-V-13.	0.7	3
607	Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. <i>Diabetes Care</i> , 2009, 32, 193-203.	4.3	2,988
608	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). <i>Diabetes Care</i> , 2009, 32, 1224-1230.	4.3	768
609	Glycaemic status influences the nature and severity of coronary artery disease. <i>Diabetologia</i> , 2010, 53, 652-658.	2.9	34
610	Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. <i>Diabetologia</i> , 2010, 53, 1076-1083.	2.9	94
611	Determinants of glucose control in patients with chronic pancreatitis. <i>Diabetologia</i> , 2010, 53, 1062-1069.	2.9	36
612	Hyperglycaemia-induced pro-inflammatory responses by retinal M $\mu$ ller glia are regulated by the receptor for advanced glycation end-products (RAGE). <i>Diabetologia</i> , 2010, 53, 2656-2666.	2.9	156
613	Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 8-19.	0.5	61
614	Management of dyslipidemia in people with type 2 diabetes mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010, 11, 41-51.	2.6	29
615	Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist. <i>Diabetology and Metabolic Syndrome</i> , 2010, 2, 2.	1.2	12
616	Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. <i>Pharmaceuticals</i> , 2010, 3, 764-781.	1.7	23
617	Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2010, 6, 145.	1.0	82
618	Inhaled insulin: overview of a novel route of insulin administration. <i>Vascular Health and Risk Management</i> , 2010, 6, 47.	1.0	48
619	Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. <i>Vascular Health and Risk Management</i> , 2010, 6, 671.	1.0	17

#	ARTICLE	IF	CITATIONS
620	Possible Links between Intestinal Permeability and Food Processing: A Potential Therapeutic Niche for Glutamine. Clinics, 2010, 65, 635-643.	0.6	38
621	The association between estimated average glucose levels and fasting plasma glucose levels. Clinics, 2010, 65, 1077-1080.	0.6	38
622	Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes. Diabetes Care, 2010, 33, 695-700.	4.3	47
623	Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care, 2010, 33, 1578-1584.	4.3	435
624	Secular Trends in Treatment and Control of Type 2 Diabetes in an American Indian Population: A 30-Year Longitudinal Study. Diabetes Care, 2010, 33, 2383-2389.	4.3	10
625	Can Postprandial Blood Glucose Excursion Be Predicted in Type 2 Diabetes?. Diabetes Care, 2010, 33, 1913-1918.	4.3	17
626	Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study. Diabetes Care, 2010, 33, 1509-1515.	4.3	160
627	Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. Pharmaceuticals, 2010, 3, 3005-3020.	1.7	115
628	DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care, 2010, 33, 1255-1261.	4.3	308
629	Neuropathy: The Crystal Ball for Cardiovascular Disease?. Diabetes Care, 2010, 33, 1688-1690.	4.3	78
630	Day-to-Day Variation of Insulin Requirements of Patients With Type 2 Diabetes and End-Stage Renal Disease Undergoing Maintenance Hemodialysis. Diabetes Care, 2010, 33, 1409-1412.	4.3	59
631	Antioxidant Protective Effect of Glibenclamide and Metformin in Combination with Honey in Pancreas of Streptozotocin-Induced Diabetic Rats. International Journal of Molecular Sciences, 2010, 11, 2056-2066.	1.8	131
632	Cost-Effectiveness of Bariatric Surgery for Severely Obese Adults With Diabetes. Diabetes Care, 2010, 33, 1933-1939.	4.3	130
633	Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. New England Journal of Medicine, 2010, 362, 800-811.	13.9	1,258
634	Recommendations for Management of Diabetes During Ramadan. Diabetes Care, 2010, 33, 1895-1902.	4.3	318
635	Sitagliptin. Drugs, 2010, 70, 489-512.	4.9	96
636	Influence of BMI, Age and Duration of Diabetes Mellitus on Glycaemic Control with Twice-Daily Injections of Biphasic Insulin Aspart 30 versus Multiple Daily Injections of Insulin Aspart (JDDM 18). Clinical Drug Investigation, 2010, 30, 35-40.	1.1	9
637	A Review of 25 Years' Experience with the NovoPen® Family of Insulin Pens in the Management of Diabetes Mellitus. Clinical Drug Investigation, 2010, 30, 643-674.	1.1	20

#	ARTICLE	IF	CITATIONS
638	Clinical efficacy and patient satisfaction with U-500 insulin use. <i>Diabetes Research and Clinical Practice</i> , 2010, 88, 259-264.	1.1	38
639	The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy. <i>Diabetes Care</i> , 2010, 33, 1224-1229.	4.3	82
640	Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 359-372.	0.6	97
641	A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment. <i>Pharmacoeconomics</i> , 2010, 28, 255-277.	1.7	48
642	Intervention Mapping as a Guide for the Development of a Diabetes Peer Support Intervention in Rural Alabama. <i>Preventing Chronic Disease</i> , 2012, 9, E36.	1.7	37
643	Insulin-Induced Hypoglycemia and Its Effect on the Brain. <i>Diabetes</i> , 2011, 60, 1856-1858.	0.3	12
644	Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 368-375.	1.4	31
645	Comparison of Antioxidant Effects of Honey, Glibenclamide, Metformin, and Their Combinations in the Kidneys of Streptozotocin-Induced Diabetic Rats. <i>International Journal of Molecular Sciences</i> , 2011, 12, 829-843.	1.8	90
646	Primary Prevention of Heart Failure. <i>ISRN Cardiology</i> , 2012, 2012, 1-15.	1.6	18
647	Management of Diabetes Mellitus: Could Simultaneous Targeting of Hyperglycemia and Oxidative Stress Be a Better Panacea?. <i>International Journal of Molecular Sciences</i> , 2012, 13, 2965-2972.	1.8	18
648	Effects of <i>Cinnamomum zeylanicum</i> (Ceylon cinnamon) on blood glucose and lipids in a diabetic and healthy rat model. <i>Pharmacognosy Research (discontinued)</i> , 2012, 4, 73.	0.3	50
649	The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease—A Retrospective Single Center Experience. <i>ISRN Cardiology</i> , 2012, 2012, 1-5.	1.6	0
650	Can tight glycemic control in diabetes benefit cognition?. <i>Nature Reviews Neurology</i> , 2012, 8, 124-126.	4.9	7
651	Vascular Complications and Diabetes: Current Therapies and Future Challenges. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-14.	0.6	43
652	Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?. <i>Current Diabetes Reports</i> , 2013, 13, 350-361.	1.7	28
653	Chapter 5: Referral to specialists and models of care. <i>Kidney International Supplements</i> , 2013, 3, 112-119.	4.6	38
654	Chapter 3: Management of progression and complications of CKD. <i>Kidney International Supplements</i> , 2013, 3, 73-90.	4.6	121
655	Computer-based diabetes self-management interventions for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2013, 2013, CD008776.	1.5	241

#	ARTICLE	IF	CITATIONS
656	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. <i>BMJ Open</i> , 2013, 3, e003834.	0.8	9
657	Red Meat, Dietary Heme Iron, and Risk of Type 2 Diabetes: The Involvement of Advanced Lipoxidation Endproducts. <i>Advances in Nutrition</i> , 2013, 4, 403-411.	2.9	53
659	Protective Effects of Astragaloside IV on db/db Mice with Diabetic Retinopathy. <i>PLoS ONE</i> , 2014, 9, e112207.	1.1	38
660	Treatment non-adherence among patients with poorly controlled type 2 diabetes in ambulatory care settings in southwestern Nigeria. <i>African Health Sciences</i> , 2014, 14, 1.	0.3	29
661	Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2014, 3, 923-943.	1.0	46
662	The Burden of Diabetes in Argentina. <i>Global Journal of Health Science</i> , 2014, 7, 124-33.	0.1	7
663	Clinical immunology Abnormal levels of age-elastin derived peptides in sera of diabetic patients with arterial hypertension. <i>Central-European Journal of Immunology</i> , 2014, 3, 345-351.	0.4	6
664	The HbA1c and All-Cause Mortality Relationship in Patients with Type 2 Diabetes is J-Shaped: A Meta-Analysis of Observational Studies. <i>Review of Diabetic Studies</i> , 2014, 11, 138-152.	0.5	77
665	Type 2 Diabetes Pharmacoeconomics Update 2014: Safety Versus Efficacy. <i>Current Diabetes Reports</i> , 2014, 14, 563.	1.7	5
666	Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipooptosis. <i>Cardiovascular Diabetology</i> , 2014, 13, 152.	2.7	37
667	Identified single-nucleotide polymorphisms and haplotypes at 16q22.1 increase diabetic nephropathy risk in Han Chinese population. <i>BMC Genetics</i> , 2014, 15, 113.	2.7	15
668	Approaches to Display of Multiple-Point Glucose Profiles. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 1233-1238.	1.3	0
669	Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb) Tj ETQq0 0 0 rgBT /Overlock Diabetes Research and Care, 2014, 2, e000021.	1.2	3
670	Vessel Ultrasound Sonographic Assessment of Soluble Receptor for Advanced Glycation End Products Efficacy in a Rat Balloon Injury Model. <i>Current Therapeutic Research</i> , 2014, 76, 110-115.	0.5	1
671	Pharmacology in Peripheral Arterial Disease: What the Interventional Radiologist Needs to Know. <i>Seminars in Interventional Radiology</i> , 2014, 31, 330-337.	0.3	6
672	Association of fasting insulin and C peptide with diabetic retinopathy in Latinos with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000027.	1.2	21
673	Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. <i>BMJ Open</i> , 2014, 4, e005752.	0.8	31
674	Dicarbonyl Stress and Atherosclerosis: Is It All RAGE?. <i>Diabetes</i> , 2014, 63, 3587-3589.	0.3	7

#	ARTICLE	IF	CITATIONS
675	Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Therapeutic Advances in Endocrinology and Metabolism, 2014, 5, 95-123.	1.4	13
676	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. The Cochrane Library, 2014, , CD008721.	1.5	43
677	Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. Diabetes Spectrum, 2014, 27, 180-188.	0.4	32
678	The effects of elevated hemoglobin A1c in patients with type 2 diabetes mellitus on dental implants. Journal of the American Dental Association, 2014, 145, 1218-1226.	0.7	71
679	Prepregnancy low-carbohydrate dietary pattern and risk of gestational diabetes mellitus: a prospective cohort study. American Journal of Clinical Nutrition, 2014, 99, 1378-1384.	2.2	109
680	Lycopene supplementation reduces TNF- $\alpha$ via RAGE in the kidney of obese rats. Nutrition and Diabetes, 2014, 4, e142-e142.	1.5	46
681	Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. BMC Cardiovascular Disorders, 2014, 14, 162.	0.7	6
682	Epidemiology of hypertension and its relationship with type 2 diabetes and obesity in eastern Morocco. SpringerPlus, 2014, 3, 644.	1.2	17
683	Costing of diabetes mellitus type II in Cambodia. Health Economics Review, 2014, 4, 24.	0.8	15
684	Clinical Considerations for Insulin Pharmacotherapy in Ambulatory Care, Part One: Introduction and Review of Current Products and Guidelines. Clinical Diabetes, 2014, 32, 66-75.	1.2	4
685	Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. Journal of Diabetes Investigation, 2014, 5, 701-708.	1.1	23
686	A Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes. Diabetes Therapy, 2014, 5, 385-402.	1.2	11
687	Chronic kidney disease in the elderly: evaluation and management. Clinical Practice (London, England), 2014, 11, 525-535.	0.1	161
688	Listening to Older Adults' Values and Preferences for Type 2 Diabetes Care: A Qualitative Study. Diabetes Spectrum, 2014, 27, 44-49.	0.4	26
689	TNF- $\alpha$ and Microalbuminuria in Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2014, 2014, 1-7.	1.0	55
690	Speaking to Patients About Diabetes Risk: Is Terminology Important?. Clinical Diabetes, 2014, 32, 90-95.	1.2	2
691	Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus. Current Cardiology Reports, 2014, 16, 541.	1.3	14
692	Peripheral Artery Disease and Chronic Kidney Disease: Clinical Synergy to Improve Outcomes. Advances in Chronic Kidney Disease, 2014, 21, 460-471.	0.6	84

#	ARTICLE	IF	CITATIONS
693	Multiple-Input Subject-Specific Modeling of Plasma Glucose Concentration for Feedforward Control. <i>Industrial &amp; Engineering Chemistry Research</i> , 2014, 53, 18216-18225.	1.8	7
694	Factors associated with a diabetes diagnosis and late diabetes diagnosis for males and females. <i>Journal of Clinical and Translational Endocrinology</i> , 2014, 1, 77-84.	1.0	28
695	Noninvasive skin fluorescence spectroscopy for detection of abnormal glucose tolerance. <i>Journal of Clinical and Translational Endocrinology</i> , 2014, 1, 92-99.	1.0	7
696	Comprehensive approach to diabetic nephropathy. <i>Kidney Research and Clinical Practice</i> , 2014, 33, 121-131.	0.9	78
697	Biomarkers in diabetic nephropathy: Present and future. <i>World Journal of Diabetes</i> , 2014, 5, 763.	1.3	116
698	Pancreas transplantation in type II diabetes mellitus. <i>World Journal of Transplantation</i> , 2014, 4, 216.	0.6	21
699	Transthyretin Cardiac Amyloidosis: Pathogenesis, Treatments, and Emerging Role in Heart Failure with Preserved Ejection Fraction. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8s1, CMC.S15719.	0.6	30
700	Role of Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 in myocardial cells in diabetes. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 67-73.	0.8	10
701	Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose. <i>Cardiovascular Diabetology</i> , 2015, 14, 94.	2.7	19
702	The Kidney Awareness Registry and Education (KARE) study: protocol of a randomized controlled trial to enhance provider and patient engagement with chronic kidney disease. <i>BMC Nephrology</i> , 2015, 16, 166.	0.8	30
703	Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1011-1020.	2.2	73
704	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin): A multicenter, randomized, open-label, non-inferiority trial. <i>Journal of Diabetes Investigation</i> , 2015, 6, 182-191.	1.1	18
705	Family interventions to improve diabetes outcomes for adults. <i>Annals of the New York Academy of Sciences</i> , 2015, 1353, 89-112.	1.8	192
706	Ribosylation triggering Alzheimer's disease-like tau hyperphosphorylation via activation of cAMP-dependent kinase II. <i>Aging Cell</i> , 2015, 14, 754-763.	3.0	42
707	The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. <i>International Journal of Clinical Practice</i> , 2015, 69, 1071-1087.	0.8	29
708	Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2015, 6, 219-226.	1.1	7
709	Current status of glucose, blood pressure and lipid management in type 2 diabetes clinic attendees in sfahan, Iran. <i>Journal of Diabetes Investigation</i> , 2015, 6, 716-725.	1.1	13
710	Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat. <i>British Journal of Nutrition</i> , 2015, 114, 1797-1806.	1.2	30

#	ARTICLE	IF	CITATIONS
711	Relief of diabetes by duodenal-jejunal bypass sleeve implantation in the high-fat diet and streptozotocin-induced diabetic rat model is associated with an increase in GLP-1 levels and the number of GLP-1-positive cells. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1355-1363.	0.8	11
712	Diabetic Retinopathy: Retina-specific Methods for Maintenance of Diabetic Rodents and Evaluation of Vascular Histopathology and Molecular Abnormalities. <i>Current Protocols in Mouse Biology</i> , 2015, 5, 247-270.	1.2	47
713	Evaluating the implementation of a national clinical programme for diabetes to standardise and improve services: a realist evaluation protocol. <i>Implementation Science</i> , 2015, 11, 107.	2.5	18
714	Associations among glycemic excursions, glycated hemoglobin and high-sensitivity C-reactive protein in patients with poorly controlled type 2 diabetes mellitus. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1937-1942.	0.8	6
715	Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e009116-e009116.	0.8	36
716	Prevalence and Management of Diabetic Nephropathy in Western Countries. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 1-14.	1.2	49
717	Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2015, 8, CMED.S31756.	1.0	2
718	Electrochemical skin conductance to detect sudomotor dysfunction, peripheral neuropathy and the risk of foot ulceration among Saudi patients with diabetes mellitus. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 15, 29.	0.8	16
719	Paradox of using intensive lowering of blood glucose in diabetics and strategies to overcome it and decrease cardiovascular risks. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 791-800.	0.7	3
720	A review of diabetes prevention program translations: use of cultural adaptation and implementation research. <i>Translational Behavioral Medicine</i> , 2015, 5, 401-414.	1.2	83
721	Comparison of the Adherence to the American Diabetes Association Guidelines of Diabetes Care in Primary Care and Subspecialty Clinics. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 14, 35.	0.8	9
722	Long-term effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM): a population-based cohort study. <i>Cardiovascular Diabetology</i> , 2015, 14, 105.	2.7	38
723	Six biases™ against patients and carers in evidence-based medicine. <i>BMC Medicine</i> , 2015, 13, 200.	2.3	176
724	Association of inpatient and outpatient glucose management with inpatient mortality among patients with and without diabetes at a major academic medical center. <i>Journal of Hospital Medicine</i> , 2015, 10, 228-235.	0.7	3
725	Treatment of periodontal disease for glycaemic control in people with diabetes mellitus. <i>The Cochrane Library</i> , 2018, 2018, CD004714.	1.5	169
726	Long-term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	9
727	New onset diabetes after transplantation: Not another acronym!. <i>JRSM Open</i> , 2015, 6, 205427041456716.	0.2	1
728	Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany - a retrospective cohort and case control study in claims data of a large statutory health insurance. <i>BMC Public Health</i> , 2015, 15, 855.	1.2	55

#	ARTICLE	IF	CITATIONS
729	Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. <i>BMC Endocrine Disorders</i> , 2015, 15, 49.	0.9	12
730	Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. <i>BMC Endocrine Disorders</i> , 2015, 15, 57.	0.9	6
731	Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. <i>BMC Endocrine Disorders</i> , 2015, 15, 67.	0.9	19
732	Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict. <i>BMC Health Services Research</i> , 2015, 16, 10.	0.9	56
733	Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. <i>Cardiovascular Diabetology</i> , 2015, 14, 83.	2.7	46
734	Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 91.	1.2	19
735	Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. <i>Diabetology and Metabolic Syndrome</i> , 2015, 7, 95.	1.2	16
736	Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. <i>Archives of Public Health</i> , 2015, 73, 43.	1.0	133
737	Effect of metabolic control on oxidative stress, subclinical atherosclerosis and peripheral artery disease in diabetic patients. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 14, 84.	0.8	14
738	Association of more negative attitude towards commencing insulin with lower glycosylated hemoglobin (HbA1c) level: a survey on insulin-naïve type 2 diabetes mellitus Chinese patients. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 15, 3.	0.8	9
739	The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2015, 28, 227-229.	0.4	4
740	Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1051-1063.	1.1	79
741	Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1194-1197.	2.2	6
742	Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 145-161.	2.3	31
743	Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients. <i>Journal of Cardiovascular Imaging</i> , 2015, 23, 233.	0.8	2
744	Low HbA1c and Increased Mortality Risk-is Frailty a Confounding Factor?. , 2015, 6, 262.		30
745	Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4355.	2.0	16
746	The Optimal Cutoff Value of Glycated Hemoglobin for Detection of Diabetic Retinopathy. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 16.	1.8	6



#	ARTICLE	IF	CITATIONS
747	Serum Ceruloplasmin Level as a Predictor for the Progression of Diabetic Nephropathy in Korean Men with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 230.	1.8	28
748	Insulin Initiation in Insulin-Naïve Korean Type 2 Diabetic Patients Inadequately Controlled on Oral Antidiabetic Drugs in Real-World Practice: The Modality of Insulin Treatment Evaluation Study. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 481.	1.8	12
749	Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease. <i>Research in Cardiovascular Medicine</i> , 2015, 4, 5.	0.2	50
750	Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 415.	1.1	41
751	Improvements in the Management of Diabetic Nephropathy. <i>Review of Diabetic Studies</i> , 2015, 12, 119-133.	0.5	65
752	Effect of Tai Chi Exercise Combined with Mental Imagery Theory in Improving Balance in a Diabetic and Elderly Population. <i>Medical Science Monitor</i> , 2015, 21, 3054-3061.	0.5	17
753	Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. <i>Vascular Health and Risk Management</i> , 2015, 11, 107.	1.0	10
754	Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 137.	1.1	8
755	1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 164.	1.8	24
756	Cost-Benefit Analysis of Internet Therapeutic Intervention on Patients With Diabetes. <i>International Journal of Endocrinology and Metabolism</i> , 2015, 13, e22803.	0.3	9
757	Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1153.	0.9	4
758	New Therapeutic Approaches in Diabetic Retinopathy. <i>Review of Diabetic Studies</i> , 2015, 12, 196-210.	0.5	28
759	Causative anti-diabetic drugs and the underlying clinical factors for hypoglycemia in patients with diabetes. <i>World Journal of Diabetes</i> , 2015, 6, 30.	1.3	27
760	Preclinical and Clinical Studies for Sodium Tungstate: Application in Humans. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2015, 06, .	1.5	9
761	Dexamethasone intravitreal implant in the treatment of diabetic macular edema. <i>Clinical Ophthalmology</i> , 2015, 9, 1321.	0.9	101
762	Genetics of Type 2 Diabetes and Clinical Utility. <i>Genes</i> , 2015, 6, 372-384.	1.0	34
763	Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 14477-14489.	1.8	14
764	Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?. <i>Journal of Clinical Medicine</i> , 2015, 4, 1866-1889.	1.0	18

#	ARTICLE	IF	CITATIONS
765	Potential Bioactive Compounds from Seaweed for Diabetes Management. <i>Marine Drugs</i> , 2015, 13, 5447-5491.	2.2	129
766	Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?. <i>Nutrients</i> , 2015, 7, 10129-10144.	1.7	36
767	Effects of a Macro-Nutrient Preload on Type 2 Diabetic Patients. <i>Frontiers in Endocrinology</i> , 2015, 6, 139.	1.5	8
768	New insights from monogenic diabetes for "common" type 2 diabetes. <i>Frontiers in Genetics</i> , 2015, 6, 251.	1.1	29
769	Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 799.	0.9	7
770	The Relationship Between Hope and Religious Coping Among Patients With Type 2 Diabetes. <i>Global Journal of Health Science</i> , 2015, 8, 208.	0.1	14
771	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. <i>Current Diabetes Reviews</i> , 2015, 11, 17-31.	0.6	44
772	Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 621.	0.9	33
773	Factors Associated with Glycemic Variability in Patients with Type 2 Diabetes: Focus on Oral Hypoglycemic Agents and Cardiovascular Risk Factors. <i>Endocrinology and Metabolism</i> , 2015, 30, 352.	1.3	9
774	Ocular complications of diabetes mellitus. <i>World Journal of Diabetes</i> , 2015, 6, 92.	1.3	225
775	Aqueous Fraction of <i>Beta vulgaris</i> Ameliorates Hyperglycemia in Diabetic Mice due to Enhanced Glucose Stimulated Insulin Secretion, Mediated by Acetylcholine and GLP-1, and Elevated Glucose Uptake via Increased Membrane Bound GLUT4 Transporters. <i>PLoS ONE</i> , 2015, 10, e0116546.	1.1	18
776	Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial. <i>PLoS ONE</i> , 2015, 10, e0121988.	1.1	26
777	Weight Changes following the Diagnosis of Type 2 Diabetes: The Impact of Recent and Past Weight History before Diagnosis. Results from the Danish Diabetes Care in General Practice (DCGP) Study. <i>PLoS ONE</i> , 2015, 10, e0122219.	1.1	20
778	Fasting Plasma Glucose as Initial Screening for Diabetes and Prediabetes in Irish Adults: The Diabetes Mellitus and Vascular Health Initiative (DMVhi). <i>PLoS ONE</i> , 2015, 10, e0122704.	1.1	23
779	Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. <i>PLoS ONE</i> , 2015, 10, e0126427.	1.1	161
780	The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. <i>PLoS ONE</i> , 2015, 10, e0130550.	1.1	54
781	Predictors for Mild and Severe Hypoglycemia in Insulin-Treated Japanese Diabetic Patients. <i>PLoS ONE</i> , 2015, 10, e0130584.	1.1	8
782	Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0131122.	1.1	17

#	ARTICLE	IF	CITATIONS
783	All-Trans Retinoic Acid Ameliorates Myocardial Ischemia/Reperfusion Injury by Reducing Cardiomyocyte Apoptosis. <i>PLoS ONE</i> , 2015, 10, e0133414.	1.1	29
784	Glycemic Control and Mortality in Diabetic Patients Undergoing Dialysis Focusing on the Effects of Age and Dialysis Type: A Prospective Cohort Study in Korea. <i>PLoS ONE</i> , 2015, 10, e0136085.	1.1	24
785	Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility. <i>PLoS ONE</i> , 2015, 10, e0145109.	1.1	26
786	The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis. <i>Frontiers in Physiology</i> , 2015, 6, 209.	1.3	31
787	Psychological Interventions for the Management of Glycemic and Psychological Outcomes of Type 2 Diabetes Mellitus in China: A Systematic Review and Meta-Analyses of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2015, 3, 252.	1.3	47
788	Cardiovascular effects of basal insulins. <i>Drug, Healthcare and Patient Safety</i> , 2015, 7, 113.	1.0	13
789	Secondary stroke prevention: challenges and solutions. <i>Vascular Health and Risk Management</i> , 2015, 11, 437.	1.0	95
790	Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 451.	1.8	84
791	In Nonobese Girls, Waist Circumference as a Predictor of Insulin Resistance Is Comparable to MRI Fat Measures and Superior to BMI. <i>Hormone Research in Paediatrics</i> , 2015, 84, 258-265.	0.8	9
792	Advanced glycation end-products: modifiable environmental factors profoundly mediate insulin resistance. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2015, 57, 1-12.	0.6	73
793	Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-9.	1.0	26
794	Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-14.	1.0	30
795	<i>NLRP3</i> Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-6.	1.0	42
796	Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-10.	1.9	41
797	Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	5
798	Manoeuvring between anxiety and control: Patients's experience of learning to live with diabetes: A lifeworld phenomenological study. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2015, 10, 27147.	0.6	15
799	Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-13.	1.0	29
800	Vascular Effects of Dietary Advanced Glycation End Products. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-8.	0.6	14

#	ARTICLE	IF	CITATIONS
801	Association of 2184AG Polymorphism in the RAGE Gene with Diabetic Nephropathy in Chinese Patients with Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-6.	1.0	17
802	Effects of Glucose Concentration on Propofol Cardioprotection against Myocardial Ischemia Reperfusion Injury in Isolated Rat Hearts. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-10.	1.0	14
803	A Novel Multidisciplinary Intervention for Long-Term Weight Loss and Glycaemic Control in Obese Patients with Diabetes. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-7.	1.0	20
804	Trends in the Levels of Serum Lipids and Lipoproteins and the Prevalence of Dyslipidemia in Adults with Newly Diagnosed Type 2 Diabetes in the Southwest Chinese Han Population during 2003â€“2012. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	0.6	8
805	Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-5.	0.6	23
806	Skewed Epigenetics: An Alternative Therapeutic Option for Diabetes Complications. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-7.	1.0	10
807	Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease. <i>Scientific World Journal</i> , The, 2015, 2015, 1-6.	0.8	26
808	Angioblast Derived from ES Cells Construct Blood Vessels and Ameliorate Diabetic Polyneuropathy in Mice. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-17.	1.0	11
809	Comorbidity between Type 2 Diabetes and Depression in the Adult Population: Directions of the Association and Its Possible Pathophysiological Mechanisms. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	0.6	63
810	Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-17.	1.0	55
811	Association of Diabetic Neuropathy with Duration of Type 2 Diabetes and Glycemic Control. <i>Cureus</i> , 2015, 7, e302.	0.2	44
812	Behavioral economics survey of patients with type 1 and type 2 diabetes. <i>Patient Preference and Adherence</i> , 2015, 9, 649.	0.8	8
813	Swim Training Improves HOMA-IR in Type 2 Diabetes Induced by High Fat Diet and Low Dose of Streptozotocin in Male Rats. <i>Advanced Pharmaceutical Bulletin</i> , 2015, 5, 379-384.	0.6	32
814	Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. <i>Review of Diabetic Studies</i> , 2015, 12, 110-118.	0.5	169
815	Impact of glucose level on morbidity and mortality in elderly with diabetes and pre-diabetes. <i>World Journal of Diabetes</i> , 2015, 6, 345.	1.3	19
816	Adherence to the American Diabetes Association standards of care among patients with type 2 diabetes in primary care in Saudi Arabia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 221-227.	0.5	18
817	Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. <i>Review of Diabetic Studies</i> , 2015, 12, 48-62.	0.5	150
818	Treatment of prediabetes. <i>World Journal of Diabetes</i> , 2015, 6, 1207.	1.3	56

#	ARTICLE	IF	CITATIONS
819	Î²-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World Journal of Diabetes, 2015, 6, 109.	1.3	173
820	Genetic Studies on Diabetic Microvascular Complications: Focusing on Genome-Wide Association Studies. Endocrinology and Metabolism, 2015, 30, 147.	1.3	18
821	The Effects of a Mobile Phone Application on Quality of Life in Patients With Type 1 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2015, 9, 1086-1091.	1.3	52
822	Management of diabetes mellitus in patients with chronic kidney disease. Clinical Diabetes and Endocrinology, 2015, 1, 2.	1.3	88
823	Diabetic retinopathy - ocular complications of diabetes mellitus. World Journal of Diabetes, 2015, 6, 489.	1.3	351
824	Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges. Current Cardiology Reports, 2015, 17, 607.	1.3	24
825	Role of Complement and Complement Regulatory Proteins in the Complications of Diabetes. Endocrine Reviews, 2015, 36, 272-288.	8.9	127
826	Primary and Secondary Prevention of Ischemic Heart Disease in Women. Current Atherosclerosis Reports, 2015, 17, 38.	2.0	2
827	Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). Advances in Therapy, 2015, 32, 391-403.	1.3	6
828	Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 2289-2302.	3.0	39
829	Primary care physicians'™ practice regarding diabetes mellitus diagnosis, evaluation and management in the West region of Cameroon. BMC Endocrine Disorders, 2015, 15, 18.	0.9	23
830	Q&A: insulin secretion and type 2 diabetes: why do Î²-cells fail?. BMC Biology, 2015, 13, 33.	1.7	102
831	Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus. Current Diabetes Reports, 2015, 15, 44.	1.7	14
832	Diabetic retinopathy and systemic factors. Middle East African Journal of Ophthalmology, 2015, 22, 151.	0.5	60
833	Association between serum albumin and glycated hemoglobin in Asian Indian subjects. Indian Journal of Endocrinology and Metabolism, 2015, 19, 52.	0.2	9
834	HbA1c below 7Â% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovascular Diabetology, 2015, 14, 124.	2.7	27
835	Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?. Diabetes, Obesity and Metabolism, 2015, 17, 919-927.	2.2	25
836	Peer-Led, Empowerment-Based Approach to Self-Management Efforts in Diabetes (PLEASED): A Randomized Controlled Trial in an African American Community. Annals of Family Medicine, 2015, 13, S27-S35.	0.9	73

#	ARTICLE	IF	CITATIONS
837	Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. <i>Endocrine Connections</i> , 2015, 4, R16-R24.	0.8	36
838	Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study. <i>BMJ</i> , The, 2015, 351, h5441-h5441.	3.0	44
839	An observational study of patient characteristics and mortality following hypoglycemia in the community. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000094.	1.2	45
840	Fructosamine measurement for diabetes mellitus diagnosis and monitoring: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2015, 5, e007689-e007689.	0.8	26
841	Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	36
842	Effect of Continuous Glucose Monitoring Accuracy on Clinicians' Retrospective Decision Making in Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 1092-1102.	1.3	2
843	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101
844	The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000090.	1.2	23
845	The ABC of diabetes: Are we doing enough?. <i>Medical Journal Armed Forces India</i> , 2015, 71, 303-304.	0.3	0
846	Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1109-1114.	0.8	25
847	Dietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 126-134.	2.2	79
848	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	2.9	598
849	Effect of Yanggyuksanhwa-Tang on non-insulin-dependent diabetes mellitus unresponsive to oral hypoglycemic agents: A case report. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 157-160.	0.7	1
850	Morbidity and Mortality in Young-Onset Type 2 Diabetes in Comparison to Type 1 Diabetes: Where Are We Now?. <i>Current Diabetes Reports</i> , 2015, 15, 566.	1.7	39
851	Blood pressure control for diabetic retinopathy. <i>The Cochrane Library</i> , 2015, 1, CD006127.	1.5	91
852	Methods and initial findings from the Durham Diabetes Coalition: Integrating geospatial health technology and community interventions to reduce death and disability. <i>Journal of Clinical and Translational Endocrinology</i> , 2015, 2, 26-36.	1.0	21
853	AGEs Promote Oxidative Stress and Induce Apoptosis in Retinal Pigmented Epithelium Cells RAGE-dependently. <i>Journal of Molecular Neuroscience</i> , 2015, 56, 449-460.	1.1	25
854	Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 170-178.	1.1	9

#	ARTICLE	IF	CITATIONS
855	The influence of body mass index on the accumulation of advanced glycation end products in hemodialysis patients. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 309-313.	1.3	9
856	Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 250-255.	1.0	0
857	Effects of 49 Different Rare Hb Variants on HbA1c Measurement in Eight Methods. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 849-856.	1.3	52
858	Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. <i>Diabetes</i> , 2015, 64, 673-686.	0.3	165
859	Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea. <i>Sleep and Breathing</i> , 2015, 19, 827-833.	0.9	8
860	Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 759-766.	2.2	62
861	Systemic arteriosclerosis and eating behavior in Japanese type 2 diabetic patients with visceral fat accumulation. <i>Cardiovascular Diabetology</i> , 2015, 14, 8.	2.7	17
862	Elevated Serum Advanced Glycation Endproducts in Obese Indicate Risk for the Metabolic Syndrome: A Link Between Healthy and Unhealthy Obesity?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1957-1966.	1.8	109
863	Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes. <i>Clinical Diabetes</i> , 2015, 33, 14-19.	1.2	8
864	Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study. <i>Diabetes Therapy</i> , 2015, 6, 153-171.	1.2	5
865	EFFECT OF THE EARLY INTENSIVE MULTIFACTORIAL THERAPY ON THE CARDIOVASCULAR RISK IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES: AN OBSERVATIONAL, PROSPECTIVE STUDY. <i>Medicine and Pharmacy Reports</i> , 2015, 88, 168-174.	0.2	3
866	Hypoglycemia in Older People - A Less Well Recognized Risk Factor for Frailty. , 2015, 6, 156.		213
867	Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 573-580.	1.3	8
868	Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea. <i>Journal of Human Hypertension</i> , 2015, 29, 713-718.	1.0	6
869	Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000044.	1.2	67
870	Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes. <i>International Journal of Obesity</i> , 2015, 39, 1531-1538.	1.6	26
871	Aortic perivascular adipose-derived interleukin-6 contributes to arterial stiffness in low-density lipoprotein receptor deficient mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H1382-H1390.	1.5	43
872	Prevalence of and Racial Disparities in Risk Factor Control in Older Adults With Diabetes: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2015, 38, 1290-1298.	4.3	30

#	ARTICLE	IF	CITATIONS
873	Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study. <i>Age and Ageing</i> , 2015, 44, 566-573.	0.7	17
874	Novel pharmacotherapies in diabetic retinopathy. <i>Middle East African Journal of Ophthalmology</i> , 2015, 22, 164.	0.5	18
875	Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. <i>Patient Preference and Adherence</i> , 2015, 9, 191.	0.8	24
876	Dietary Advanced Glycation End Products and Their Role in Health and Disease. <i>Advances in Nutrition</i> , 2015, 6, 461-473.	2.9	252
877	Time to be cautious about prescribing sulfonylureas?. <i>British Journal of General Practice</i> , 2015, 65, 93-94.	0.7	0
878	Progenitor Cell Dysfunctions Underlie Some Diabetic Complications. <i>American Journal of Pathology</i> , 2015, 185, 2607-2618.	1.9	36
879	Quality of HbA1c Measurement in the Practice. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 687-695.	1.3	30
880	Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. <i>Medical Principles and Practice</i> , 2015, 24, 401-415.	1.1	1,060
881	Parental Characteristics Associated With Outcomes in Youth With Type 2 Diabetes: Results From the TODAY Clinical Trial. <i>Diabetes Care</i> , 2015, 38, 784-792.	4.3	13
882	Emerging treatments for post-transplantation diabetes mellitus. <i>Nature Reviews Nephrology</i> , 2015, 11, 465-477.	4.1	62
883	Contributions of Basal Glucose and Postprandial Glucose Concentrations to Hemoglobin A1c in the Newly Diagnosed Patients with Type 2 Diabetes—The Preliminary Study. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 445-448.	2.4	12
884	Evaluation of hemoglobin A1c measurement by Capillarys 2 electrophoresis for detection of abnormal glucose tolerance in African immigrants to the United States. <i>Clinica Chimica Acta</i> , 2015, 446, 54-60.	0.5	6
885	Predicting risk of severe hypoglycaemia in type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 1143-1145.	2.9	0
886	Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. <i>Diabetologia</i> , 2015, 58, 1430-1435.	2.9	69
887	Lifestyle Therapy for the Treatment of Youth with Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2015, 15, 568.	1.7	46
888	Clinical Trials in Youth-Onset Type 2 Diabetes: Needs, Barriers, and Options. <i>Current Diabetes Reports</i> , 2015, 15, 28.	1.7	20
889	Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2015, 32, 341-355.	1.3	86
890	Liraglutide as Add-On Therapy to Insulin in Type 2 Diabetes Mellitus: A Retrospective, Observational Study From a Daily Clinical Practice Setting in Switzerland. <i>Diabetes Therapy</i> , 2015, 6, 41-47.	1.2	7



#	ARTICLE	IF	CITATIONS
891	An informed shared decision making programme on the prevention of myocardial infarction for patients with type 2 diabetes in primary care: protocol of a cluster randomised, controlled trial. <i>BMC Family Practice</i> , 2015, 16, 43.	2.9	8
892	Effect of vitamin D supplementation on glycemic control in patients with type 2 diabetes: a systematic review of interventional studies. <i>Journal of Diabetes and Metabolic Disorders</i> , 2015, 14, 3.	0.8	54
894	Non-ICU Hospital Care of Diabetes Mellitus in the Elderly Population. <i>Current Diabetes Reports</i> , 2015, 15, 26.	1.7	4
895	Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus. <i>Biomolecules</i> , 2015, 5, 194-222.	1.8	752
896	Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2015, 48, 40-61.	7.3	245
897	Update on Glycemic Control for the Treatment of Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2015, 15, 42.	1.7	9
898	Hypoglycemia in Type 2 Diabetes - More Common Than You Think. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 999-1005.	1.3	100
899	Nuclear DAMP complex-mediated RAGE-dependent macrophage cell death. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 650-655.	1.0	24
900	Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 200-208.	2.8	21
901	Neighborhood Social Environment and Patterns of Adherence to Oral Hypoglycemic Agents Among Patients With Type 2 Diabetes Mellitus. <i>Family and Community Health</i> , 2015, 38, 169-179.	0.5	28
902	Body Mass Index and Mortality Relationship in Severe Hypoglycemic Patients With Type 2 Diabetes. <i>American Journal of the Medical Sciences</i> , 2015, 349, 192-198.	0.4	7
903	Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 78-89.	0.9	298
904	Sulfonylurea Use and Risk of Hip Fractures Among Elderly Men and Women with Type 2 Diabetes. <i>Drugs and Aging</i> , 2015, 32, 321-327.	1.3	45
905	Psychosocial stress and changes in estimated glomerular filtration rate among adults with diabetes mellitus. <i>Kidney Research and Clinical Practice</i> , 2015, 34, 146-153.	0.9	4
906	Preclinical Performance Evaluation of Percutaneous Glucose Biosensors. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 978-984.	1.3	6
907	Effect of an Experiential Exercise in Diabetes Management on Pharmacy Students' Fear and Perceived Pain of Injection and Fingertip Lancing. <i>American Journal of Pharmaceutical Education</i> , 2015, 79, 05.	0.7	0
908	Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 12.	0.6	30
909	Investigating the Evidence of the Real-Life Impact of Acute Hyperglycaemia. <i>Diabetes Therapy</i> , 2015, 6, 389-393.	1.2	4

#	ARTICLE	IF	CITATIONS
910	Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies. <i>Current Diabetes Reports</i> , 2015, 15, 117.	1.7	10
911	Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 234-245.	1.1	28
912	Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus. <i>JAMA Internal Medicine</i> , 2015, 175, 1942.	2.6	137
913	Physiologic Concepts That May Revise the Interpretation and Implications of HbA1C in Clinical Medicine. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 696-700.	1.3	6
914	Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. <i>Diabetologia</i> , 2015, 58, 2288-2297.	2.9	73
915	Smoking, Central Adiposity, and Poor Glycemic Control Increase Risk of Hearing Impairment. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 918-924.	1.3	132
916	Differential Effect of Race, Education, Gender, and Language Discrimination on Glycemic Control in Adults with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 243-247.	2.4	24
917	Epigenetics and Cardiovascular Disease in Diabetes. <i>Current Diabetes Reports</i> , 2015, 15, 108.	1.7	32
918	Therapies on the Horizon for Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2015, 15, 111.	1.7	28
919	Endocrinology researchâ€”reflecting on the past decade and looking to the next. <i>Nature Reviews Endocrinology</i> , 2015, 11, 672-680.	4.3	2
920	Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2015, 6, 98-104.	1.1	31
921	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a <i>Diabetes Care</i> Editorsâ€™ Expert Forum. <i>Diabetes Care</i> , 2015, 38, 1567-1582.	4.3	180
922	Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. <i>Diabetes Care</i> , 2015, 38, 2000-2008.	4.3	33
923	Home-based diabetes symptom self-management education for Mexican Americans with type 2 diabetes. <i>Health Education Research</i> , 2015, 30, 484-496.	1.0	31
924	Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. <i>Diabetes Spectrum</i> , 2015, 28, 167-174.	0.4	18
925	Monitoring for proteinuria in patients with type 2 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000071.	1.2	11
926	Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention. <i>Circulation</i> , 2015, 132, 1157-1213.	1.6	446
927	Hypoglycemia and Comorbidities in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2015, 15, 80.	1.7	13

#	ARTICLE	IF	CITATIONS
928	Translational research in nephrology: chronic kidney disease prevention and public health. CKJ: Clinical Kidney Journal, 2015, 8, 647-655.	1.4	33
929	Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy. Diabetes Spectrum, 2015, 28, 121-126.	0.4	1
930	Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. American Journal of Physiology - Renal Physiology, 2015, 309, F889-F900.	1.3	113
931	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ, The, 2015, 351, h5364.	3.0	53
932	Hypertension and Diabetic Kidney Disease in Children and Adolescents. Diabetes Spectrum, 2015, 28, 220-224.	0.4	5
933	Physical activity, sedentary behavior and all-cause mortality among blacks and whites with diabetes. Annals of Epidemiology, 2015, 25, 649-655.	0.9	18
934	Burden of type 2 diabetes in Mexico: past, current and future prevalence and incidence rates. Preventive Medicine, 2015, 81, 445-450.	1.6	82
935	HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes. Diabetes Care, 2015, 38, 2285-2292.	4.3	53
936	S100A12 and the S100/Calgranulins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2496-2507.	1.1	74
937	Phosphoinositides: Key modulators of energy metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 857-866.	1.2	39
938	PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control. Diabetes, 2015, 64, 1688-1697.	0.3	8
939	Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice. Diabetologia, 2015, 58, 845-853.	2.9	59
940	Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes, Obesity and Metabolism, 2015, 17, 268-275.	2.2	160
941	Treating Coronary Disease and the Impact of Endothelial Dysfunction. Progress in Cardiovascular Diseases, 2015, 57, 431-442.	1.6	50
942	Antidiabetic Medications and Polypharmacy. Clinics in Geriatric Medicine, 2015, 31, 17-27.	1.0	74
943	The major predictors of amputation and length of stay in diabetic patients with acute foot ulceration. Wiener Klinische Wochenschrift, 2015, 127, 45-50.	1.0	47
944	Incidental detection of haemoglobin (Hb) variants during high performance liquid chromatography (HPLC) analysis of HbA1c: is it time for a standardised approach to reporting?. Irish Journal of Medical Science, 2015, 184, 353-355.	0.8	5
945	Death Investigation of Diabetes Mellitus: Scene Investigation and Interrogation of Technology. Academic Forensic Pathology, 2016, 6, 164-173.	0.3	2

#	ARTICLE	IF	CITATIONS
946	Factors affecting screening for diabetic complications in the community: a multilevel analysis. <i>Epidemiology and Health</i> , 2016, 38, e2016017.	0.8	2
947	AGEs induce ectopic endochondral ossification in intervertebral discs. , 2016, 32, 257-270.		35
948	Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. <i>Current Diabetes Reviews</i> , 2016, 12, 331-358.	0.6	27
949	Multi-ethnic differences in HbA1c, blood pressure, and low-density-lipid cholesterol control among South Africans living with type 2 diabetes after a 4-year follow-up. <i>International Journal of General Medicine</i> , 2016, Volume 9, 419-426.	0.8	8
950	Type 2 diabetes: cost-effectiveness of medication adherence and lifestyle interventions. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2039-2049.	0.8	7
951	A socioeconomic and behavioral survey of patients with difficult-to-control type 2 diabetes mellitus reveals an association between diabetic retinopathy and educational attainment. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2151-2162.	0.8	19
952	Improving Care in Older Patients with Diabetes: A Focus on Glycemic Control. , 2016, 20, 15-080.		6
953	1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy. <i>Endocrinology and Metabolism</i> , 2016, 31, 284.	1.3	5
954	Practical combination therapy based on pathophysiology of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, Volume 9, 355-369.	1.1	16
955	Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 423.	1.8	46
956	Patients&rsquo; attitudes to the use of modern technologies in the treatment of diabetes. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1869-1879.	0.8	10
957	Recent advances in managing and understanding diabetic nephropathy. <i>F1000Research</i> , 2016, 5, 1044.	0.8	29
958	Impact of Total Risk Management on Coronary Plaque Regression in Diabetic Patients with Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 922-931.	0.9	7
959	Total saponin of <i>Dioscoreae hypoglaucae</i> rhizoma ameliorates streptozotocin-induced diabetic nephropathy. <i>Drug Design, Development and Therapy</i> , 2016, 10, 799.	2.0	8
960	Sodium&ndash;glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin&ndash;metformin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, 9, 71.	1.1	4
961	The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. <i>BMB Reports</i> , 2016, 49, 139-148.	1.1	57
962	The relationship of management modality in Saudi patients with type 2 diabetes to components of metabolic syndrome, I <sup>3</sup> glutamyl transferase and highly sensitive C-reactive protein. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 246-254.	1.1	5
963	Do diabetes-specialty clinics differ in management approach and outcome? A cross-sectional assessment of ambulatory type 2 diabetes patients in two teaching hospitals in Nigeria. <i>Ghana Medical Journal</i> , 2016, 50, 90.	0.2	3

#	ARTICLE	IF	CITATIONS
964	Integrating Undergraduate Patient Partners into Diabetes self-management education: Evaluating a free clinic pilot program for the Underserved. <i>Journal of Health Care for the Poor and Underserved</i> , 2016, 27, 1689-1708.	0.4	11
965	Dietary glycotoxins and infant formulas. <i>Turk Pediatri Arsivi</i> , 2016, 51, 179-185.	0.9	12
966	Glycated Hemoglobin (HbA1c): Clinical Applications of a Mathematical Concept. <i>Acta Informatica Medica</i> , 2016, 24, 233.	0.5	9
967	The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 354.	1.8	32
968	A review of hypoglycaemia in a South African family practice setting. <i>African Journal of Primary Health Care and Family Medicine</i> , 2016, 8, e1-6.	0.3	5
969	Incretin-Based Therapy for Prevention of Diabetic Vascular Complications. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-12.	1.0	26
970	Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-16.	1.0	160
971	Randomized, Double-Blinded, Double-Dummy, Active-Controlled, and Multiple-Dose Clinical Study Comparing the Efficacy and Safety of Mulberry Twig ( <i>Ramulus Mori</i> , Sangzhi) Alkaloid Tablet and Acarbose in Individuals with Type 2 Diabetes Mellitus. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-10.	0.5	13
972	Administration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9.	1.0	28
973	Comparison of the Current Diagnostic Criterion of HbA1c with Fasting and 2-Hour Plasma Glucose Concentration. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-11.	1.0	32
974	Social Support Groups in the Maintenance of Glycemic Control after Community-Based Intervention. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-8.	1.0	16
975	Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-8.	1.0	25
976	Mesenchymal Stem Cells as a Prospective Therapy for the Diabetic Foot. <i>Stem Cells International</i> , 2016, 2016, 1-18.	1.2	30
977	Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-13.	1.0	66
978	The Efficacy and Safety of Chinese Herbal Decoction in Type 2 Diabetes: A 5-Year Retrospective Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-8.	0.5	19
979	The Role of Liuwei Dihuang Pills and Ginkgo Leaf Tablets in Treating Diabetic Complications. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-8.	0.5	12
980	Antidiabetic Properties, Bioactive Constituents, and Other Therapeutic Effects of <i>Scoparia dulcis</i> . <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-11.	0.5	44
981	Identification of cysteinylated transthyretin, a predictive biomarker of treatment response to partially hydrolyzed guar gum in type 2 diabetes rats, by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2016, 58, 23-33.	0.6	6

#	ARTICLE	IF	CITATIONS
982	The Influence of Health Literacy and Depression on Diabetes Self-Management: A Cross-Sectional Study. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-8.	1.0	30
983	Diabetic foot disease: From the evaluation of the "foot at risk" to the novel diabetic ulcer treatment modalities. <i>World Journal of Diabetes</i> , 2016, 7, 153.	1.3	205
984	Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics. <i>International Journal of Nanomedicine</i> , 2015, Volume 10, 281-292.	3.3	24
985	The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 61.	0.8	35
986	Molecular Markers of Diabetic Retinopathy: Potential Screening Tool of the Future?. <i>Frontiers in Physiology</i> , 2016, 7, 200.	1.3	67
987	Applicability of the Spoken Knowledge in Low Literacy Patients with Diabetes in Brazilian elderly. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 513-519.	0.3	12
988	Postprandial C-Peptide to Glucose Ratio as a Marker of $\beta$ Cell Function: Implication for the Management of Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2016, 17, 744.	1.8	63
989	How Can Diet Affect the Accumulation of Advanced Glycation End-Products in the Human Body?. <i>Foods</i> , 2016, 5, 84.	1.9	60
990	Effectiveness of a Lifestyle Intervention in Patients with Type 2 Diabetes: The Physical Activity and Nutrition for Diabetes in Alberta (PANDA) Trial. <i>Healthcare (Switzerland)</i> , 2016, 4, 73.	1.0	17
991	Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1498.	1.8	82
992	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease " cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. <i>BMC Nephrology</i> , 2016, 17, 59.	0.8	18
993	Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. <i>Cardiovascular Diabetology</i> , 2016, 15, 78.	2.7	10
994	Changes in antidiabetic prescription patterns and indicators of diabetic control among 200,000 patients over 13 years at a single institution in Japan. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 72.	1.2	5
995	The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. <i>PLoS Medicine</i> , 2016, 13, e1001992.	3.9	101
996	Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. <i>PLoS ONE</i> , 2016, 11, e0157915.	1.1	23
997	The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo. <i>PLoS ONE</i> , 2016, 11, e0153389.	1.1	9
998	Glucocorticoids Suppress Mitochondrial Oxidant Production via Upregulation of Uncoupling Protein 2 in Hyperglycemic Endothelial Cells. <i>PLoS ONE</i> , 2016, 11, e0154813.	1.1	34
999	Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing Dialysis. <i>PLoS ONE</i> , 2016, 11, e0160436.	1.1	6

#	ARTICLE	IF	CITATIONS
1000	Diabetic Cardiovascular Autonomic Neuropathy Predicts Recurrent Cardiovascular Diseases in Patients with Type 2 Diabetes. PLoS ONE, 2016, 11, e0164807.	1.1	33
1001	Coordinated Activation of VEGF/VEGFR-2 and PPAR $\gamma$ Pathways by a Multi-Component Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in Type 2 Diabetic Mice. PLoS ONE, 2016, 11, e0167305.	1.1	13
1002	Update on the treatment of type 2 diabetes mellitus. World Journal of Diabetes, 2016, 7, 354.	1.3	407
1003	The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications. Diseases (Basel, Switzerland), 2016, 4, 24.	1.0	60
1004	Dietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled Trials. Nutrients, 2016, 8, 125.	1.7	142
1005	Diabetic retinopathy clinical practice guidelines: Customized for Iranian population. Journal of Ophthalmic and Vision Research, 2016, 11, 394.	0.7	10
1006	The influence of sample freezing at -80 $^{\circ}$ C for 2-12 weeks on glycated haemoglobin (HbA1c) concentration assayed by HPLC method on Bio-Rad D-10 $\text{\AA}$ auto-analyzer. Biochimica Medica, 2016, 26, 346-352.	1.2	8
1007	Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics. Medicine (United States), 2016, 95, e2457.	0.4	41
1008	Future opportunities in diabetic retinopathy research. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 91-96.	1.2	11
1009	Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial. BMJ Open, 2016, 6, e012220.	0.8	6
1010	Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus. BMC Nephrology, 2016, 17, 67.	0.8	21
1011	Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes. Journal of Hypertension, 2016, 34, 907-913.	0.3	18
1012	Randomized trial of technology-assisted self-monitoring of blood glucose by low-income seniors: improved glycemic control in type 2 diabetes mellitus. Journal of Behavioral Medicine, 2016, 39, 1001-1008.	1.1	58
1013	Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm. Drugs, 2016, 76, 1081-1091.	4.9	17
1014	The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovascular Diabetology, 2016, 15, 85.	2.7	16
1015	Glycaemic control and risk of incident urinary incontinence in women with Type 1 diabetes: results from the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications (<sc>DCCT</sc>/<sc>EDIC</sc>) study. Diabetic Medicine, 2016, 33, 1528-1535.	1.2	17
1016	AGE-RAGE signal generates a specific NF- $\kappa$ B RelA $\text{\AA}$ that directs collagen I expression. Scientific Reports, 2016, 6, 18822.	1.6	34
1017	Several Aspects of Internet and Web-Based Technology in Diabetes Management. Diabetes Spectrum, 2016, 29, 245-248.	0.4	3

#	ARTICLE	IF	CITATIONS
1018	Skin advanced glycation end-products evaluation in infants according to the type of feeding and mother's smoking habits. <i>SAGE Open Medicine</i> , 2016, 4, 205031211668212.	0.7	12
1019	Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study. <i>BMC Endocrine Disorders</i> , 2016, 16, 35.	0.9	5
1020	More Than 7 Years of Hindsight: Revisiting the FDA's 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications. <i>Clinical Diabetes</i> , 2016, 34, 173-180.	1.2	31
1021	The effect of cumulative glyceic burden on the incidence of diabetic foot disease. <i>Journal of Orthopaedic Surgery and Research</i> , 2016, 11, 143.	0.9	28
1022	The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2016, 15, 101.	2.7	17
1023	Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden. <i>Diabetes Therapy</i> , 2016, 7, 321-333.	1.2	7
1024	Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease. <i>Scientific Reports</i> , 2016, 6, 20028.	1.6	39
1025	Diabetes awareness, treatment, control rates and associated risk factors among Beijing residents in 2011: A cross-sectional survey. <i>Chronic Diseases and Translational Medicine</i> , 2016, 2, 147-158.	0.9	9
1026	Management Protocols of stable coronary artery disease in India: Executive summary. <i>Indian Heart Journal</i> , 2016, 68, 868-873.	0.2	6
1027	Management standards for stable coronary artery disease in India. <i>Indian Heart Journal</i> , 2016, 68, S31-S49.	0.2	11
1028	Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. <i>Lipids in Health and Disease</i> , 2016, 15, 204.	1.2	22
1029	Improving rural and remote practitioners' knowledge of the diabetic foot: findings from an educational intervention. <i>Journal of Foot and Ankle Research</i> , 2016, 9, 26.	0.7	15
1030	Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care. <i>Clinical Diabetes</i> , 2016, 34, 34-43.	1.2	6
1031	Do advanced glycation end-products play a role in malaria susceptibility?. <i>Parasite</i> , 2016, 23, 15.	0.8	16
1032	Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. <i>Herz</i> , 2016, 41, 184-192.	0.4	48
1033	Reduced insulin secretion function is associated with pancreatic islet redistribution of cell adhesion molecules (CAMs) in diabetic mice after prolonged high-fat diet. <i>Histochemistry and Cell Biology</i> , 2016, 146, 13-31.	0.8	26
1034	How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. <i>Bone Marrow Transplantation</i> , 2016, 51, 1041-1049.	1.3	27
1035	Glucose variability and inner retinal sensory neuropathy in persons with type 1 diabetes mellitus. <i>Eye</i> , 2016, 30, 825-832.	1.1	33



#	ARTICLE	IF	CITATIONS
1036	Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes. <i>Diabetes Care</i> , 2016, 39, 502-510.	4.3	180
1037	Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome. <i>European Journal of Cancer</i> , 2016, 59, 90-98.	1.3	19
1038	A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. <i>Cancer Epidemiology</i> , 2016, 42, 115-123.	0.8	14
1039	Epigenetic Changes in Diabetes and Cardiovascular Risk. <i>Circulation Research</i> , 2016, 118, 1706-1722.	2.0	98
1040	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016, 118, 1830-1843.	2.0	51
1041	Inhibition of tumor suppressor p53 preserves glycation-serum induced pancreatic beta-cell demise. <i>Endocrine</i> , 2016, 54, 383-395.	1.1	11
1042	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
1044	Effect of a macronutrient preload on blood glucose level and pregnancy outcome in gestational diabetes. <i>Journal of Clinical and Translational Endocrinology</i> , 2016, 5, 36-41.	1.0	8
1045	Human Type 1 Diabetes Is Characterized by an Early, Marked, Sustained, and Islet-Selective Loss of Sympathetic Nerves. <i>Diabetes</i> , 2016, 65, 2322-2330.	0.3	70
1046	Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?. <i>Indian Heart Journal</i> , 2016, 68, 564-571.	0.2	15
1047	Diabetes Dyslipidemia. <i>Diabetes Therapy</i> , 2016, 7, 203-219.	1.2	259
1048	Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children. <i>Hormone Research in Paediatrics</i> , 2016, 85, 291-300.	0.8	2,853
1049	Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. <i>Diabetes Care</i> , 2016, 39, 668-676.	4.3	105
1050	Enzymatically Modified Low-Density Lipoprotein Promotes Foam Cell Formation in Smooth Muscle Cells via Macropinocytosis and Enhances Receptor-Mediated Uptake of Oxidized Low-Density Lipoprotein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1101-1113.	1.1	56
1051	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , 2016, 39, 717-725.	4.3	244
1054	Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?. <i>Diabetes Therapy</i> , 2016, 7, 175-185.	1.2	9
1055	Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract. <i>Journal of Natural Products</i> , 2016, 79, 1439-1444.	1.5	26
1056	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 117-127.	2.6	5

#	ARTICLE	IF	CITATIONS
1057	IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 389-397.	1.3	21
1058	The Type 2 Diabetic Heart: Its Role in Exercise Intolerance and the Challenge to Find Effective Exercise Interventions. <i>Sports Medicine</i> , 2016, 46, 1605-1617.	3.1	23
1059	Prospective study on microangiopathy in type 2 diabetic foot ulcer. <i>Diabetologia</i> , 2016, 59, 1542-1548.	2.9	39
1060	Cellular mechanisms and consequences of glycation in atherosclerosis and obesity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2244-2252.	1.8	56
1061	Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. <i>American Journal of Pathology</i> , 2016, 186, 1688-1700.	1.9	46
1062	LEADER-4. <i>Journal of Hypertension</i> , 2016, 34, 1140-1150.	0.3	13
1063	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 2603-2612.	2.9	8
1064	Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS). <i>American Heart Journal</i> , 2016, 181, 43-51.	1.2	25
1065	Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAic study baseline data. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 41.	1.2	10
1066	Current perspectives on cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 139.	2.7	59
1067	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. <i>International Journal of Clinical Practice</i> , 2016, 70, 775-785.	0.8	17
1068	Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK). <i>BMC Endocrine Disorders</i> , 2016, 16, 42.	0.9	12
1069	Is Stem Cell Transplantation Ready for Prime Time in Diabetic Polyneuropathy?. <i>Current Diabetes Reports</i> , 2016, 16, 86.	1.7	4
1070	Health and Psychosocial Outcomes of a Telephonic Couples Behavior Change Intervention in Patients With Poorly Controlled Type 2 Diabetes: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 2165-2173.	4.3	64
1071	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. <i>Metabolomics</i> , 2016, 12, 1.	1.4	10
1072	A randomized, controlled trial of a stress management intervention for Latinos with type 2 diabetes delivered by community health workers: Outcomes for psychological wellbeing, glycemic control, and cortisol. <i>Diabetes Research and Clinical Practice</i> , 2016, 120, 162-170.	1.1	44
1073	Selective association of electrocardiographic abnormalities with insulin sensitivity and beta-cell function in type 2 diabetes mellitus: a cross-sectional analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 736-744.	1.7	6
1074	Falsification Testing of Instrumental Variables Methods for Comparative Effectiveness Research. <i>Health Services Research</i> , 2016, 51, 790-811.	1.0	63

#	ARTICLE	IF	CITATIONS
1075	Mismatch between health care professionals' and patients' views on a diabetes patient decision aid: a qualitative study. <i>Health Expectations</i> , 2016, 19, 427-436.	1.1	11
1076	Structural model of self-care agency in patients with diabetes: A path analysis of the Instrument of Diabetes Self-Care Agency and body self-awareness. <i>Japan Journal of Nursing Science</i> , 2016, 13, 478-486.	0.5	8
1077	Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. <i>Diabetologia</i> , 2016, 59, 2181-2192.	2.9	102
1078	Factors associated with failure to achieve a glycated haemoglobin target of <math>\leq 8.0\%</math> in the ACTION to CONTROL cardiovascular risk in Diabetes (ACCORD) trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 92-95.	2.2	14
1079	Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 317-332.	2.2	211
1080	Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 152-158.	2.2	30
1081	Early diabetes screening in women with previous gestational diabetes: a new insight. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 61.	1.2	6
1082	Recent advances in the noninvasive strategies of cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2016, 21, 703-721.	1.7	12
1083	Diabetic kidney disease patients on hemodialysis: a retrospective survival analysis across different socioeconomic groups. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 833-838.	1.4	14
1084	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. <i>Current Diabetes Reports</i> , 2016, 16, 94.	1.7	2
1085	Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 504-512.	0.9	125
1086	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. <i>Cardiovascular Diabetology</i> , 2016, 15, 111.	2.7	44
1087	Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. <i>Cardiovascular Diabetology</i> , 2016, 15, 94.	2.7	36
1088	Hyperlipidemia and the development of diabetic retinopathy: Comparison between type 1 and type 2 animal models. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1570-1581.	1.5	56
1089	Cultural Differences and Considerations When Initiating Insulin. <i>Diabetes Spectrum</i> , 2016, 29, 185-190.	0.4	21
1090	Consistency of Hemoglobin A1c Testing and Cardiovascular Outcomes in Medicare Patients With Diabetes. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	10
1091	Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. <i>Scientific Reports</i> , 2016, 6, 26428.	1.6	119
1092	Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for pharmacists. <i>Canadian Pharmacists Journal</i> , 2016, 149, 337-344.	0.4	6

#	ARTICLE	IF	CITATIONS
1093	Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. <i>Diabetes Care</i> , 2016, 39, 2126-2140.	4.3	694
1094	New glyceimic targets for patients with diabetes from the Japan Diabetes Society. <i>Diabetology International</i> , 2016, 7, 327-330.	0.7	6
1095	Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2016, 7, 881-888.	1.1	13
1096	Pancreatic Î²â€cell identity in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 110-116.	2.2	94
1097	Conversation Maps and Diabetes Education Groups: An Evaluation at an Australian Rural Health Service. <i>Diabetes Spectrum</i> , 2016, 29, 32-36.	0.4	9
1098	First Prospective Cohort Study of Diabetic Retinopathy from Sub-Saharan Africa. <i>Ophthalmology</i> , 2016, 123, 1919-1925.	2.5	11
1099	When Î²â€cells fail: lessons from dedifferentiation. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 117-122.	2.2	76
1100	European Obesity Summit (EOS) - Joint Congress of EASOand IFSO-EC, Gothenburg, Sweden, June 1 - 4, 2016: Abstracts. <i>Obesity Facts</i> , 2016, 9, 1-376.	1.6	5
1101	Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. <i>The Cochrane Library</i> , 2016, 9, CD006992.	1.5	32
1102	Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? AÂNarrative Review. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2016, 116, 1794-1802.	0.4	74
1103	Follow the LEADERâ€”Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. <i>Diabetes Therapy</i> , 2016, 7, 601-609.	1.2	10
1104	Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. <i>Pharmacoeconomics</i> , 2016, 34, 953-966.	1.7	25
1105	Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome. <i>Canadian Journal of Cardiology</i> , 2016, 32, S349-S357.	0.8	17
1106	Modifying effect of intravenous laser therapy on the protein expression of arginase and epidermal growth factor receptor in type 2 diabetic patients. <i>Lasers in Medical Science</i> , 2016, 31, 1537-1545.	1.0	9
1107	Psychological conditions in adults with diabetes.. <i>American Psychologist</i> , 2016, 71, 552-562.	3.8	124
1108	Metabolomic Response of Skeletal Muscle to Aerobic Exercise Training in Insulin Resistant Type 1 Diabetic Rats. <i>Scientific Reports</i> , 2016, 6, 26379.	1.6	23
1109	Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2177-2185.	2.2	10
1110	Attitude towards diabetes and social and family support among type 2 diabetes patients attending a tertiary-care hospital in Bangladesh: a cross-sectional study. <i>BMC Research Notes</i> , 2016, 9, 286.	0.6	16

#	ARTICLE	IF	CITATIONS
1111	Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. <i>Science Translational Medicine</i> , 2016, 8, 359ra130.	5.8	84
1112	Relationship between Advanced Glycation End Products and Steroidogenesis in PCOS. <i>Reproductive Biology and Endocrinology</i> , 2016, 14, 71.	1.4	38
1113	Biomarkers of Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2016, 16, 125.	1.7	61
1114	Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin. <i>Journal of Drug Assessment</i> , 2016, 5, 29-33.	1.1	1
1115	Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet. <i>Current Atherosclerosis Reports</i> , 2016, 18, 79.	2.0	6
1116	Interactions between kidney disease and diabetes: dangerous liaisons. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 50.	1.2	108
1117	Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. <i>BMC Endocrine Disorders</i> , 2016, 16, 39.	0.9	41
1118	How information about the time requirements and legacy effects of treatments influence decision-making in patients with diabetes and hypertension. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000210.	1.2	3
1119	Blood glucose self-monitoring and internet diabetes management on A1C outcomes in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000134.	1.2	10
1120	Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. <i>BMJ</i> , 2016, 352, i1450.	3.0	84
1121	PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000216.	1.2	3
1122	Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000123.	1.2	26
1123	Analysis of a Delivery Device Conversion for Insulin Aspart: Potential Clinical Impact in Veterans. <i>Clinical Diabetes</i> , 2016, 34, 92-96.	1.2	0
1124	Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers. <i>Drug Target Insights</i> , 2016, 10, DTI.S38339.	0.9	0
1125	Self-reported hypoglycaemia in patients with type 2 diabetes treated with insulin in the Hoorn Diabetes Care System Cohort, the Netherlands: a prospective cohort study. <i>BMJ Open</i> , 2016, 6, e012793.	0.8	7
1126	Evaluation, intervention, and follow-up of patients with diabetes in a primary health care setting in Brazil: the importance of a specialized mobile consultancy. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 56.	1.2	5
1127	Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed?. <i>Clinical Diabetes</i> , 2016, 34, 115-120.	1.2	2
1128	Excess cost burden of diabetes in Southern India: a clinic-based, comparative cost-of-illness study. <i>Global Health, Epidemiology and Genomics</i> , 2016, 1, e8.	0.2	15

#	ARTICLE	IF	CITATIONS
1129	Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region. <i>BMC Family Practice</i> , 2016, 17, 144.	2.9	14
1130	Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 470.	0.7	4
1131	The Clinical and Economic Impact of the V-Go <sup>®</sup> Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk. <i>Drugs - Real World Outcomes</i> , 2016, 3, 191-199.	0.7	15
1132	Economic aspects in the management of diabetes in Italy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000197.	1.2	22
1133	Acute effect of fast walking on postprandial blood glucose control in type 2 diabetes. <i>Diabetology International</i> , 2016, 7, 119-123.	0.7	4
1134	Are glucose levels, glucose variability and autonomic control influenced by inspiratory muscle exercise in patients with type 2 diabetes? Study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 38.	0.7	4
1135	Cardiovascular effects of anti-diabetes drugs. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1239-1257.	1.0	14
1136	Changes in beta cell function occur in prediabetes and early disease in the Lepr db mouse model of diabetes. <i>Diabetologia</i> , 2016, 59, 1222-1230.	2.9	31
1137	Structured therapeutic education in diabetes: is it time to re-write the chapter on the prevention of diabetic complications?. <i>Endocrine</i> , 2016, 53, 347-349.	1.1	17
1138	Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records. <i>Diabetes Therapy</i> , 2016, 7, 483-496.	1.2	24
1139	The Contribution of Diabetes Education in the Treatment of People with Type 2 Diabetes and Risk of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2016, 18, 44.	2.0	4
1140	Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain. <i>BMC Endocrine Disorders</i> , 2016, 16, 10.	0.9	15
1141	Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2016, 15, 22.	2.7	85
1142	Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?. <i>Glycoconjugate Journal</i> , 2016, 33, 645-652.	1.4	22
1143	Is Transforming Stem Cells to Pancreatic Beta Cells Still the Holy Grail for Type 2 Diabetes?. <i>Current Diabetes Reports</i> , 2016, 16, 70.	1.7	13
1144	International Models of Care that Address the Growing Diabetes Prevalence in Developing Countries. <i>Current Diabetes Reports</i> , 2016, 16, 69.	1.7	7
1145	The Impact of Laparoscopic Adjustable Gastric Banding on an NHS Cohort of Type 2 Diabetics: a Prospective Cohort Study. <i>Obesity Surgery</i> , 2016, 26, 2006-2013.	1.1	6
1146	Has the safety of diabetes therapy improved? Lessons from an analysis of diabetic medication-induced severe hypoglycemic cases in an emergency department from 2005 to 2013. <i>Diabetology International</i> , 2016, 7, 274-280.	0.7	2

#	ARTICLE	IF	CITATIONS
1147	Evaluation of low-level laser therapy on skeletal muscle ischemiaâ€“reperfusion in streptozotocin-induced diabetic rats by assaying biochemical markers and histological changes. <i>Lasers in Medical Science</i> , 2016, 31, 1211-1217.	1.0	2
1148	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. <i>Endocrine</i> , 2016, 54, 32-37.	1.1	1
1149	A randomised controlled trial evaluating the impact of targeted vitamin D supplementation on endothelial function in type 2 diabetes mellitus: The DIMENSION trial. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 192-200.	0.9	40
1150	Point-of-care capillary HbA1c measurement in the emergency department: a useful tool to detect unrecognized and uncontrolled diabetes. <i>International Journal of Emergency Medicine</i> , 2016, 9, 7.	0.6	18
1151	Exploring interprofessional collaboration during the integration of diabetes teams into primary care. <i>BMC Family Practice</i> , 2016, 17, 12.	2.9	60
1152	Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 15.	1.2	11
1153	Simulation of a computed HbA1c using a weighted average glucose. <i>SpringerPlus</i> , 2016, 5, 226.	1.2	5
1154	Management of diabetes mellitus in older people with comorbidities. <i>BMJ, The</i> , 2016, 353, i2200.	3.0	52
1155	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. <i>Diabetes Care</i> , 2016, 39, 1089-1100.	4.3	119
1156	Stress and A1c Among People with Diabetes Across the Lifespan. <i>Current Diabetes Reports</i> , 2016, 16, 67.	1.7	90
1157	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
1158	Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 13.	1.0	24
1159	Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions. <i>Glycoconjugate Journal</i> , 2016, 33, 607-617.	1.4	35
1160	Successful glycemic control with three times a week degludec injection by medical staff for an elderly hemodialysis patient with type 2 diabetes. <i>Diabetology International</i> , 2016, 7, 95-99.	0.7	1
1161	Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report. <i>Diabetology International</i> , 2016, 7, 12-15.	0.7	11
1162	Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study. <i>Glycoconjugate Journal</i> , 2016, 33, 599-606.	1.4	12
1163	Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 151-160.	0.9	8
1164	A synopsis on agingâ€“Theories, mechanisms and future prospects. <i>Ageing Research Reviews</i> , 2016, 29, 90-112.	5.0	277

#	ARTICLE	IF	CITATIONS
1166	Concepts and clinical use of ultra-long basal insulin. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 2.	1.2	10
1167	Quality of HbA1c Measurement in Trinidad and Tobago. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 768-771.	1.3	1
1168	Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience. <i>Drugs</i> , 2016, 76, 41-74.	4.9	33
1169	Pre-pregnancy potato consumption and risk of gestational diabetes mellitus: prospective cohort study. <i>BMJ, The</i> , 2016, 352, h6898.	3.0	45
1170	How Should Blood Glucose Meter System Analytical Performance Be Assessed?. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 178-184.	1.3	20
1171	Restoration of Nrf2 Signaling Normalizes the Regenerative Niche. <i>Diabetes</i> , 2016, 65, 633-646.	0.3	60
1172	Past Decline Versus Current eGFR and Subsequent Mortality Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2456-2466.	3.0	40
1173	Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors. <i>Endocrine</i> , 2016, 53, 373-380.	1.1	6
1174	The EMPA-REG study: What has it told us? A diabetologist's perspective. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1-2.	1.2	38
1175	Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010). <i>TJ ETQq1 1 0.784314 rgBT /Over</i>	1.3	15
1176	Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. <i>Cmaj</i> , 2016, 188, E104-E112.	0.9	14
1177	Making sense of change: patients' views of diabetes and GP-led integrated diabetes care. <i>Health Expectations</i> , 2016, 19, 74-86.	1.1	33
1178	Biobehavioral determinants of glycemic control in type 2 diabetes: A systematic review and meta-analysis. <i>Patient Education and Counseling</i> , 2016, 99, 1558-1567.	1.0	85
1179	Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2056-2062.	1.8	34
1180	Effects of hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by twelve methods. <i>Clinica Chimica Acta</i> , 2016, 455, 80-83.	0.5	40
1181	Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. <i>Diabetes Therapy</i> , 2016, 7, 187-201.	1.2	29
1182	Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes. <i>Diabetes Therapy</i> , 2016, 7, 45-60.	1.2	116
1183	Chewing the fat for better insulin secretion. <i>Molecular Metabolism</i> , 2016, 5, 3-4.	3.0	2



#	ARTICLE	IF	CITATIONS
1184	Ascorbic acid repletion: A possible therapy for diabetic macular edema?. <i>Free Radical Biology and Medicine</i> , 2016, 94, 47-54.	1.3	15
1185	Design, development and deployment of a Diabetes Research Registry to facilitate recruitment in clinical research. <i>Contemporary Clinical Trials</i> , 2016, 47, 202-208.	0.8	13
1186	Association between self-stigma and self-care behaviors in patients with type 2 diabetes: a cross-sectional study. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000156.	1.2	47
1187	Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. <i>Diabetes Care</i> , 2016, 39, 686-693.	4.3	470
1188	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. <i>Diabetes Care</i> , 2016, 39, 701-708.	4.3	150
1189	Statistical Methods for Cardiovascular Researchers. <i>Circulation Research</i> , 2016, 118, 439-453.	2.0	26
1190	Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor $\kappa$ B signaling pathways. <i>Endocrine</i> , 2016, 53, 107-116.	1.1	33
1191	Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes. <i>Current Cardiology Reports</i> , 2016, 18, 29.	1.3	6
1192	Altered Plasma Profile of Antioxidant Proteins as an Early Correlate of Pancreatic $\beta$ Cell Dysfunction. <i>Journal of Biological Chemistry</i> , 2016, 291, 9648-9656.	1.6	16
1193	The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 898-904.	1.3	57
1194	Hypoglycemia as an indicator of good diabetes care:. <i>BMJ, The</i> , 2016, 352, i1084.	3.0	26
1195	Pre-morbid glycemic control modifies the interaction between acute hypoglycemia and mortality. <i>Intensive Care Medicine</i> , 2016, 42, 562-571.	3.9	78
1196	Polypharmacy in the Aging Patient. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1034.	3.8	236
1197	Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity. <i>Current Gastroenterology Reports</i> , 2016, 18, 2.	1.1	16
1198	Impact of diagnosing diabetic complications on future hemoglobin A1c levels. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 323-328.	1.2	10
1199	Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011. <i>Diabetes Care</i> , 2016, 39, 363-370.	4.3	121
1200	miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway. <i>Diabetologia</i> , 2016, 59, 644-654.	2.9	82
1201	Performance Evaluation of Three Blood Glucose Monitoring Systems Using ISO 15197. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 85-92.	1.3	24

#	ARTICLE	IF	CITATIONS
1202	Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. <i>Journal of Epidemiology and Global Health</i> , 2016, 6, 29.	1.1	10
1203	RIFLE classification in geriatric patients with acute kidney injury in the intensive care unit. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 402-410.	0.7	4
1204	HbA1c and all-cause mortality risk among patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2016, 202, 490-496.	0.8	39
1205	Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention. <i>Heart and Vessels</i> , 2016, 31, 855-862.	0.5	6
1206	Predictors of Excess Weight Loss in Obese Patients After Gastric Bypass: a 60-Month Follow-up. <i>Obesity Surgery</i> , 2016, 26, 1178-1185.	1.1	36
1207	Toward Big Data Analytics. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 27-34.	1.3	73
1208	Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 305-314.	1.8	36
1209	Structural Changes by Spectral Domain Optical Coherence Tomography in Patients With Type 1 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 271-276.	1.3	10
1210	Stem cell therapies in the treatment of diabetic retinopathy and keratopathy. <i>Experimental Biology and Medicine</i> , 2016, 241, 559-568.	1.1	23
1211	Uremic Toxicity of Advanced Glycation End Products in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 354-370.	3.0	175
1213	Pathophysiological Links Among Hypertension and Alzheimer's Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 3-7.	1.0	39
1214	Step On It! Workplace Cardiovascular Risk Assessment of New York City Yellow Taxi Drivers. <i>Journal of Immigrant and Minority Health</i> , 2016, 18, 118-134.	0.8	22
1215	Diabetes 2030: Insights from Yesterday, Today, and Future Trends. <i>Population Health Management</i> , 2017, 20, 6-12.	0.8	445
1216	Ayurpharmacoepidemiology Perspective. <i>Journal of Evidence-Based Complementary &amp; Alternative Medicine</i> , 2017, 22, 242-250.	1.5	3
1217	Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 1037-1045.	1.8	430
1218	The relationship of regional hemoglobin A1c testing and amputation rate among patients with diabetes. <i>Vascular</i> , 2017, 25, 142-148.	0.4	3
1219	Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience. <i>Pediatric Obesity</i> , 2017, 12, 337-345.	1.4	27
1220	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. <i>Diabetes Care</i> , 2017, 40, 325-331.	4.3	32

#	ARTICLE	IF	CITATIONS
1221	Beta-blockers for hypertension. The Cochrane Library, 2017, 2017, CD002003.	1.5	205
1222	Treating psychological insulin resistance in type 2 diabetes. Journal of Clinical and Translational Endocrinology, 2017, 7, 1-6.	1.0	24
1223	Evaluation the effect of 50 and 100Âmg doses of Cuminum cyminum essential oil on glycemic indices, insulin resistance and serum inflammatory factors on patients with diabetes type II: A double-blind randomized placebo-controlled clinical trial. Journal of Traditional and Complementary Medicine, 2017, 7, 332-338.	1.5	38
1224	Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. Applied Health Economics and Health Policy, 2017, 15, 237-248.	1.0	26
1225	An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. Circulation, 2017, 135, 180-195.	1.6	39
1226	Effect of a Longâ€Term Intensive Lifestyle Intervention on Cognitive Function: Action for Health in Diabetes Study. Journal of the American Geriatrics Society, 2017, 65, 966-972.	1.3	42
1227	The number of microvascular complications is associated with an increased risk for severity of periodontitis in type 2 diabetes patients: Results of a multicenter hospitalâ€based crossâ€sectional study. Journal of Diabetes Investigation, 2017, 8, 677-686.	1.1	32
1228	Prevention of complications in type 2 diabetes: is drug glucose control evidence based?. British Journal of General Practice, 2017, 67, 85-87.	0.7	17
1229	Sustained kidney biochemical derangement in treated experimental diabetes: a clue to metabolic memory. Scientific Reports, 2017, 7, 40544.	1.6	13
1231	Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovascular Diabetology, 2017, 16, 10.	2.7	46
1232	A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 13.	2.7	29
1233	Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 412-418.	4.3	596
1234	Hemoglobin A1c and Mortality in Older Adults With and Without Diabetes: Results From the National Health and Nutrition Examination Surveys (1988â€2011). Diabetes Care, 2017, 40, 453-460.	4.3	84
1235	Predominant contribution of L-type Cav1.2 channel stimulation to impaired intracellular calcium and cerebral artery vasoconstriction in diabetic hyperglycemia. Channels, 2017, 11, 340-346.	1.5	16
1236	Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes and Endocrinology, the, 2017, 5, 271-279.	5.5	111
1237	Diet and Diabetic Kidney Disease: Plant Versus Animal Protein. Current Diabetes Reports, 2017, 17, 15.	1.7	16
1238	Diagnosis and Management of Type 2 Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1366-1373.	2.2	227
1239	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2017, 2, CD009966.	1.5	20

#	ARTICLE	IF	CITATIONS
1240	The undoing and redoing of the diabetic $\beta$ -cell. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 912-917.	1.2	15
1241	Therapeutic effect of <i>Linum usitatissimum</i> L. in STZ-nicotinamide induced diabetic nephropathy via inhibition of AGEs and oxidative stress. <i>Journal of Food Science and Technology</i> , 2017, 54, 408-421.	1.4	19
1242	The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2017, 8, 209-212.	1.2	16
1243	Increased odds of metabolic syndrome with consumption of high dietary advanced glycation end products in adolescents. <i>Diabetes and Metabolism</i> , 2017, 43, 469-471.	1.4	14
1244	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. <i>Current Cardiology Reports</i> , 2017, 19, 25.	1.3	2
1245	Protective effect of mangiferin on myocardial ischemia-reperfusion injury in streptozotocin-induced diabetic rats: role of AGE-RAGE/MAPK pathways. <i>Scientific Reports</i> , 2017, 7, 42027.	1.6	71
1246	Five Simple Steps to Optimize Bolus Insulin Therapy in Type 2 Diabetes. <i>Clinical Diabetes</i> , 2017, 35, 108-111.	1.2	2
1247	Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
1248	Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study. <i>Osteoporosis International</i> , 2017, 28, 2053-2060.	1.3	35
1249	Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. <i>Diabetes Therapy</i> , 2017, 8, 587-599.	1.2	9
1250	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1353-1362.	2.2	120
1251	Effect of antihyperglycemic drug monotherapy to prevent the progression of mild hyperglycemia in early type 2 diabetic patients: the Japan Early Diabetes Intervention Study (JEDIS). <i>Diabetology International</i> , 2017, 8, 350-365.	0.7	0
1252	Mediators of diabetic neuropathy: is hyperglycemia the only culprit?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 103-111.	1.2	71
1253	Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects. <i>Kidney Diseases (Basel)</i> , 2017, 12, 103-111.	1.2	30
1254	Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bovine aortic endothelial cells. <i>Journal of Diabetes Investigation</i> , 2017, 8, 750-761.	1.1	33
1255	Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 1-7.	1.8	23
1256	Can chronic disease be managed through integrated care cost-effectively? Evidence from a systematic review. <i>Irish Journal of Medical Science</i> , 2017, 186, 827-834.	0.8	28
1257	Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. <i>Nephron</i> , 2017, 135, 147-153.	0.9	23

#	ARTICLE	IF	CITATIONS
1258	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2263-2274.	3.0	59
1259	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 315-322.	2.4	3
1260	Gaps and barriers in the control of blood glucose in people with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 172-183.	0.9	102
1261	Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	21
1262	Impact of HbA1c Testing at Point of Care on Diabetes Management. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 611-617.	1.3	85
1263	Maternal intake of fried foods and risk of gestational diabetes mellitus. <i>Annals of Epidemiology</i> , 2017, 27, 384-390.e1.	0.9	22
1264	Obstructive Sleep Apnea and Diabetes. <i>Chest</i> , 2017, 152, 1070-1086.	0.4	398
1265	Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. <i>Eye</i> , 2017, 31, S1-S20.	1.1	25
1266	Features of glycemic variations in drug naïve type 2 diabetic patients with different HbA1c values. <i>Scientific Reports</i> , 2017, 7, 1583.	1.6	11
1267	Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 2032-2045.	2.2	1,600
1268	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 313-329.	1.0	9
1269	The Impact of Structured Self-Monitoring of Blood Glucose Combined With Intensive Education on HbA1c Levels, Hospitalizations, and Quality-of-Life Parameters in Insulin-Treated Patients With Diabetes at Primary Care in Serbia: The Multicenter SPA-EDU Study. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 746-752.	1.3	10
1270	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017, 40, 813-820.	4.3	109
1271	<i>Ager</i> Deletion Enhances Ischemic Muscle Inflammation, Angiogenesis, and Blood Flow Recovery in Diabetic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1536-1547.	1.1	31
1272	Closing the Loop. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-27-S-41.	2.4	7
1273	The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100AU/mL. <i>Cardiovascular Diabetology</i> , 2017, 16, 66.	2.7	9
1274	Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. <i>Journal of General Internal Medicine</i> , 2017, 32, 1044-1051.	1.3	20
1275	The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group: Report 3: Baseline Retinopathy and Clinical Features Predict Progression of Diabetic Retinopathy. <i>American Journal of Ophthalmology</i> , 2017, 180, 64-71.	1.7	34

#	ARTICLE	IF	CITATIONS
1276	Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-3-S-12.	2.4	31
1277	Hemoglobin Glycation Index Is Associated With Cardiovascular Diseases in People With Impaired Glucose Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2905-2913.	1.8	55
1278	Metformin combined with acarbose vs. single medicine in the treatment of type 2 diabetes: A meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 3137-3145.	0.8	8
1279	Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 561-586.	3.1	31
1280	Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. <i>Glycobiology</i> , 2017, 27, 691-695.	1.3	39
1281	Gamma-linolenic acid ameliorated glycation-induced memory impairment in rats. <i>Pharmaceutical Biology</i> , 2017, 55, 1817-1823.	1.3	6
1282	Development of glucose-responsive "smart" insulin systems. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 267-278.	1.2	47
1283	Risk of Cardiovascular Events in Patients With Diabetes Mellitus on $\beta$ -Blockers. <i>Hypertension</i> , 2017, 70, 103-110.	1.3	61
1284	Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-16-S-26.	2.4	130
1285	Role of B-type Natriuretic Peptide and N-terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
1286	A study to evaluate the prevalence of impaired awareness of hypoglycaemia in adults with type 2 diabetes in outpatient clinic in a tertiary care centre in Singapore. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2017, 8, 69-74.	1.4	16
1287	Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1349-1355.	4.3	118
1288	High glucose increases the formation and pro-oxidative activity of endothelial microparticles. <i>Diabetologia</i> , 2017, 60, 1791-1800.	2.9	79
1289	Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study. <i>Diabetes Therapy</i> , 2017, 8, 611-621.	1.2	0
1290	Do health information technology self-management interventions improve glycemic control in medically underserved adults with diabetes? A systematic review and meta-analysis. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 1024-1035.	2.2	92
1291	Treat to Target in Axial Spondyloarthritis: What Are the Issues?. <i>Current Rheumatology Reports</i> , 2017, 19, 22.	2.1	17
1292	Does Length of Relationship or Gender Predict Response to Behavioral Diabetes Intervention?. <i>The Diabetes Educator</i> , 2017, 43, 216-222.	2.6	0
1293	Anti-hyperglycaemic activity of <i>Moringa oleifera</i> is partly mediated by carbohydrase inhibition and glucose-fibre binding. <i>Bioscience Reports</i> , 2017, 37, .	1.1	37

#	ARTICLE	IF	CITATIONS
1294	Aleglitazar, a dual peroxisome proliferator-activated receptor- $\alpha$ and - $\beta$ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 152-162.	0.9	8
1295	Insulin signaling via the PI3-kinase/Akt pathway regulates airway glucose uptake and barrier function in a CFTR-dependent manner. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L688-L702.	1.3	36
1296	Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. <i>Advances in Therapy</i> , 2017, 34, 954-965.	1.3	18
1297	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 687-693.	4.3	45
1298	Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 23.	0.4	69
1299	Metrics for glycaemic control – from HbA1c to continuous glucose monitoring. <i>Nature Reviews Endocrinology</i> , 2017, 13, 425-436.	4.3	185
1300	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>International Journal of Behavioral Medicine</i> , 2017, 24, 321-419.	0.8	84
1301	Diabetes and Aging: Unique Considerations and Goals of Care. <i>Diabetes Care</i> , 2017, 40, 440-443.	4.3	146
1302	Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. <i>Diabetes Therapy</i> , 2017, 8, 365-376.	1.2	44
1303	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 136-154.	4.3	1,452
1304	Understanding the impact of hypoglycemia on the cardiovascular system. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 21-33.	1.2	26
1305	Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2017, 8, 55-73.	1.2	433
1306	The gene polymorphisms of IL-8(-251T/A) and IP-10(-1596C/T) are associated with susceptibility and progression of type 2 diabetic retinopathy in northern Chinese population. <i>Eye</i> , 2017, 31, 601-607.	1.1	16
1307	Patterns of diabetes care in Slovenia, Croatia, Serbia, Bulgaria and Romania. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 192-200.	1.0	8
1308	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. <i>Nature Reviews Nephrology</i> , 2017, 13, 11-26.	4.1	398
1309	Determinants of hemoglobin A1c level in patients with type 2 diabetes after in-hospital diabetes education: A study based on continuous glucose monitoring. <i>Journal of Diabetes Investigation</i> , 2017, 8, 314-320.	1.1	8
1310	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. <i>Current Diabetes Reports</i> , 2017, 17, 124.	1.7	17
1311	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. <i>Clinical Diabetes</i> , 2017, 35, 141-153.	1.2	1

#	ARTICLE	IF	CITATIONS
1312	Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic. <i>Diabetes Therapy</i> , 2017, 8, 1331-1347.	1.2	10
1313	β <sup>2</sup> -Cell Function Over Time in Adolescents With New Type 2 Diabetes and Obese Adolescents Without Diabetes. <i>Journal of Adolescent Health</i> , 2017, 61, 703-708.	1.2	10
1314	The association of vitamin D deficiency and glucose control among diabetic patients. <i>Saudi Pharmaceutical Journal</i> , 2017, 25, 1179-1183.	1.2	12
1315	DL-3-n-butylphthalide protects endothelial cells against advanced glycation end product-induced injury by attenuating oxidative stress and inflammation responses. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 2241-2248.	0.8	18
1316	Sitagliptin 100 mg vs glimepiride 3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). <i>Endocrine Connections</i> , 2017, 6, 748-757.	0.8	2
1317	Genetically Determined Plasma Lipid Levels and Risk of Diabetic Retinopathy: A Mendelian Randomization Study. <i>Diabetes</i> , 2017, 66, 3130-3141.	0.3	17
1318	Diabetic Nephropathy: a Tangled Web to Unweave. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 579-592.	1.3	135
1319	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2017, 8, 1175-1185.	1.2	3
1320	Insulin and Its Cardiovascular Effects: What Is the Current Evidence?. <i>Current Diabetes Reports</i> , 2017, 17, 120.	1.7	25
1321	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017, 40, 1530-1536.	4.3	45
1322	Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study. <i>Diabetes Therapy</i> , 2017, 8, 1097-1109.	1.2	34
1323	Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. <i>Npj Aging and Mechanisms of Disease</i> , 2017, 3, 12.	4.5	45
1324	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
1325	Marine collagen peptides reduce endothelial cell injury in diabetic rats by inhibiting apoptosis and the expression of coupling factor 6 and microparticles. <i>Molecular Medicine Reports</i> , 2017, 16, 3947-3957.	1.1	12
1326	Suppression of diabetic retinopathy with GLUT1 siRNA. <i>Scientific Reports</i> , 2017, 7, 7437.	1.6	41
1327	Life Expectancy Predictions for Older Diabetic Patients as Estimated by Physicians and a Prognostic Model. <i>MDM Policy and Practice</i> , 2017, 2, 238146831771371.	0.5	4
1328	Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. <i>Current Diabetes Reports</i> , 2017, 17, 67.	1.7	4
1329	Attenuation of diabetic retinopathy in rats by ellagic acid through inhibition of AGE formation. <i>Journal of Food Science and Technology</i> , 2017, 54, 2411-2421.	1.4	36



#	ARTICLE	IF	CITATIONS
1330	Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials. <i>Scientific Reports</i> , 2017, 7, 2266.	1.6	58
1331	Academic and Government Partnerships to Address Diabetes in the USA: a Narrative Review. <i>Current Diabetes Reports</i> , 2017, 17, 75.	1.7	2
1332	Health selection into neighborhoods among patients enrolled in a clinical trial. <i>Preventive Medicine Reports</i> , 2017, 8, 51-54.	0.8	3
1333	Psychometric validation of the Hypoglycemia Fear Survey-II (HFS-II) in Singapore. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000329.	1.2	15
1334	Discovering successful strategies for diabetic self-management: a qualitative comparative study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000349.	1.2	12
1335	Diabetes Care in Brazil. <i>Journal of Ambulatory Care Management</i> , 2017, 40, S12-S23.	0.5	29
1336	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 70, 883-893.	1.2	125
1337	Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 637.	3.8	154
1338	Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E631-E640.	1.8	43
1339	Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 498-506.	2.4	48
1340	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. <i>Current Geriatrics Reports</i> , 2017, 6, 175-186.	1.1	20
1341	A Randomized Controlled Trial to Assess the Impact of Proper Insulin Injection Technique Training on Glycemic Control. <i>Diabetes Therapy</i> , 2017, 8, 1309-1318.	1.2	34
1342	Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients. <i>Scientific Reports</i> , 2017, 7, 16382.	1.6	7
1343	Type 2 diabetes in general practice in Norway 2005–2014: moderate improvements in risk factor control but still major gaps in complication screening. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000459.	1.2	35
1344	Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis. <i>Scientific Reports</i> , 2017, 7, 15795.	1.6	15
1345	Effect of dietary advanced glycation end products on inflammation and cardiovascular risks in healthy overweight adults: a randomised crossover trial. <i>Scientific Reports</i> , 2017, 7, 4123.	1.6	35
1346	Coronary microvascular dysfunction in diabetes mellitus. <i>Journal of International Medical Research</i> , 2017, 45, 1901-1929.	0.4	95
1347	Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 275-283.	1.3	15

#	ARTICLE	IF	CITATIONS
1348	Identification of genetic variants in pharmacogenetic genes associated with type 2 diabetes in a Mexican-Mestizo population. <i>Biomedical Reports</i> , 2017, 7, 21-28.	0.9	2
1349	Dietary Advanced Glycation End Products and Cardiometabolic Risk. <i>Current Diabetes Reports</i> , 2017, 17, 63.	1.7	48
1350	Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. <i>Current Diabetes Reports</i> , 2017, 17, 64.	1.7	4
1351	Comorbidity of periodontal disease: two sides of the same coin? An introduction for the clinician. <i>Journal of Oral Microbiology</i> , 2017, 9, 1332710.	1.2	127
1352	Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. <i>Diabetes Care</i> , 2017, 40, 1226-1232.	4.3	202
1353	Kidney dysfunction in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 38-54.	0.8	47
1354	An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin. <i>Diabetes Therapy</i> , 2017, 8, 767-780.	1.2	5
1355	Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2017, 8, 829-836.	1.2	4
1356	Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial. <i>BMC Nephrology</i> , 2017, 18, 83.	0.8	36
1357	Diabetes care in a complex humanitarian emergency setting: a qualitative evaluation. <i>BMC Health Services Research</i> , 2017, 17, 431.	0.9	31
1358	Age dependent accumulation patterns of advanced glycation end product receptor (RAGE) ligands and binding intensities between RAGE and its ligands differ in the liver, kidney, and skeletal muscle. <i>Immunity and Ageing</i> , 2017, 14, 12.	1.8	24
1359	Understanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 46.	1.2	8
1360	Introduction of the DiaGene study: clinical characteristics, pathophysiology and determinants of vascular complications of type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 47.	1.2	18
1361	HbA1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice?. <i>Journal of Diabetes and Metabolic Disorders</i> , 2017, 16, 14.	0.8	8
1362	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). <i>Pharmacoeconomics</i> , 2017, 35, 375-396.	1.7	24
1363	Renoprotection From Diabetic Complications in <i>OVE</i> Transgenic Mice by Endothelial Cell Specific Overexpression of Metallothionein: A <i>TEM</i> Stereological Analysis. <i>Anatomical Record</i> , 2017, 300, 560-576.	0.8	2
1364	Four-year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2017, 8, 369-376.	1.1	10
1365	Cerebral glycogen in humans following acute and recurrent hypoglycemia: Implications on a role in hypoglycemia unawareness. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2883-2893.	2.4	30

#	ARTICLE	IF	CITATIONS
1366	Optimizing Medical Management in Patients with Sight-Threatening Diabetic Retinopathy. <i>Ophthalmology and Therapy</i> , 2017, 6, 105-114.	1.0	3
1367	Ten-year hemoglobin A1c trajectories and outcomes in type 2 diabetes mellitus: The Diabetes & Aging Study. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 94-100.	1.2	72
1368	Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women. <i>European Journal of Nutrition</i> , 2017, 56, 2557-2564.	1.8	37
1369	Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database. <i>Journal of Diabetes Investigation</i> , 2017, 8, 227-234.	1.1	37
1370	Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 173-182.	1.3	61
1371	Cardiovascular safety trials of incretin-based drugs: What do they mean?. <i>Journal of Diabetes Investigation</i> , 2017, 8, 272-276.	1.1	7
1372	Hyperpalatable Diet and Physical Exercise Modulate the Expression of the Glial Monocarboxylate Transporters MCT1 and 4. <i>Molecular Neurobiology</i> , 2017, 54, 5807-5814.	1.9	10
1373	Cardiovascular safety of therapies for type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 13-25.	1.0	7
1374	Impact of Endurance Exercise Training in the Fasted State on Muscle Biochemistry and Metabolism in Healthy Subjects: Can These Effects be of Particular Clinical Benefit to Type 2 Diabetes Mellitus and Insulin-Resistant Patients?. <i>Sports Medicine</i> , 2017, 47, 415-428.	3.1	44
1375	Usefulness of glycated albumin in decisions regarding the discontinuation of a diabetes drug and factors associated with poor glycemic control following discontinuation in patients with type 2 diabetes mellitus. <i>Diabetology International</i> , 2017, 8, 39-44.	0.7	3
1376	How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? A Systematic Review. <i>Pharmacoeconomics</i> , 2017, 35, 319-329.	1.7	13
1377	Markers of Islet Endothelial Dysfunction Occur in Male B6.BKS(D)-Leprdb/J Mice and May Contribute to Reduced Insulin Release. <i>Endocrinology</i> , 2017, 158, 293-303.	1.4	27
1378	Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. <i>Diabetes Care</i> , 2017, 40, 218-225.	4.3	13
1379	Forskolin attenuates retinal inflammation in diabetic mice. <i>Molecular Medicine Reports</i> , 2018, 17, 2321-2326.	1.1	6
1380	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4343-4410.	1.8	323
1381	Protocol for the specialist supervised individualised multifactorial treatment of new clinically diagnosed type 2 diabetes in general practice (IDA): a prospective controlled multicentre open-label intervention study. <i>BMJ Open</i> , 2017, 7, e017493.	0.8	6
1382	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. <i>Clinical Diabetes</i> , 2017, 35, 321-328.	1.2	4
1383	If DSME Were a Pill, Would You Prescribe It?. <i>Diabetes Spectrum</i> , 2017, 30, 51-57.	0.4	1

#	ARTICLE	IF	CITATIONS
1384	In silico screening for identification of pyrrolidine derivatives dipeptidyl peptidase-IV inhibitors using COMFA, CoMSIA, HQSAR and docking studies. <i>In Silico Pharmacology</i> , 2017, 5, 13.	1.8	2
1385	Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 825.	3.8	471
1386	Patient navigation to improve diabetes outpatient care at a safety-net hospital: a retrospective cohort study. <i>BMC Health Services Research</i> , 2017, 17, 759.	0.9	27
1387	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	1.3	4
1388	Recruitment and Baseline Characteristics of Participants in the Lifestyle Improvement Through Food and Exercise (LIFE) Study. <i>Journal of Health Care for the Poor and Underserved</i> , 2017, 28, 463-486.	0.4	2
1389	Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and activity of semicarbazide-sensitive amine oxidase. <i>Croatian Medical Journal</i> , 2017, 58, 106-116.	0.2	14
1390	Vascular Calcification. <i>Chinese Medical Journal</i> , 2017, 130, 1113-1121.	0.9	25
1391	Urine Albumin Excretion as a Marker of Acute Glycemic Changes in Isolated Postprandial Hyperglycemia. <i>Journal of Laboratory Physicians</i> , 2017, 9, 036-041.	0.4	3
1392	Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2017, 8, 845.	1.6	10
1393	N-acetylcysteine Counteracts Adipose Tissue Macrophage Infiltration and Insulin Resistance Elicited by Advanced Glycated Albumin in Healthy Rats. <i>Frontiers in Physiology</i> , 2017, 8, 723.	1.3	13
1394	Ophthalmic manifestations of endocrine disorders—endocrinology and the eye. <i>Translational Pediatrics</i> , 2017, 6, 286-299.	0.5	9
1395	Devices for continuous monitoring of glucose: update in technology. <i>Medical Devices: Evidence and Research</i> , 2017, Volume 10, 215-224.	0.4	16
1396	Effects of Incretin-Based Therapies on Diabetic Microvascular Complications. <i>Endocrinology and Metabolism</i> , 2017, 32, 316.	1.3	11
1397	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 69-79.	0.9	6
1398	Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1965.	1.8	273
1399	Indexing Natural Products for Their Potential Anti-Diabetic Activity: Filtering and Mapping Discriminative Physicochemical Properties. <i>Molecules</i> , 2017, 22, 1563.	1.7	18
1400	Stirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?. <i>Nutrients</i> , 2017, 9, 265.	1.7	39
1401	Effects of Two Different Dietary Patterns on Inflammatory Markers, Advanced Glycation End Products and Lipids in Subjects without Type 2 Diabetes: A Randomised Crossover Study. <i>Nutrients</i> , 2017, 9, 336.	1.7	26

#	ARTICLE	IF	CITATIONS
1402	Dietary Metabolites and Chronic Kidney Disease. <i>Nutrients</i> , 2017, 9, 358.	1.7	32
1403	Retrospective Evaluation of Metformin and/or Metformin Plus a New Polysaccharide Complex in Treating Severe Hyperinsulinism and Insulin Resistance in Obese Children and Adolescents with Metabolic Syndrome. <i>Nutrients</i> , 2017, 9, 524.	1.7	19
1404	Cardio-Metabolic Benefits of Plant-Based Diets. <i>Nutrients</i> , 2017, 9, 848.	1.7	255
1405	Resveratrol and Amyloid-Beta: Mechanistic Insights. <i>Nutrients</i> , 2017, 9, 1122.	1.7	67
1406	Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD. <i>Nutrients</i> , 2017, 9, 634.	1.7	33
1407	Diabetes in the elderly. <i>Przegląd Menopauzalny</i> , 2017, 2, 38-43.	0.6	30
1408	The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes. <i>Internal Medicine</i> , 2017, 56, 605-613.	0.3	10
1409	Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. <i>Current Diabetes Reviews</i> , 2017, 13, 405-423.	0.6	135
1410	Effects of Weight Loss on Advanced Glycation End Products in Subjects with and without Diabetes: A Preliminary Report. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 1553.	1.2	22
1411	Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 174.	1.8	14
1412	Methylglyoxal-Derived Advanced Glycation Endproducts in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 421.	1.8	57
1413	Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention. <i>International Journal of Molecular Sciences</i> , 2017, 18, 984.	1.8	152
1414	Molecular Pathways Involved in the Amelioration of Myocardial Injury in Diabetic Rats by Kaempferol. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1001.	1.8	72
1415	Diabetic Neuropathy Evaluated by a Novel Device: Sural Nerve Conduction Is Associated with Glycemic Control and Ankleâ€“Brachial Pressure Index in Japanese Patients with Diabetes. <i>Frontiers in Endocrinology</i> , 2017, 8, 203.	1.5	14
1416	Exercise after You Eat: Hitting the Postprandial Glucose Target. <i>Frontiers in Endocrinology</i> , 2017, 8, 228.	1.5	13
1417	Influenza Virus and Glycemic Variability in Diabetes: A Killer Combination?. <i>Frontiers in Microbiology</i> , 2017, 8, 861.	1.5	91
1418	Cerebral Hemodynamic and White Matter Changes of Type 2 Diabetes Revealed by Multi-TI Arterial Spin Labeling and Double Inversion Recovery Sequence. <i>Frontiers in Neurology</i> , 2017, 8, 717.	1.1	19
1419	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. <i>BioMed Research International</i> , 2017, 2017, 1-15.	0.9	1

#	ARTICLE	IF	CITATIONS
1420	Comparative Analysis of AGE and RAGE Levels in Human Somatic and Embryonic Stem Cells under H <sub>2</sub> O <sub>2</sub> -Induced Noncytotoxic Oxidative Stress Conditions. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-14.	1.9	8
1421	Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	111
1422	Medication Adherence Mediates the Association between Type D Personality and High HbA <sub>1c</sub> Level in Chinese Patients with Type 2 Diabetes Mellitus: A Six-Month Follow-Up Study. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-10.	1.0	12
1423	Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-6.	1.0	13
1424	A Systematic Review and Meta-Analysis of the Effect of Lifestyle Modification on Metabolic Control in Overweight Children. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-12.	0.5	6
1425	Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). <i>Journal of Ophthalmology</i> , 2017, 2017, 1-10.	0.6	54
1426	Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-19.	1.0	16
1427	Health Literacy, Diabetes Prevention, and Self-Management. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-3.	1.0	18
1428	Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-9.	1.0	39
1429	Barriers and facilitators to adherence to anti-diabetic medications: Ethiopian patients' perspectives. <i>African Journal of Primary Health Care and Family Medicine</i> , 2017, 9, e1-e9.	0.3	23
1430	Determinants of Long-Term Durable Glycemic Control in New-Onset Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 284.	1.8	12
1431	Mitochondrial Haplogroups Modify the Effect of Diabetes Duration and HbA <sub>1c</sub> on Proliferative Diabetic Retinopathy Risk in Patients With Type 2 Diabetes. , 2017, 58, 6481.		7
1432	Prevalence of diabetes and obesity in association with prematurity and growth restriction. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 285-295.	1.1	50
1433	Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 157-168.	0.9	5
1434	Diabetes in sub-Saharan Africa &ndash; from policy to practice to progress: targeting the existing gaps for future care for diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 247-263.	1.1	106
1435	Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 79-87.	1.1	24
1436	Type D personality as a predictor of self-efficacy and social support in patients with type 2 diabetes mellitus. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 855-861.	1.0	28
1437	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1569-1576.	0.9	4

#	ARTICLE	IF	CITATIONS
1438	Association between hemoglobin glycation index with insulin resistance and carotid atherosclerosis in non-diabetic individuals. PLoS ONE, 2017, 12, e0175547.	1.1	46
1439	Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. PLoS ONE, 2017, 12, e0177646.	1.1	35
1440	Validation of the diabetes screening tools proposed by the American Diabetes Association in an aging Chinese population. PLoS ONE, 2017, 12, e0184840.	1.1	13
1441	Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?. PLoS ONE, 2017, 12, e0171781.	1.1	9
1442	Intensive Patient Education Improves Glycaemic Control in Diabetes Compared to Conventional Education: A Randomised Controlled Trial in a Nigerian Tertiary Care Hospital. PLoS ONE, 2017, 12, e0168835.	1.1	37
1443	Association between HbA1c and carotid atherosclerosis among elderly Koreans with normal fasting glucose. PLoS ONE, 2017, 12, e0171761.	1.1	11
1444	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovascular Disorders, 2017, 17, 229.	0.7	25
1445	Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis. BMC Endocrine Disorders, 2017, 17, 63.	0.9	42
1446	Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya. BMC Endocrine Disorders, 2017, 17, 73.	0.9	14
1447	A combination of process of care and clinical target among type 2 diabetes mellitus patients in general medical clinics and specialist diabetes clinics at hospital levels. BMC Health Services Research, 2017, 17, 533.	0.9	5
1448	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. Cardiovascular Diabetology, 2017, 16, 114.	2.7	27
1449	Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0%. Cardiovascular Diabetology, 2017, 16, 151.	2.7	24
1450	Psychometric properties of the Diabetes Self-Management Questionnaire (DSMQ) in Urdu. Health and Quality of Life Outcomes, 2017, 15, 200.	1.0	25
1451	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetology and Metabolic Syndrome, 2017, 9, 53.	1.2	34
1452	Educ@dom: comparative study of the telemonitoring of patients with type 2 diabetes versus standard monitoring study protocol for a randomized controlled study. Diabetology and Metabolic Syndrome, 2017, 9, 52.	1.2	7
1453	Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells. BMC Pharmacology & Toxicology, 2017, 18, 67.	1.0	30
1454	Improved treatment satisfaction and medication adherence after readjusting oral medication regimens with the cooperation of health insurance pharmacy in type 2 diabetic patients in Japan. Journal of Pharmaceutical Health Care and Sciences, 2017, 3, 27.	0.4	4
1455	Diabetic retinopathy: research to clinical practice. Clinical Diabetes and Endocrinology, 2017, 3, 9.	1.3	41

#	ARTICLE	IF	CITATIONS
1456	The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction. <i>Diabetes Therapy</i> , 2017, 8, 1215-1226.	1.2	17
1457	Yang-warming method in the treatment of diabetic peripheral neuropathy: an updated systematic review and meta-analysis. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 424.	3.7	4
1458	The effectiveness of text message-based self-management interventions for poorly-controlled diabetes: A systematic review. <i>Digital Health</i> , 2017, 3, 205520761774031.	0.9	30
1459	Cystatin C Adiponectin Complex in Plasma Associates with Coronary Plaque Instability. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 970-979.	0.9	3
1460	A qualitative study of health education experiences and self-management practices among patients with type 2 diabetes at Malamulo Adventist Hospital in Thyolo District, Malawi. <i>Malawi Medical Journal</i> , 2017, 29, 118.	0.2	13
1461	Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?. <i>Annals of Translational Medicine</i> , 2017, 5, 476-476.	0.7	4
1462	Recent advances in understanding/managing type 2 diabetes mellitus. <i>F1000Research</i> , 2017, 6, 1922.	0.8	5
1463	Methylglyoxal-Glyoxalase 1 Balance: The Root of Vascular Damage. <i>International Journal of Molecular Sciences</i> , 2017, 18, 188.	1.8	80
1464	Treatment of type 2 diabetes mellitus in the elderly. <i>World Journal of Diabetes</i> , 2017, 8, 278.	1.3	62
1465	Probing Protein Glycation by Chromatography and Mass Spectrometry: Analysis of Glycation Adducts. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2557.	1.8	52
1466	Hypertension and blood pressure variability management practices among physicians in Singapore. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 275-285.	1.0	14
1467	A Lab-on-a-Chip-Based Non-Invasive Optical Sensor for Measuring Glucose in Saliva. <i>Sensors</i> , 2017, 17, 2607.	2.1	45
1468	Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 337.	1.8	49
1469	Monotherapy in Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 349.	1.8	13
1470	Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 630-642.	0.9	26
1471	Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 128.	1.8	43
1472	Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup. <i>Ethnicity and Disease</i> , 2017, 27, 45.	1.0	1
1473	Effects of glycaemic management on diabetic kidney disease. <i>World Journal of Diabetes</i> , 2017, 8, 172.	1.3	58



#	ARTICLE	IF	CITATIONS
1474	Multidisciplinary Team-Based Obesity Treatment in Patients With Diabetes: Current Practices and the State of the Science. <i>Diabetes Spectrum</i> , 2017, 30, 244-249.	0.4	27
1475	Diabetes risk reduction in primary care: Evaluation of the Ontario Primary Care Diabetes Prevention Program. <i>Canadian Journal of Public Health</i> , 2017, 108, e176-e184.	1.1	7
1476	Anti-diabetic medications: How to make a choice?. <i>Sudanese Journal of Paediatrics</i> , 2017, 17, 11-20.	0.6	20
1477	Frequency of Type-2 diabetes mellitus in Nephropathic patients and comparison of mean magnesium levels in Nephropathic patients with and without Type-2 diabetes mellitus. <i>Pakistan Journal of Medical Sciences</i> , 2017, 33, 1254-1259.	0.3	1
1478	Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. <i>Journal of Thoracic Disease</i> , 2017, 9, 2124-2134.	0.6	20
1479	Metabolic surgery: gastric bypass for the treatment of type 2 diabetes mellitus. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 58-58.	1.5	15
1480	The influence of pharmacist-led adherence support on glycaemic control in people with type 2 diabetes. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 354-359.	1.0	13
1481	EADSG Guidelines: Insulin Therapy in Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 449-492.	1.2	103
1482	Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes. <i>Diabetes Therapy</i> , 2018, 9, 501-519.	1.2	18
1483	The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018, 23, 303-323.	1.7	41
1484	The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. <i>Clinical Science</i> , 2018, 132, 489-507.	1.8	75
1485	Dietary Behaviors and Glucose Metabolism in Young Adults at Risk for Type 2 Diabetes. <i>The Diabetes Educator</i> , 2018, 44, 158-167.	2.6	5
1486	Use of Decision Support Software to Titrate Multiple Daily Injections Yielded Sustained A1c Reductions After 1 Year. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 124-128.	1.3	11
1487	AGE-Related RAGE Stress, Stressors, and Antistressors in Health and Disease. <i>International Journal of Angiology</i> , 2018, 27, 001-012.	0.2	69
1488	Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 817-827.	1.3	7
1489	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1060-1073.	1.6	26
1490	Economic Evaluation of Quality Improvement Interventions Designed to Improve Glycemic Control in Diabetes: A Systematic Review and Weighted Regression Analysis. <i>Diabetes Care</i> , 2018, 41, 985-993.	4.3	30
1491	Transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin-treated Sprague-Dawley rats with type 2 diabetes mellitus. <i>International Journal of Molecular Medicine</i> , 2018, 41, 3327-3341.	1.8	13

#	ARTICLE	IF	CITATIONS
1492	A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. <i>Cancer Medicine</i> , 2018, 7, 2180-2191.	1.3	13
1493	Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03). <i>Internal Medicine</i> , 2018, 57, 1229-1240.	0.3	20
1494	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. <i>Annals of Vascular Diseases</i> , 2018, 11, 2-14.	0.2	8
1495	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Journal of Diabetes Investigation</i> , 2018, 9, 657-697.	1.1	158
1496	Diabetic Kidney Disease: Is There a Role for Glycemic Variability?. <i>Current Diabetes Reports</i> , 2018, 18, 13.	1.7	13
1497	Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 480-487.	1.2	6
1498	Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. <i>Current Opinion in Lipidology</i> , 2018, 29, 95-103.	1.2	23
1499	Different Indexes of Glycemic Variability as Identifiers of Patients with Risk of Hypoglycemia in Type 2 Diabetes Mellitus. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 1007-1015.	1.3	28
1500	Evaluation of a New Noninvasive Glucose Monitoring Device by Means of Standardized Meal Experiments. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 1178-1183.	1.3	24
1501	Sevelamer reduces endothelial inflammatory response to advanced glycation end products. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 89-98.	1.4	21
1502	Vitamin E Supplementation in Pediatric Nonalcoholic Fatty Liver Disease. <i>Topics in Clinical Nutrition</i> , 2018, 33, 50-68.	0.2	2
1503	Cardiometabolic risk in obese children. <i>Annals of the New York Academy of Sciences</i> , 2018, 1411, 166-183.	1.8	131
1504	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. <i>Heart Failure Reviews</i> , 2018, 23, 377-388.	1.7	16
1505	Cannabinoid Receptors in Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2018, 18, 9.	1.7	19
1506	Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. <i>Diabetes Therapy</i> , 2018, 9, 297-307.	1.2	15
1507	Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. <i>Diabetes Therapy</i> , 2018, 9, 521-543.	1.2	55
1508	Cost-Effectiveness Analysis of Canagliflozin 300Âmg Versus Dapagliflozin 10Âmg Added to Metformin in Patients with Type 2 Diabetes in the United States. <i>Diabetes Therapy</i> , 2018, 9, 565-581.	1.2	13
1509	Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 33-50.	1.1	30

#	ARTICLE	IF	CITATIONS
1510	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. <i>CMAJ Open</i> , 2018, 6, E31-E38.	1.1	27
1511	Clinical impact of oral antidiabetic medications in heart failure patients. <i>Heart Failure Reviews</i> , 2018, 23, 325-335.	1.7	10
1512	Effect of glucose-lowering therapies on heart failure. <i>Nature Reviews Cardiology</i> , 2018, 15, 282-291.	6.1	45
1513	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. <i>Heart Failure Reviews</i> , 2018, 23, 445-459.	1.7	9
1514	Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study. <i>American Journal of Ophthalmology</i> , 2018, 187, 138-147.	1.7	17
1515	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
1516	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. <i>Heart Failure Reviews</i> , 2018, 23, 469-479.	1.7	4
1517	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. <i>Drugs</i> , 2018, 78, 203-214.	4.9	5
1518	The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey. <i>BMC Ophthalmology</i> , 2018, 18, 91.	0.6	35
1519	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 360, k119.	2.4	132
1520	Development of the Weight-Related Sign and Symptom Measure. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 17.	0.9	3
1521	Glycemic control and its associated factors among diabetes mellitus patients at Ayder comprehensive specialized hospital, Mekelle-Ethiopia. <i>Adipocyte</i> , 2018, 7, 197-203.	1.3	18
1522	Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 693-701.	1.2	25
1523	A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672). <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00004.	1.0	2
1524	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.	0.1	63
1525	Glycaemic control in type 2 diabetes patients and its predictors: a retrospective database study at a tertiary care diabetes centre in Ningbo, China. <i>BMJ Open</i> , 2018, 8, e019697.	0.8	25
1526	Comparison of incidence, rate and length of all-cause hospital admissions between adults with normoglycaemia, impaired fasting glucose and diabetes: a retrospective cohort study in Geelong, Australia. <i>BMJ Open</i> , 2018, 8, e020346.	0.8	3
1527	Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 193-205.	0.6	40

#	ARTICLE	IF	CITATIONS
1528	Compliance with guidelines for disease management in diabetes: results from the SwissDiab Registry. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000454.	1.2	11
1529	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000464.	1.2	18
1530	Different lasers and techniques for proliferative diabetic retinopathy. <i>The Cochrane Library</i> , 2018, 2018, CD012314.	1.5	32
1531	Changing Patients'™ Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2018, 9, 803-814.	1.2	8
1532	The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis. <i>Diabetes Therapy</i> , 2018, 9, 963-971.	1.2	2
1533	Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial. <i>Diabetes Therapy</i> , 2018, 9, 987-999.	1.2	5
1534	Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. <i>Diabetes Therapy</i> , 2018, 9, 951-961.	1.2	16
1535	Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2018, 38, 491-501.	1.1	3
1536	Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic $\beta$ -cell apoptosis. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2970-2980.	1.6	46
1537	Comprehensive risk management of diabetic kidney disease in patients with type 2 diabetes mellitus. <i>Diabetology International</i> , 2018, 9, 100-107.	0.7	4
1538	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	1.2	50
1539	“The More I Do, the Better I Be”: The Treatment Preferences of Type 2 Diabetes Among African American Men. <i>American Journal of Men's Health</i> , 2018, 12, 779-787.	0.7	1
1540	Real-life glycemic control in patients with type 2 diabetes treated with insulin therapy: A prospective, longitudinal cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 9]). <i>Journal of Diabetes Investigation</i> , 2018, 9, 294-302.	1.1	1
1541	Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2018, 9, 119-126.	1.1	21
1542	Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies. <i>Journal of the American Statistical Association</i> , 2018, 113, 1-13.	1.8	66
1543	Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. <i>Pediatric Diabetes</i> , 2018, 19, 36-44.	1.2	19
1544	Impact of estimated glomerular filtration rate on diabetic macular edema. <i>International Ophthalmology</i> , 2018, 38, 1043-1050.	0.6	10
1545	Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 335-338.	2.2	22

#	ARTICLE	IF	CITATIONS
1546	Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. <i>Primary Care Diabetes</i> , 2018, 12, 139-146.	0.9	24
1547	Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 41-48.	1.2	20
1548	The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN Pharmacoepidemiology study. <i>Osteoporosis International</i> , 2018, 29, 347-354.	1.3	29
1549	Prognostic value of coronary atherosclerosis progression evaluated by coronary CT angiography in patients with stable angina. <i>European Radiology</i> , 2018, 28, 1066-1076.	2.3	19
1550	Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. <i>Diabetologia</i> , 2018, 61, 29-38.	2.9	230
1551	Overtreatment and Deintensification of Diabetic Therapy among Medicare Beneficiaries. <i>Journal of General Internal Medicine</i> , 2018, 33, 34-41.	1.3	36
1552	Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 481-497.	1.7	4
1553	Secretogranin III: a diabetic retinopathy-selective angiogenic factor. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 635-647.	2.4	21
1554	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. <i>Journal of Diabetes Investigation</i> , 2018, 9, 579-586.	1.1	11
1555	High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. <i>Journal of Vascular Surgery</i> , 2018, 67, 217-228.e1.	0.6	48
1556	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. <i>Endocrine</i> , 2018, 60, 224-228.	1.1	11
1557	HbA1c is associated with altered expression in blood of cell cycle- and immune response-related genes. <i>Diabetologia</i> , 2018, 61, 138-146.	2.9	10
1558	Endothelial Cell Metabolism. <i>Physiological Reviews</i> , 2018, 98, 3-58.	18.1	351
1559	The Role of Glycemic Control and Variability in Diabetic Retinopathy. <i>Diabetes Therapy</i> , 2018, 9, 431-434.	1.2	27
1560	Lower mean blood glucose during short-term intensive insulin therapy is associated with long-term glycemic remission in patients with newly diagnosed type 2 diabetes: Evidence-based recommendations for standardization. <i>Journal of Diabetes Investigation</i> , 2018, 9, 908-916.	1.1	11
1561	Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart. <i>Heart Failure Reviews</i> , 2018, 23, 37-54.	1.7	38
1562	Management of diabetic macular edema in Japan: a review and expert opinion. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 1-23.	0.9	44
1563	Influence of comorbidities on the implementation of the fundus examination in patients with newly diagnosed type 2 diabetes. <i>Japanese Journal of Ophthalmology</i> , 2018, 62, 68-76.	0.9	5

#	ARTICLE	IF	CITATIONS
1564	Glycemic control among primary care patients with type 2 diabetes mellitus in the Gaza Strip, Palestine. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2018, 9, 3-14.	1.4	33
1565	Dietary Advanced Glycation End Products Have Sex- and Age-Dependent Effects on Vertebral Bone Microstructure and Mechanical Function in Mice. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 437-448.	3.1	25
1566	Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. <i>Islets</i> , 2018, 10, 10-24.	0.9	23
1567	The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 104-111.	4.3	149
1568	Translating aetiological insight into sustainable management of type 2 diabetes. <i>Diabetologia</i> , 2018, 61, 273-283.	2.9	33
1569	The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France. <i>Diabetes Therapy</i> , 2018, 9, 13-25.	1.2	11
1570	The Comprehensive Glucose Pentagon: A Glucose-Centric Composite Metric for Assessing Glycemic Control in Persons With Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 114-123.	1.3	35
1571	Chronic Silymarin, Quercetin and Naringenin Treatments Increase Monoamines Synthesis and Hippocampal Sirt1 Levels Improving Cognition in Aged Rats. <i>Journal of NeuroImmune Pharmacology</i> , 2018, 13, 24-38.	2.1	76
1572	Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control – Continuous Glucose Monitoring is the Solution. <i>European Endocrinology</i> , 2018, 14, 50.	0.8	17
1573	Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark. <i>BMJ Open</i> , 2018, 8, e019214.	0.8	15
1574	Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-5.	1.0	1
1575	Audit of insulin prescription patterns and associated burden among diabetics in a tertiary health institution in Nigeria. <i>African Health Sciences</i> , 2018, 18, 852.	0.3	13
1576	Determination of the optimal diabetes duration for bone regeneration experiments in an alloxan-induced diabetic rabbit calvarial defect model. <i>Journal of Periodontal and Implant Science</i> , 2018, 48, 383.	0.9	2
1577	Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin. <i>Diabetes Spectrum</i> , 2018, 31, 261-266.	0.4	1
1578	Accumulated or continuous exercise for glycaemic regulation and control: a systematic review with meta-analysis. <i>BMJ Open Sport and Exercise Medicine</i> , 2018, 4, e000470.	1.4	9
1579	Patient expectations of hypertension and diabetes medication: Excessive focus on short-term benefits. <i>SAGE Open Medicine</i> , 2018, 6, 205031211882111.	0.7	9
1580	In vitro differentiation of human multilineage differentiating stress-enduring (Muse) cells into insulin producing cells. <i>Journal of Genetic Engineering and Biotechnology</i> , 2018, 16, 433-440.	1.5	6
1581	Factors influencing variation in participation in the National Diabetes Audit and the impact on the Quality and Outcomes Framework indicators of diabetes care management. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000554.	1.2	4

#	ARTICLE	IF	CITATIONS
1582	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 2018, 9, CD011798.	1.5	48
1583	Effects of a Low Advanced Glycation End Products Diet on Insulin Levels: The Feasibility of a Crossover Comparison Test. Journal of Clinical Medicine Research, 2018, 10, 405-410.	0.6	1
1584	SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists. Journal of Clinical Medicine Research, 2018, 10, 615-625.	0.6	12
1585	Impact of Socioeconomic Status on Health Behaviors, Metabolic Control, and Chronic Complications in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2018, 42, 380.	1.8	16
1586	Glycemic control and diabetes complications among diabetes mellitus patients attending at University of Gondar Hospital, Northwest Ethiopia. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 75-83.	1.1	65
1587	Treatment approach to type 2 diabetes: Past, present and future. World Journal of Diabetes, 2018, 9, 209-219.	1.3	56
1588	Diabetes management in a Primary Care Network (PCN) of private general practitioners in Singapore. Medicine (United States), 2018, 97, e12929.	0.4	6
1589	Diabetes: learning from the past 25 years and looking to the future. Cardiovascular Endocrinology and Metabolism, 2018, 7, 70-72.	0.5	0
1590	Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. The Cochrane Library, 2018, 12, CD013228.	1.5	33
1591	Impact of a multidisciplinary intensive education program on type 2 diabetes mellitus patients' glycemic control and cardiovascular risk factors. Journal of King Abdulaziz University, Islamic Economics, 2018, 39, 705-710.	0.5	12
1592	The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes. Current Diabetes Reports, 2018, 18, 144.	1.7	7
1593	Automated closed-loop control of diabetes: the artificial pancreas. Bioelectronic Medicine, 2018, 4, 14.	1.0	53
1594	Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience. Frontiers in Endocrinology, 2018, 9, 634.	1.5	3
1595	Newly diagnosed type 2 diabetes in an ethnic minority population: clinical presentation and comparison to other populations. BMJ Open Diabetes Research and Care, 2018, 6, e000568.	1.2	3
1596	Management of Chronic Disease and Hospitalization Due to Diabetes among Type 2 Diabetes Patients in Korea: Using the National Sample Cohort Data 2002-2013. International Journal of Environmental Research and Public Health, 2018, 15, 2541.	1.2	2
1597	Hypoglycemia incidence and awareness among insulin-treated patients with diabetes: the HAT study in Brazil. Diabetology and Metabolic Syndrome, 2018, 10, 83.	1.2	38
1598	S100/RAGE-Mediated Inflammation and Modified Cholesterol Lipoproteins as Mediators of Osteoblastic Differentiation of Vascular Smooth Muscle Cells. Frontiers in Cardiovascular Medicine, 2018, 5, 163.	1.1	19
1599	The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Molecular Medicine, 2018, 24, 59.	1.9	202

#	ARTICLE	IF	CITATIONS
1600	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3200-3223.	1.2	251
1601	Evaluation of the analytical performances of the Cobas c513 analyser for HbA1c assay. <i>Biochimica Medica</i> , 2018, 28, 030708.	1.2	3
1602	Defining the target: clinical aims in axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, vi18-vi22.	0.9	17
1603	Advancing Health Policy and Program Research in Diabetes: Findings from the Natural Experiments for Translation in Diabetes (NEXT-D) Network. <i>Current Diabetes Reports</i> , 2018, 18, 146.	1.7	14
1604	Diabetes and TelecommunicationS (DATES) study to support self-management for people with type 2 diabetes: a randomized controlled trial. <i>BMC Public Health</i> , 2018, 18, 1249.	1.2	8
1605	Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-8.	1.0	69
1606	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1629-1647.	1.4	31
1607	Early-onset diabetes: an epidemic in China. <i>Frontiers of Medicine</i> , 2018, 12, 624-633.	1.5	27
1608	Association of HbA1C Variability and Renal Progression in Patients with Type 2 Diabetes with Chronic Kidney Disease Stages 3&#x2014;4. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4116.	1.8	29
1609	The Intersection of Diabetes and Cardiovascular Disease&#x2014;A Focus on New Therapies. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 160.	1.1	4
1610	Ethyl Rosmarinate Protects High Glucose-Induced Injury in Human Endothelial Cells. <i>Molecules</i> , 2018, 23, 3372.	1.7	13
1611	Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study. <i>International Journal of Angiology</i> , 2018, 27, 213-222.	0.2	4
1612	Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2018, 1, e186125.	2.8	69
1613	Nerve conduction velocity is negatively associated with intima-media thickness and brachial-ankle pulse wave velocity in men with type 2 diabetes mellitus. <i>PLoS ONE</i> , 2018, 13, e0209503.	1.1	2
1614	Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. <i>Nutrients</i> , 2018, 10, 1872.	1.7	19
1615	Legacy effect in medicine&#x2014;the expanding horizon!. <i>Indian Heart Journal</i> , 2018, 70, 769-771.	0.2	4
1616	Psychosocial interventions for reducing diabetes distress in vulnerable people with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 19-33.	1.1	39
1617	Coating rice with mulberry leaves rich in deoxyojirimycin ameliorates hyperglycemia and dyslipidemia in C57BL/KsJ<i>db</i>/<i>J</i> mice. <i>Nutrition Research and Practice</i> , 2018, 12, 469.	0.7	11



#	ARTICLE	IF	CITATIONS
1618	Strategies and Research Progress of Chinese Medicine in Prevention and Treatment of Diabetic Peripheral Neuropathy. Chinese Journal of Integrative Medicine, 2018, 24, 794-800.	0.7	9
1619	Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. Current Cardiology Reports, 2018, 20, 112.	1.3	6
1620	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is it a Class Effect?. Current Cardiology Reports, 2018, 20, 113.	1.3	19
1621	Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial. Nutrients, 2018, 10, 1315.	1.7	37
1622	Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. Current Diabetes Reports, 2018, 18, 102.	1.7	6
1623	Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention. Journal of the American College of Cardiology, 2018, 72, 1829-1844.	1.2	32
1624	Effect of pharmaceutical care interventions on glycemic control in patients with diabetes: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1813-1829.	0.9	20
1625	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.	2.9	1,002
1626	Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 217-226.	1.1	6
1627	Methods for combining continuously measured glucose and activity data in people with Type 2 diabetes: Challenges and solutions. Journal of Rehabilitation and Assistive Technologies Engineering, 2018, 5, 205566831878280.	0.6	4
1628	The Main Determinants of Diabetes Mellitus Vascular Complications: Endothelial Dysfunction and Platelet Hyperaggregation. International Journal of Molecular Sciences, 2018, 19, 2968.	1.8	56
1629	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1693-1702.	2.2	32
1630	Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovascular Diabetology, 2018, 17, 138.	2.7	104
1631	Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Therapy, 2018, 9, 2383-2392.	1.2	23
1632	Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus. Diabetology and Metabolic Syndrome, 2018, 10, 73.	1.2	8
1633	Factors that Correlate with Poor Glycemic Control in Type 2 Diabetes Mellitus Patients with Complications. Osong Public Health and Research Perspectives, 2018, 9, 167-174.	0.7	68
1634	An Overview of Our Current Understanding of Diabetic Macular Ischemia (DMI). Cureus, 2018, 10, e3064.	0.2	14
1635	Evidence-Based Management of Diabetes in Older Adults. Drugs and Aging, 2018, 35, 1065-1078.	1.3	19

#	ARTICLE	IF	CITATIONS
1636	Xiao-Shen-Formula, a Traditional Chinese Medicine, Improves Glomerular Hyper-Filtration in Diabetic Nephropathy via Inhibiting Arginase Activation and Heparanase Expression. <i>Frontiers in Physiology</i> , 2018, 9, 1195.	1.3	13
1637	Association between Neutrophil-to-Lymphocyte Ratio and Gut Microbiota in a Large Population: a Retrospective Cross-Sectional Study. <i>Scientific Reports</i> , 2018, 8, 16031.	1.6	18
1638	Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. <i>Nutrition and Metabolism</i> , 2018, 15, 72.	1.3	108
1639	Quality of care delivered to type 2 diabetes mellitus patients in public and private sector facilities in Johannesburg, South Africa. <i>International Journal of General Medicine</i> , 2018, Volume 11, 383-390.	0.8	9
1640	Microvascular Parameters Help to Predict Stroke Risk in the Asian Diabetic Population in Taiwan: A Population Based Case-Control Study. <i>Frontiers in Neurology</i> , 2018, 9, 719.	1.1	3
1641	A cross-sectional assessment of diabetes self-management, education and support needs of Syrian refugee patients living with diabetes in Bekaa Valley Lebanon. <i>Conflict and Health</i> , 2018, 12, 40.	1.0	19
1642	Metabolic Syndrome-Related Features in Controlled and Resistant Hypertensive Subjects. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 110, 514-521.	0.3	10
1643	Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome. <i>Korean Circulation Journal</i> , 2018, 48, 430.	0.7	0
1644	Higher Prevalence and Progression Rate of Chronic Kidney Disease in Elderly Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2018, 42, 224.	1.8	42
1645	Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. <i>Diabetes Therapy</i> , 2018, 9, 2067-2079.	1.2	2
1646	Update on the Management of Diabetic Neuropathy. <i>Diabetes Spectrum</i> , 2018, 31, 224-233.	0.4	42
1647	iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2018, 31, 145-154.	0.4	22
1648	Acute saccharin infusion has no effect on renal glucose handling in normal rats in vivo. <i>Physiological Reports</i> , 2018, 6, e13804.	0.7	1
1650	Patient Understanding of Hypoglycemia in Tertiary Referral Centers. <i>Diabetes and Metabolism Journal</i> , 2018, 42, 43.	1.8	6
1651	The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. <i>Cell Metabolism</i> , 2018, 28, 337-352.	7.2	371
1652	Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0202563.	1.1	12
1653	Treatment of Diabetes in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2018, 20, 97.	1.3	1
1654	Mechanistic targeting of advanced glycation end-products in age-related diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3631-3643.	1.8	145

#	ARTICLE	IF	CITATIONS
1655	Continuous positive airway pressure effect on visual acuity in patients with type 2 diabetes and obstructive sleep apnoea: a multicentre randomised controlled trial. <i>European Respiratory Journal</i> , 2018, 52, 1801177.	3.1	18
1656	Association between insulin resistance and the development of cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2018, 17, 122.	2.7	1,031
1657	Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance. <i>Internal Medicine</i> , 2018, 57, 2923-2927.	0.3	0
1658	The Impacts of Gastroileostomy Rat Model on Glucagon-like Peptide-1: a Promising Model to Control Type 2 Diabetes Mellitus. <i>Obesity Surgery</i> , 2018, 28, 3246-3252.	1.1	6
1659	National Rates of Initiation and Intensification of Antidiabetic Therapy Among Patients With Commercial Insurance. <i>Diabetes Care</i> , 2018, 41, 1776-1782.	4.3	5
1660	Is there a relationship between body mass index and diabetic retinopathy in type II diabetic patients? A cross sectional study. <i>Journal of Diabetes and Metabolic Disorders</i> , 2018, 17, 63-69.	0.8	15
1661	Telemedicine in Complex Diabetes Management. <i>Current Diabetes Reports</i> , 2018, 18, 42.	1.7	70
1662	Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments. <i>Diabetes Therapy</i> , 2018, 9, 1431-1440.	1.2	31
1663	Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. <i>Cell Stem Cell</i> , 2018, 22, 810-823.	5.2	189
1664	Are the U.S. territories lagging behind in diabetes care practices?. <i>Primary Care Diabetes</i> , 2018, 12, 432-437.	0.9	4
1665	Advanced glycation end products-induced insulin resistance involves repression of skeletal muscle GLUT4 expression. <i>Scientific Reports</i> , 2018, 8, 8109.	1.6	54
1666	Effects of acute ingestion of whey protein with or without prior aerobic exercise on postprandial glycemia in type 2 diabetics. <i>European Journal of Applied Physiology</i> , 2018, 118, 1959-1968.	1.2	1
1667	Patient-Related Determinants of Glycaemic Control in People with Type 2 Diabetes in the Gulf Cooperation Council Countries: A Systematic Review. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-14.	1.0	20
1668	Changes in Serum Electrolytes, ECG, and Baroreflex Sensitivity during Combined Pituitary Stimulation Test. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	1
1669	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test. <i>Diabetes Care</i> , 2018, 41, 1707-1716.	4.3	80
1670	Impact of Insulin and Metformin Versus Metformin Alone on $\beta$ -Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1717-1725.	4.3	112
1671	Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?. <i>Diabetes Care</i> , 2018, 41, 1560-1562.	4.3	10
1672	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. <i>Diabetes Care</i> , 2018, 41, 1696-1706.	4.3	127

#	ARTICLE	IF	CITATIONS
1673	Diabetic Retinopathy –Incidence And Risk Factors In A Community Setting- A Longitudinal Study. Scandinavian Journal of Primary Health Care, 2018, 36, 237-241.	0.6	11
1674	Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus. Integrative Medicine Research, 2018, 7, 248-256.	0.7	16
1675	Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events. International Journal of Endocrinology, 2018, 2018, 1-7.	0.6	6
1676	Association of Metformin Treatment with Reduced Severity of Diabetic Retinopathy in Type 2 Diabetic Patients. Journal of Diabetes Research, 2018, 2018, 1-8.	1.0	37
1677	Medication adherence and factors associated with poor adherence among type 2 diabetes mellitus patients on follow-up at Kenyatta National Hospital, Kenya. Pan African Medical Journal, 2018, 29, 82.	0.3	43
1678	Contribution of BHG and PPHG to Overall Hyperglycemia in T2DM Patients Treated with LM25 and LM50: Post Hoc Analysis of a Randomized Crossover Trial. Diabetes Therapy, 2018, 9, 1605-1614.	1.2	1
1679	Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review. Journal of Ophthalmology, 2018, 2018, 1-13.	0.6	32
1680	Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. Journal of Transplantation, 2018, 2018, 1-14.	0.3	19
1681	The Relationship between Diabetes-Related Complications and Obstructive Sleep Apnea in Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-9.	1.0	40
1682	Hypoglycemia Among Patients with Type 2 Diabetes: Epidemiology, Risk Factors, and Prevention Strategies. Current Diabetes Reports, 2018, 18, 53.	1.7	127
1683	Prehypertension increases the risk of atherosclerosis in drug-naïve Japanese patients with type 2 diabetes mellitus. PLoS ONE, 2018, 13, e0201055.	1.1	5
1684	Critical limb ischemia: current challenges and future prospects. Vascular Health and Risk Management, 2018, Volume 14, 63-74.	1.0	117
1685	Relationship of Hyperglycaemia, Hypoglycaemia, and Glucose Variability to Atherosclerotic Disease in Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-9.	1.0	17
1686	Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial. Diabetes Care, 2018, 41, 2187-2194.	4.3	99
1687	Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World Journal of Diabetes, 2018, 9, 1-24.	1.3	145
1688	Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care. Annals of Internal Medicine, 2018, 169, 300-310.	2.0	129
1689	Mitochondrial regulation of diabetic vascular disease: an emerging opportunity. Translational Research, 2018, 202, 83-98.	2.2	35
1690	Medicaid Eligibility Expansions May Address Gaps In Access To Diabetes Medications. Health Affairs, 2018, 37, 1200-1207.	2.5	23

#	ARTICLE	IF	CITATIONS
1691	Inhibition of RAGE Attenuates Cigarette Smoke-Induced Lung Epithelial Cell Damage via RAGE-Mediated Nrf2/DAMP Signaling. <i>Frontiers in Pharmacology</i> , 2018, 9, 684.	1.6	36
1692	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 133-148.	1.1	21
1693	GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000519.	1.2	29
1694	Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 413-421.	0.7	7
1695	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. <i>Diabetes Care</i> , 2018, 41, 2229-2235.	4.3	74
1696	Nurse-led psychological intervention for type 2 diabetes: a cluster randomised controlled trial (Diabetes-6 study) in primary care. <i>British Journal of General Practice</i> , 2018, 68, e531-e540.	0.7	26
1697	Factors associated with glycemic control among diabetic adult out-patients in Northeast Ethiopia. <i>BMC Research Notes</i> , 2018, 11, 316.	0.6	49
1698	Impact of Normoglycemia in Reducing Microvascular Complications in Patients with Type 2 Diabetes: A Follow-Up Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 52.	1.5	9
1699	Cardiovascular Autonomic Neuropathy and Glucose Variability in Patients With Type 1 Diabetes: Is There an Association?. <i>Frontiers in Endocrinology</i> , 2018, 9, 174.	1.5	21
1700	Modeling of Diabetes and Its Clinical Impact. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 976-984.	1.3	20
1701	The Effect of Low-Carbohydrate Diet on Glycemic Control in Patients with Type 2 Diabetes Mellitus. <i>Nutrients</i> , 2018, 10, 661.	1.7	58
1702	Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach. <i>Current Diabetes Reports</i> , 2018, 18, 64.	1.7	27
1703	The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2018, 19, 110.	1.8	249
1704	Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detectionâ€™The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2018, 19, 797.	1.8	14
1705	Dietary Flavonoids in the Prevention of T2D: An Overview. <i>Nutrients</i> , 2018, 10, 438.	1.7	73
1706	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). <i>Toxins</i> , 2018, 10, 237.	1.5	28
1707	Changes in HbA1c and weight, and treatment persistence, over the 18Âmonths following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018, 16, 116.	2.3	36
1708	A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2). <i>European Journal of Pediatrics</i> , 2018, 177, 1497-1503.	1.3	4

#	ARTICLE	IF	CITATIONS
1709	HbA1c and hypoglycaemia in intensively treated type 2 diabetes: a retrospective cohort study in primary care. <i>JRSM Open</i> , 2018, 9, 205427041877366.	0.2	1
1710	SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials. <i>Current Diabetes Reports</i> , 2018, 18, 63.	1.7	12
1711	Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007â€”2017. <i>Cardiovascular Diabetology</i> , 2018, 17, 83.	2.7	1,198
1712	Senescent Microvesicles: A Novel Advance in Molecular Mechanisms of Atherosclerotic Calcification. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2003.	1.8	41
1713	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Diabetology International</i> , 2018, 9, 1-45.	0.7	215
1714	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. <i>Cardiovascular Diabetology</i> , 2018, 17, 9.	2.7	31
1715	Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke. <i>Cardiovascular Diabetology</i> , 2018, 17, 2.	2.7	22
1716	Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1Year: an open label, non-randomized, controlled study. <i>Cardiovascular Diabetology</i> , 2018, 17, 56.	2.7	135
1717	Prevalence, awareness, treatment and control of diabetes mellitus among middle-aged and elderly people in a rural Chinese population: A cross-sectional study. <i>PLoS ONE</i> , 2018, 13, e0198343.	1.1	98
1718	Coenzyme Q10 Prevents Senescence and Dysfunction Caused by Oxidative Stress in Vascular Endothelial Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-15.	1.9	65
1719	PkcÎ´ Activation is Involved in ROS-Mediated Mitochondrial Dysfunction and Apoptosis in Cardiomyocytes Exposed to Advanced Glycation End Products (Ages). , 2018, 9, 647.		41
1720	The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 15-21.	1.1	83
1721	The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 955-963.	0.9	8
1722	Too much TRAFFic at the crossroads of diabetes and endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H65-H67.	1.5	1
1723	Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 726-735.	2.7	35
1724	Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000527.	1.2	22
1725	Effect of Strict Volume Control on Renal Progression and Mortality in Non-Dialysis-Dependent Chronic Kidney Disease Patients: A Prospective Interventional Study. <i>Medical Principles and Practice</i> , 2018, 27, 420-427.	1.1	13
1726	Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-17.	1.0	102

#	ARTICLE	IF	CITATIONS
1727	Effectiveness of Systematic Health Education Model for Type 2 Diabetes Patients. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-9.	0.6	21
1728	Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. <i>BMC Neurology</i> , 2018, 18, 126.	0.8	30
1729	Incidence and predictors of chronic kidney diseases among type 2 diabetes mellitus patients at St. Paulâ€™s Hospital, Addis Ababa, Ethiopia. <i>BMC Research Notes</i> , 2018, 11, 532.	0.6	17
1730	Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy. <i>PLoS ONE</i> , 2018, 13, e0202103.	1.1	26
1731	Medications that cause weight gain and alternatives in Canada: a narrative review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 427-438.	1.1	57
1732	The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2018, 9, 187-197.	1.4	6
1733	Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000521.	1.2	42
1734	Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications from the Japan Diabetes Outcome Intervention Trial 3. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1022-1024.	1.1	1
1735	Glutathione metabolism in type 2 diabetes and its relationship with microvascular complications and glycemia. <i>PLoS ONE</i> , 2018, 13, e0198626.	1.1	111
1736	Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT). <i>Current Diabetes Reports</i> , 2018, 18, 51.	1.7	25
1737	Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. <i>PLoS ONE</i> , 2018, 13, e0191953.	1.1	12
1738	Magnitude of glycemic control and its associated factors among patients with type 2 diabetes at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. <i>PLoS ONE</i> , 2018, 13, e0193442.	1.1	48
1739	Prevalence of diabetic retinopathy and diabetic macular edema in a primary care-based teleophthalmology program for American Indians and Alaskan Natives. <i>PLoS ONE</i> , 2018, 13, e0198551.	1.1	54
1740	Culturally responsive approaches to health promotion for Native Hawaiians and Pacific Islanders. <i>Annals of Human Biology</i> , 2018, 45, 249-263.	0.4	76
1741	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2291-2301.	1.8	225
1742	Correlation of the anterior ocular segment biometry with HbA1c level in type 2 diabetes mellitus patients. <i>PLoS ONE</i> , 2018, 13, e0191134.	1.1	12
1743	Metabolic Surgery for the Treatment of Diabetes Mellitus Positioning of Leading Medical Associations in Mexico. <i>Obesity Surgery</i> , 2018, 28, 3474-3483.	1.1	4
1744	Historical trends in modifiable indicators of cardiovascular health and self-rated health among older adults: Cohort differences over 20 years between the Berlin Aging Study (BASE) and the Berlin Aging Study II (BASE-II). <i>PLoS ONE</i> , 2018, 13, e0191699.	1.1	30

#	ARTICLE	IF	CITATIONS
1745	HbA1c and retinal sensitivity in diabetics using microperimetry. <i>Journal of Optometry</i> , 2019, 12, 174-179.	0.7	9
1746	Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. <i>Journal of Diabetes Investigation</i> , 2019, 10, 367-374.	1.1	15
1747	Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study. <i>Endocrine</i> , 2019, 63, 44-51.	1.1	8
1748	Verification of Kumamoto Declaration 2013 and Glycemic Targets for Elderly Patients with Diabetes in Japan for prevention of diabetic complications: A retrospective longitudinal study using outpatient clinical data. <i>Journal of Diabetes Investigation</i> , 2019, 10, 290-301.	1.1	7
1749	False measurement of glycosylated hemoglobin in patients without hemoglobin A. <i>Bioscience Reports</i> , 2019, 39, .	1.1	7
1750	The Role of Occupational Therapy in Secondary Prevention of Diabetes. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-7.	0.6	2
1751	Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments. <i>European Cardiology Review</i> , 2019, 14, 23-32.	0.7	44
1752	Poor Glycaemic Control Is Associated with Increased Lipid Peroxidation and Glutathione Peroxidase Activity in Type 2 Diabetes Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-10.	1.9	28
1753	Prevalence and determinants of psychological insulin resistance among type 2 diabetic patients in Kinshasa, Democratic Republic of Congo. <i>African Journal of Primary Health Care and Family Medicine</i> , 2019, 11, e1-e5.	0.3	5
1754	Risk factors for prevalent diabetic retinopathy and proliferative diabetic retinopathy in type 1 diabetes. <i>Endocrine</i> , 2019, 66, 201-209.	1.1	14
1755	Asymptomatic Pontine Lesion and Diabetic Amyotrophy after Rapid Improvement of Poor Glycemic Control in a Patient with Type 1 Diabetes. <i>Internal Medicine</i> , 2019, 58, 3433-3439.	0.3	4
1756	Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY trial. <i>Pediatric Diabetes</i> , 2019, 20, 871-879.	1.2	13
1757	Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2626-2634.	2.2	1
1758	The Modern Western Diet Rich in Advanced Glycation End-Products (AGEs): An Overview of Its Impact on Obesity and Early Progression of Renal Pathology. <i>Nutrients</i> , 2019, 11, 1748.	1.7	77
1759	Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 77.	1.7	19
1760	Therapeutic Potential of <i>Lespedeza bicolor</i> to Prevent Methylglyoxal-Induced Glucotoxicity in Familial Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1138.	1.0	15
1762	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2019, 42, 2098-2107.	4.3	37
1763	SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2965.	1.2	153



#	ARTICLE	IF	CITATIONS
1764	Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently). <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 48.	1.2	5
1765	Could AGE/RAGE-Related Oxidative Homeostasis Dysregulation Enhance Susceptibility to Pathogenesis of Cardio-Metabolic Complications in Childhood Obesity?. <i>Frontiers in Endocrinology</i> , 2019, 10, 426.	1.5	31
1766	Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy. , 2019, 60, 3119.		65
1767	Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality. <i>Postgraduate Medicine</i> , 2019, 131, 376-382.	0.9	11
1768	Glycation in Huntingtonâ€™s Disease: A Possible Modifier and Target for Intervention. <i>Journal of Huntington's Disease</i> , 2019, 8, 245-256.	0.9	19
1769	Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study. <i>Diabetes Therapy</i> , 2019, 10, 1847-1858.	1.2	4
1770	Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 13.	0.6	5
1771	Obesity and Comorbidity: Could Simultaneous Targeting of esRAGE and sRAGE Be the Panacea?. <i>Frontiers in Physiology</i> , 2019, 10, 787.	1.3	19
1772	A novel natural tracer method to measure complex carbohydrate metabolism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E483-E493.	1.8	7
1773	A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2019, 62, 2066-2078.	2.9	98
1774	Risk Factors of Thyroid Dysfunction in Patients With Type 2 Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2019, 10, 440.	1.5	31
1775	Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach. <i>Medicina (Lithuania)</i> , 2019, 55, 382.	0.8	5
1776	Diabetic Retinopathy, lncRNAs, and Inflammation: A Dynamic, Interconnected Network. <i>Journal of Clinical Medicine</i> , 2019, 8, 1033.	1.0	34
1777	Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2019, 21, 100.	1.3	4
1778	Effects of coenzyme Q10 intervention on diabetic kidney disease. <i>Medicine (United States)</i> , 2019, 98, e15850.	0.4	22
1779	&lt;p&gt;Association between glycemic status and thyroid dysfunction in patients with type 2 diabetes mellitus&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1113-1122.	1.1	17
1780	&lt;p&gt;SGLT2 inhibitors and the changing landscape for treatment of diabetes&lt;/p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 861-867.	0.9	6
1781	Screening and Isolating Major Aldose Reductase Inhibitors from the Seeds of Evening Primrose ( <i>Oenothera biennis</i> ). <i>Molecules</i> , 2019, 24, 2709.	1.7	7

#	ARTICLE	IF	CITATIONS
1782	Treatment of Diabetic Macular Edema. <i>Current Diabetes Reports</i> , 2019, 19, 68.	1.7	83
1783	Determining minimum set of features for diabetes mobile apps. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 333-340.	0.8	15
1784	Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. <i>Cardiovascular Diabetology</i> , 2019, 18, 96.	2.7	206
1785	Diabetes Mellitus: An Independent Risk Factor of In-Hospital Mortality in Patients with Infective Endocarditis in a New Era of Clinical Practice. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2248.	1.2	10
1786	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 38.	0.4	1
1787	Advanced Technology in the Management of Diabetes: Which Comes First—Continuous Glucose Monitor or Insulin Pump?. <i>Current Diabetes Reports</i> , 2019, 19, 50.	1.7	19
1788	Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications. <i>World Journal of Diabetes</i> , 2019, 10, 324-332.	1.3	13
1789	Rationale of family medicine physicians in effectively identifying patients with chronic hyperglycemia through point-of-care hemoglobin A1C screenings. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 155-162.	0.8	0
1790	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3264.	1.8	93
1791	The Regulatory Role of Rac1, a Small Molecular Weight GTPase, in the Development of Diabetic Retinopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 965.	1.0	21
1792	&lt;p&gt;Comparison of the effect of two therapeutic exercises on the inflammatory and physiological conditions and complications of diabetic neuropathy in female patients&lt;p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1493-1501.	1.1	18
1793	Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5037.	1.8	98
1794	Chronic Kidney Disease Diagnosis and Management. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1294.	3.8	774
1795	&lt;p&gt;A Retrospective Time Trend Study Of Diabetes Overtreatment In Geriatric Patients&lt;p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2023-2032.	1.1	6
1796	Relationships Between the Cardio-Ankle Vascular Index and Pulsatility Index of the Common Carotid Artery in Patients With Cardiovascular Risk Factors. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 593-599.	0.6	6
1797	Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. <i>Advances in Therapy</i> , 2019, 36, 3483-3493.	1.3	17
1798	Prevalence of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus in a Rural Health Center in South India. <i>Journal of Primary Care and Community Health</i> , 2019, 10, 215013271988063.	1.0	14
1799	The Importance of Lactose in the Human Diet: Outcomes of a Mexican Consensus Meeting. <i>Nutrients</i> , 2019, 11, 2737.	1.7	34

#	ARTICLE	IF	CITATIONS
1800	Diabetic Retinopathy May Indicate an Increased Risk of Cardiovascular Disease in Patients With Type 1 Diabetes—A Nested Case-Control Study in Brazil. <i>Frontiers in Endocrinology</i> , 2019, 10, 689.	1.5	11
1801	&lt;p&gt;De-Intensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1775-1783.	0.8	9
1802	Appropriateness of insulin commencement and adequacy of glycemic control among ambulatory patients with type 2 diabetes in Ethiopia. <i>Journal of Diabetes and Metabolic Disorders</i> , 2019, 18, 461-469.	0.8	3
1803	The effect of guideline revisions on vascular complications of type 2 diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987540.	1.4	4
1804	Feasibility study of automated interactive voice response telephone calls with community health nurse follow-up to improve glycaemic control in patients with type 2 diabetes. <i>International Journal of Nursing Practice</i> , 2019, 25, e12781.	0.8	10
1805	Trends in Lifestyle Counseling for Adults With and Without Diabetes in the U.S., 2005–2015. <i>American Journal of Preventive Medicine</i> , 2019, 57, e153-e161.	1.6	10
1806	Hospital outcomes and cumulative burden from complications in type 2 diabetic sepsis patients: a cohort study using administrative and hospital-based databases. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881987540.	1.4	12
1807	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 1733-1752.	1.2	47
1808	What should governments be doing to prevent diabetes throughout the life course?. <i>Diabetologia</i> , 2019, 62, 1842-1853.	2.9	25
1809	Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2019, 4, 144-150.	0.5	5
1810	Associations of Chronic Inflammation, Insulin Resistance, and Severe Obesity With Mortality, Myocardial Infarction, Cancer, and Chronic Pulmonary Disease. <i>JAMA Network Open</i> , 2019, 2, e1910456.	2.8	50
1811	A retrospective cross-sectional study of type 2 diabetes overtreatment in patients admitted to the geriatric ward. <i>BMC Geriatrics</i> , 2019, 19, 242.	1.1	11
1812	Associations between the Haell Single Nucleotide Polymorphism in the SLC2A1 Gene and Diabetic Nephropathy in Korean Patients with Type 2 Diabetes Mellitus. <i>Journal of Korean Medical Science</i> , 2019, 34, e171.	1.1	2
1813	Brain Senescence Caused by Elevated Levels of Reactive Metabolite Methylglyoxal on D-Galactose-Induced Aging Mice. <i>Frontiers in Neuroscience</i> , 2019, 13, 1004.	1.4	23
1814	Efficacy of vitamin D supplementation on glycemic control in type 2 diabetes patients. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 1</i>	0.4	60
1815	Determinants of poor glycemic control among adult patients with type 2 diabetes mellitus in Jimma University Medical Center, Jimma zone, south west Ethiopia: a case control study. <i>BMC Endocrine Disorders</i> , 2019, 19, 91.	0.9	64
1816	Glycated albumin is correlated with glycated hemoglobin in type 2 diabetes. <i>Medicine and Pharmacy Reports</i> , 2019, 92, 134-138.	0.2	6
1817	Severe Hypoglycemia Attributable to Intensive Glucose-Lowering Therapy Among US Adults With Diabetes. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1731-1742.	1.4	18

#	ARTICLE	IF	CITATIONS
1818	The Effects of Bariatric Surgery on Islet Function, Insulin Secretion, and Glucose Control. <i>Endocrine Reviews</i> , 2019, 40, 1394-1423.	8.9	55
1819	Interventions to Improve Blood Pressure Control Among Socioeconomically Disadvantaged Patients With CKD: Kidney Awareness Registry and Education Pilot Randomized Controlled Trial. <i>Kidney Medicine</i> , 2019, 1, 242-252.	1.0	10
1820	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. <i>Diabetes Therapy</i> , 2019, 10, 2115-2130.	1.2	15
1821	&lt;p&gt;Multivariable Logistic Regression And Back Propagation Artificial Neural Network To Predict Diabetic Retinopathy&lt;p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1943-1951.	1.1	24
1822	Bioremediation of a Common Product of Food Processing by a Human Gut Bacterium. <i>Cell Host and Microbe</i> , 2019, 26, 463-477.e8.	5.1	43
1823	Detecting time-evolving phenotypic topics via tensor factorization on electronic health records: Cardiovascular disease case study. <i>Journal of Biomedical Informatics</i> , 2019, 98, 103270.	2.5	32
1824	Antidiabetic Effect of Fenugreek Seed Powder Solution (<i>Trigonella foenum-graecum L</i>.) on Hyperlipidemia in Diabetic Patients. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-8.	1.0	89
1825	Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners. <i>Advances in Therapy</i> , 2019, 36, 579-596.	1.3	58
1826	Interventions for self-management of type 2 diabetes: An integrative review. <i>International Journal of Nursing Sciences</i> , 2019, 6, 70-91.	0.5	80
1827	Dietary Advanced Glycation End Products: Digestion, Metabolism and Modulation of Gut Microbial Ecology. <i>Nutrients</i> , 2019, 11, 215.	1.7	146
1828	Earliest Evidence of Preclinical Diabetic Retinopathy Revealed Using Optical Coherence Tomography Angiography Perfused Capillary Density. <i>American Journal of Ophthalmology</i> , 2019, 203, 103-115.	1.7	112
1829	Glycemic Variability: Risk Factors, Assessment, and Control. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 627-635.	1.3	58
1830	Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 374.	3.8	31
1831	Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model. <i>Medical Decision Making</i> , 2019, 39, 137-151.	1.2	4
1832	Analysis of â€œArtificial Pancreas (AP) Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Projectâ€. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 268-270.	1.3	2
1833	Diabetes Diagnosis and Control: Missed Opportunities to Improve Health. <i>Diabetes Care</i> , 2019, 42, 994-1004.	4.3	35
1834	Does Adjuvant Treatment with Chinese Herbal Medicine to Antidiabetic Agents Have Additional Benefits in Patients with Type 2 Diabetes? A System Review and Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-14.	0.5	8
1835	Accuracy and precision of four main glucometers used in a Sub-Saharan African Country: a cross-sectional study. <i>Pan African Medical Journal</i> , 2019, 32, 118.	0.3	5

#	ARTICLE	IF	CITATIONS
1836	Text messaging support for patients with diabetes or coronary artery disease (SupportMe): protocol for a pragmatic randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e025923.	0.8	9
1837	Team-Based Care to Improve Diabetes Management: A Community Guide Meta-analysis. <i>American Journal of Preventive Medicine</i> , 2019, 57, e17-e26.	1.6	47
1838	GLUcose COntrol Safety & Efficacy in type 2 Diabetes, a systematic review and NETwork meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0217701.	1.1	14
1839	&lt;p&gt;Quercetin improves lipid metabolism via SCAP-SREBP2-LDLr signaling pathway in early stage diabetic nephropathy&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 827-839.	1.1	32
1840	Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study. <i>Diabetes Care</i> , 2019, 42, 1549-1559.	4.3	12
1841	Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on Î²-Cell Function: Comparison of Responses In Youth And Adults. <i>Diabetes</i> , 2019, 68, db190299.	0.3	52
1842	A brief interactive training with medical students improves their diabetes knowledge about hypoglycemia. <i>BMC Medical Education</i> , 2019, 19, 171.	1.0	5
1843	Intensive Glucose Control in Patients with Type 2 Diabetes â€” 15-Year Follow-up. <i>New England Journal of Medicine</i> , 2019, 380, 2215-2224.	13.9	173
1844	Impact of serum 1,5-anhydro-d-glucitol level on the prediction of severe coronary artery calcification: an intravascular ultrasound study. <i>Cardiovascular Diabetology</i> , 2019, 18, 69.	2.7	12
1845	The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. <i>Advances in Therapy</i> , 2019, 36, 2034-2051.	1.3	11
1846	Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. <i>Diabetes Spectrum</i> , 2019, 32, 93-103.	0.4	15
1847	Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial. <i>Diabetes Care</i> , 2019, 42, 1390-1397.	4.3	34
1848	Can blood glucose value really be referred to as a metabolic parameter?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 20, 151-160.	2.6	13
1849	Analysis: Investigating the quality of POCT devices for HbA1c, what are our next steps?. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 1154-1157.	1.3	7
1850	Î²-Cell Fate in Human Insulin Resistance and Type 2 Diabetes: A Perspective on Islet Plasticity. <i>Diabetes</i> , 2019, 68, 1121-1129.	0.3	87
1851	Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol). <i>BMC Health Services Research</i> , 2019, 19, 284.	0.9	5
1852	The role of membrane excitability in pancreatic Î²-cell glucotoxicity. <i>Scientific Reports</i> , 2019, 9, 6952.	1.6	16
1853	Psychometric properties of the Norwegian version of the short form of The Problem Areas in Diabetes scale (PAID-5): a validation study. <i>BMJ Open</i> , 2019, 9, e022903.	0.8	7

#	ARTICLE	IF	CITATIONS
1854	Epigenetic Regulation of Vascular Diseases. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 984-990.	1.1	45
1855	Hypertriglyceridemic waist phenotype and abnormal glucose metabolism: a system review and meta-analysis. <i>Endocrine</i> , 2019, 64, 469-485.	1.1	18
1856	Progress in understanding youth-onset type 2 diabetes in the United States: recent lessons from clinical trials. <i>World Journal of Pediatrics</i> , 2019, 15, 315-321.	0.8	22
1857	Physical activity and dietary interventions in diabetic neuropathy: a systematic review. <i>Clinical Autonomic Research</i> , 2019, 29, 443-455.	1.4	45
1858	Overlap in the Genetic Architecture of Stroke Risk, Early Neurological Changes, and Cardiovascular Risk Factors. <i>Stroke</i> , 2019, 50, 1339-1345.	1.0	17
1859	Effectiveness of Technologically Enhanced Peer Support in Improving Glycemic Management Among Predominantly African American, Low-Income Adults With Diabetes. <i>The Diabetes Educator</i> , 2019, 45, 260-271.	2.6	26
1860	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , 2019, 10, 1297-1317.	1.2	23
1861	Metformin Inhibits the Expression of Biomarkers of Fibrosis of EPCs In Vitro. <i>Stem Cells International</i> , 2019, 2019, 1-10.	1.2	8
1862	Influence of Type 2 Diabetes Mellitus and Preoperative Hemoglobin A1c Levels on Outcomes of Liver Transplantation. <i>Hepatology Communications</i> , 2019, 3, 574-586.	2.0	6
1863	Patterns of Glycemic Variability During a Diabetes Self-Management Educational Program. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 52.	1.3	6
1864	Diabetes Screening Through Community Pharmacies in England: A Cost-Effectiveness Study. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 30.	0.6	11
1865	Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. <i>Cancer</i> , 2019, 125, 2861-2867.	2.0	20
1866	A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies. <i>BMC Endocrine Disorders</i> , 2019, 19, 39.	0.9	8
1867	Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project. <i>Diabetes Therapy</i> , 2019, 10, 1099-1111.	1.2	4
1868	Measuring What Matters in Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1865.	3.8	36
1869	Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 158.	1.8	17
1870	A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury. <i>Journal of Clinical Medicine</i> , 2019, 8, 499.	1.0	29
1871	<p>Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 271-282.	0.7	3

#	ARTICLE	IF	CITATIONS
1872	Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIABetes COHoRtE (DIACORE) study. PLoS ONE, 2019, 14, e0213157.	1.1	8
1873	Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial. BMC Cardiovascular Disorders, 2019, 19, 60.	0.7	16
1874	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e596-e646.	1.6	1,789
1875	Glycated whey proteins protect NOD mice against type 1 diabetes by increasing anti-inflammatory responses and decreasing autoreactivity to self-antigens. Journal of Functional Foods, 2019, 56, 171-181.	1.6	7
1876	Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis. Heliyon, 2019, 5, e01257.	1.4	0
1877	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019, 42, 1284-1289.	4.3	42
1878	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Advances in Therapy, 2019, 36, 1190-1199.	1.3	7
1879	Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela. BMJ Open, 2019, 9, e023401.	0.8	46
1880	The Association Between Insulin Initiation and Adverse Outcomes After Hospital Discharge in Older Adults: a Population-Based Cohort Study. Journal of General Internal Medicine, 2019, 34, 575-582.	1.3	11
1881	Optimal cardiac strategy based on the history of myocardial infarction in type 2 diabetic patients with coronary artery disease. Scientific Reports, 2019, 9, 3502.	1.6	1
1882	Heart failure and diabetes: management and open issues. Herz, 2019, 44, 203-209.	0.4	2
1883	The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward. Journal of Diabetes Science and Technology, 2019, 13, 424-427.	1.3	11
1884	Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrinology and Metabolism, 2019, 34, 80.	1.3	42
1885	Sodium-glucose cotransporter inhibitors: beyond glycaemic control. CKJ: Clinical Kidney Journal, 2019, 12, 322-325.	1.4	23
1886	Poor glycemic control and posterior circulation ischemic stroke. Neurology: Clinical Practice, 2019, 9, 129-139.	0.8	9
1887	Capsule Commentary on Correa et al., Assessing the Effect of Clinical Inertia on Diabetes Outcomes: a Modeling Approach. Journal of General Internal Medicine, 2019, 34, 443-443.	1.3	0
1888	Effects of sarpogrelate on microvascular complications with type 2 diabetes. International Journal of Clinical Pharmacy, 2019, 41, 563-573.	1.0	8
1889	Context-sensitive network analysis identifies food metabolites associated with Alzheimer's disease: an exploratory study. BMC Medical Genomics, 2019, 12, 17.	0.7	10

#	ARTICLE	IF	CITATIONS
1890	Cost-effectiveness analysis of a cluster-randomized, culturally tailored, community health worker home-visiting diabetes intervention versus standard care in American Samoa. <i>Human Resources for Health</i> , 2019, 17, 17.	1.1	19
1891	Severe Hypoglycemia as a Predictor of End-Stage Renal Disease in Type 2 Diabetes: A National Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 681.	1.2	6
1892	Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes. <i>Endocrine</i> , 2019, 64, 536-543.	1.1	19
1893	The relationship between diabetic retinopathy and psychosocial functioning: a systematic review. <i>Quality of Life Research</i> , 2019, 28, 2017-2039.	1.5	45
1894	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, e177-e232.	1.2	1,038
1895	Glycine Suppresses AGE/RAGE Signaling Pathway and Subsequent Oxidative Stress by Restoring Glo1 Function in the Aorta of Diabetic Rats and in HUVECs. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	49
1896	Accuracy of a Point-of-Care Hemoglobin A1c Assay. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 1149-1153.	1.3	14
1897	Receptor for advanced glycation end-products and environmental exposure related obstructive airways disease: a systematic review. <i>European Respiratory Review</i> , 2019, 28, 180096.	3.0	15
1898	Mobile-based insulin dose adjustment for type 2 diabetes in community and rural populations: study protocol for a pilot randomized controlled trial. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881983664.	1.4	5
1902	Clinical factors associated with persistently poor diabetes control in the Veterans Health Administration: A nationwide cohort study. <i>PLoS ONE</i> , 2019, 14, e0214679.	1.1	7
1903	Laboratory Computer-Based Interventions for Better Adherence to Guidelines in the Diagnosis and Monitoring of Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019, 10, 995-1003.	1.2	7
1904	Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes. <i>Diabetology International</i> , 2019, 10, 279-287.	0.7	4
1905	Soluble Receptor for Advanced Glycation End Products: A Protective Molecule against Intramyocardial Lipid Accumulation in Obese Zucker Rats?. <i>Mediators of Inflammation</i> , 2019, 2019, 1-8.	1.4	10
1906	Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus. <i>Journal of General and Family Medicine</i> , 2019, 20, 129-138.	0.3	13
1907	Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes. <i>Clinical Diabetes</i> , 2019, 37, 211-220.	1.2	1
1908	Clinical implications of cardiovascular outcome trials in type 2 diabetes. <i>Herz</i> , 2019, 44, 192-202.	0.4	4
1909	Visit-to-visit HbA1c and glucose variability and the risks of macrovascular and microvascular events in the general population. <i>Scientific Reports</i> , 2019, 9, 1374.	1.6	37
1910	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 657-664.	4.3	32



#	ARTICLE	IF	CITATIONS
1911	Self-reported hypoglycemia in adult diabetic patients in East Gojjam, Northwest Ethiopia: institution based cross-sectional study. <i>BMC Endocrine Disorders</i> , 2019, 19, 17.	0.9	8
1912	Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations. <i>Current Diabetes Reports</i> , 2019, 19, 9.	1.7	8
1913	Beta cells in type 1 diabetes: mass and function; sleeping or dead?. <i>Diabetologia</i> , 2019, 62, 567-577.	2.9	100
1914	The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2019, 79, 231-242.	4.9	18
1915	Variation of Adolescent Snack Food Choices and Preferences along a Continuum of Processing Levels: The Case of Apples. <i>Foods</i> , 2019, 8, 50.	1.9	8
1916	Evaluating All Potential Oral Complications of Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2019, 10, 56.	1.5	155
1917	Association between thyroid function and diabetic nephropathy in euthyroid subjects with type 2 diabetes mellitus: a cross-sectional study in China. <i>Oncotarget</i> , 2019, 10, 88-97.	0.8	18
1918	Utility of Real-Time and Retrospective Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-10.	1.0	55
1919	Diabetes Mellitus-Related Cause and Cardiovascular Mortality in a National Cohort of Adults. <i>Journal of the American Heart Association</i> , 2019, 8, e011295.	1.6	271
1920	Exercise and Arterial Modulation in Children: The EXAMIN YOUTH Study. <i>Frontiers in Physiology</i> , 2019, 10, 43.	1.3	14
1921	The Association Between Type 2 Diabetes and Cardiovascular Disease: The "For Your SweetHeart" Survey. <i>Advances in Therapy</i> , 2019, 36, 746-755.	1.3	9
1922	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , 2019, 10, 1-13.	1.2	15
1923	Quality of medical products for diabetes management: a systematic review. <i>BMJ Global Health</i> , 2019, 4, e001636.	2.0	16
1924	Implementation of A1C Point-of-Care Testing: Serving Under-Resourced Adults With Type 2 Diabetes in a Public Health Department. <i>Clinical Diabetes</i> , 2019, 37, 242-249.	1.2	5
1925	Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea. <i>Endocrinology and Metabolism</i> , 2019, 34, 282.	1.3	16
1926	Addition of Dulaglutide for a High-Dose Insulin Requiring Patient with Type 2 Diabetes Mellitus: A Remarkable Response. <i>AACE Clinical Case Reports</i> , 2019, 5, e142-e145.	0.4	1
1927	Effectiveness of strategies for nutritional therapy for patients with type 2 diabetes and/or hypertension in primary care: protocol of a systematic review of randomised controlled trials. <i>BMJ Open</i> , 2019, 9, e030450.	0.8	3
1928	Improving Diabetes Control Through Remote Glucose Monitoring in a Diabetes Self-Management Program for Employees of a Health System. <i>Clinical Diabetes</i> , 2019, 37, 203-210.	1.2	5

#	ARTICLE	IF	CITATIONS
1929	Living With Hypoglycemia: An Exploration of Patients'™ Emotions: Qualitative Findings From the InHypo-DM Study, Canada. <i>Diabetes Spectrum</i> , 2019, 32, 270-276.	0.4	13
1930	Associations of health literacy with risk factors for diabetic foot disease: a cross-sectional analysis of the Southern Tasmanian Health Literacy and Foot Ulcer Development in Diabetes Mellitus Study. <i>BMJ Open</i> , 2019, 9, e025349.	0.8	6
1931	Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000705.	1.2	26
1932	Clinic and patient variation in intermediate clinical outcomes for type 2 diabetes: a multilevel analysis. <i>BMC Family Practice</i> , 2019, 20, 158.	2.9	1
1933	Diabetes care in the dispersed population of Greenland. A new model based on continued monitoring, analysis and adjustment of initiatives taken. <i>International Journal of Circumpolar Health</i> , 2019, 78, 1709257.	0.5	21
1934	Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5668.	1.8	13
1935	Relationship between Random Blood Glucose, Fasting Blood Glucose, and Gensini Score in Patients with Acute Myocardial Infarction. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	11
1936	Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-18.	1.9	120
1937	Putting Heart (and Kidneys) Into Diabetes Care. <i>Clinical Diabetes</i> , 2019, 37, 314-315.	1.2	0
1938	Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 487.	1.8	105
1939	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. <i>Clinical Diabetes</i> , 2019, 37, 316-337.	1.2	11
1940	Cigarette smoke inhalation aggravates diabetic kidney injury in rats. <i>Toxicology Research</i> , 2019, 8, 964-971.	0.9	13
1941	Changes in HbA1c during the first six years after the diagnosis of Type 2 diabetes mellitus predict long-term microvascular outcomes. <i>PLoS ONE</i> , 2019, 14, e0225230.	1.1	12
1942	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5853.	1.8	11
1943	Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-8.	1.0	31
1944	Clinical Implications of Extracellular HMGA1 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5950.	1.8	20
1945	Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 132.	1.7	15
1946	Emerging Concepts in the Treatment of Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2019, 19, 137.	1.7	23

#	ARTICLE	IF	CITATIONS
1947	<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2515-2529.	1.1	20
1948	mHealth Interventions for Disadvantaged and Vulnerable People with Type 2 Diabetes. Current Diabetes Reports, 2019, 19, 148.	1.7	57
1949	Retinopathy progression and the risk of end-stage kidney disease: results from a longitudinal Japanese cohort of 232 patients with type 2 diabetes and biopsy-proven diabetic kidney disease. BMJ Open Diabetes Research and Care, 2019, 7, e000726.	1.2	34
1950	Contributions of Fasting and Postprandial Glucose Concentrations to Haemoglobin A1c in Drug-Naïve Mal-Glucose Metabolism in Chinese Population Using Continuous Glucose Monitoring System. International Journal of Endocrinology, 2019, 2019, 1-5.	0.6	5
1951	Regulation of Heparanase in Diabetes-Associated Pancreatic Carcinoma. Frontiers in Oncology, 2019, 9, 1405.	1.3	8
1952	Advanced Glycation End Products (AGEs) May Be a Striking Link Between Modern Diet and Health. Biomolecules, 2019, 9, 888.	1.8	118
1953	Dietary and Plasma Carboxymethyl Lysine and Tumor Necrosis Factor- $\alpha$ as Mediators of Body Mass Index and Waist Circumference among Women in Indonesia. Nutrients, 2019, 11, 3057.	1.7	6
1954	Prevalence and epidemiological characteristics of patients with diabetic retinopathy in Slovakia: 12-month results from the DIARET SK study. PLoS ONE, 2019, 14, e0223788.	1.1	7
1955	Effectiveness of Dose Adjustment of Insulin in Type 2 Diabetes among Hemodialysis Patients with End-Stage Renal Disease: A Randomized Crossover Study. Journal of Diabetes Research, 2019, 2019, 1-5.	1.0	8
1956	The trials and tribulations of the University Group Diabetes Program 2: lessons and reflections. Journal of the Royal Society of Medicine, 2019, 112, 503-511.	1.1	3
1957	Advanced Glycation End-Products and Hyperglycemia Increase Angiopoietin-2 Production by Impairing Angiopoietin-1-Tie-2 System. Journal of Diabetes Research, 2019, 2019, 1-7.	1.0	11
1958	Effects of Propolis Extract and Propolis-Derived Compounds on Obesity and Diabetes: Knowledge from Cellular and Animal Models. Molecules, 2019, 24, 4394.	1.7	40
1959	Mitochondria-related reversal of early-stage diabetic nephropathy in donor kidney after transplantation in mice. Annals of Translational Medicine, 2019, 7, 801-801.	0.7	4
1960	Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. Clinical Pharmacology and Therapeutics, 2019, 105, 730-737.	2.3	16
1961	Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2019, 10, 429-438.	1.1	7
1962	Out-of-home informal support important for medication adherence, diabetes distress, hemoglobin A1c among adults with type 2 diabetes. Journal of Behavioral Medicine, 2019, 42, 493-501.	1.1	12
1963	Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes Therapy, 2019, 10, 159-176.	1.2	11
1964	Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. Journal of Diabetes Investigation, 2019, 10, 1012-1021.	1.1	41

#	ARTICLE	IF	CITATIONS
1965	Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation Research</i> , 2019, 124, 121-141.	2.0	411
1966	The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone. <i>In Vivo</i> , 2019, 33, 99-108.	0.6	11
1967	Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 45.	1.0	37
1968	Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?. <i>Kidney Diseases (Basel, Switzerland)</i> , 2019, 5, 69-80.	1.2	10
1969	Skin autofluorescence in children with and without obesity. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2019, 32, 41-47.	0.4	6
1970	Diabetes: the place of new therapies. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881880759.	1.4	10
1971	The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in $\beta$ -Cell Function in TODAY. <i>Diabetes Care</i> , 2019, 42, 164-172.	4.3	34
1972	Impact of Duodeno-Jejunal Bypass Liner (EndoBarrier™) Implantation on Insulin Sensitivity in Patients with Type 2 Diabetes Mellitus (T2DM): A Study Protocol for a Pilot Trial. <i>Diabetes Therapy</i> , 2019, 10, 299-309.	1.2	5
1973	The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 296-301.	1.2	12
1974	Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. <i>PLoS ONE</i> , 2019, 14, e0210367.	1.1	13
1975	Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2019, 137, 363.	1.4	74
1976	Resistance Exercise Intensity is Correlated with Attenuation of HbA1c and Insulin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 140.	1.2	105
1977	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 121-127.	0.6	13
1978	Toward Better Understanding of Insulin Therapy by Translation of a PK&PD Model to Visualize Insulin and Glucose Action Profiles. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 258-270.	1.0	2
1979	Accuracy of flash glucose monitoring in insulin-treated patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2019, 10, 846-850.	1.1	25
1980	The National Glycohemoglobin Standardization Program: Over 20 Years of Improving Hemoglobin A1c Measurement. <i>Clinical Chemistry</i> , 2019, 65, 839-848.	1.5	84
1981	Outcomes that patients perceive and value are systematically unassessed in randomized clinical trials of endocrine-related illnesses: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 140-143.	2.4	4
1982	Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 495-503.	1.8	48

#	ARTICLE	IF	CITATIONS
1983	Meat intake and incidence of cardiovascular disease in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDCS). <i>European Journal of Nutrition</i> , 2019, 58, 281-290.	1.8	15
1984	Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification. <i>American Journal of Lifestyle Medicine</i> , 2019, 13, 384-404.	0.8	50
1985	Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 62-71.	0.7	4
1986	Predictive Value of the Acute-to-Chronic Glycemic Ratio for In-Hospital Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Angiology</i> , 2020, 71, 38-47.	0.8	31
1987	Transplantation of adipose-derived mesenchymal stem cell sheets directly into the kidney suppresses the progression of renal injury in a diabetic nephropathy rat model. <i>Journal of Diabetes Investigation</i> , 2020, 11, 545-553.	1.1	35
1988	Advanced Glycation End Products: Building on the Concept of the "Common Soil" in Metabolic Disease. <i>Endocrinology</i> , 2020, 161, .	1.4	104
1989	Evidence-based comparison of glucagon-like peptide receptor agonists and sodium-glucose cotransporter-2 inhibitors. <i>Journal of Diabetes Investigation</i> , 2020, 11, 17-19.	1.1	3
1990	Dietary intake of advanced glycation end products (AGEs) and changes in body weight in European adults. <i>European Journal of Nutrition</i> , 2020, 59, 2893-2904.	1.8	33
1991	Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Tenzeligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial. <i>Diabetes Therapy</i> , 2020, 11, 347-358.	1.2	2
1992	Association between glucose variation and lower extremity amputation incidence in individuals with type 2 diabetes: a nationwide retrospective cohort study. <i>Diabetologia</i> , 2020, 63, 194-205.	2.9	9
1993	Three-component non-invasive risk score for undiagnosed diabetes in Chinese people: Development, validation and longitudinal evaluation. <i>Journal of Diabetes Investigation</i> , 2020, 11, 341-348.	1.1	8
1994	Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities. <i>Paediatric Drugs</i> , 2020, 22, 55-71.	1.3	3
1995	Status of glycosylated hemoglobin and prediction of glycemic control among patients with insulin-treated type 2 diabetes in North China: a multicenter observational study. <i>Chinese Medical Journal</i> , 2020, 133, 17-24.	0.9	14
1996	Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 4.	2.7	24
1997	Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type-2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 279-291.	1.2	45
1998	Strategies of Unloading the Failing Heart from Metabolic Stress. <i>American Journal of Medicine</i> , 2020, 133, 290-296.	0.6	15
1999	Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. <i>Diabetes Therapy</i> , 2020, 11, 259-277.	1.2	34
2000	Association of physical fitness with skin autofluorescence-derived advanced glycation end products in children. <i>Pediatric Research</i> , 2020, 87, 1106-1111.	1.1	6

#	ARTICLE	IF	CITATIONS
2001	Elevation of the renal threshold for glucose is associated with insulin resistance and higher glycated hemoglobin levels. <i>Journal of Diabetes Investigation</i> , 2020, 11, 617-625.	1.1	9
2002	Selecting the optimal risk threshold of diabetes risk scores to identify high-risk individuals for diabetes prevention: a cost-effectiveness analysis. <i>Acta Diabetologica</i> , 2020, 57, 447-454.	1.2	8
2003	Protective Effects and Molecular Signaling of n-3 Fatty Acids on Oxidative Stress and Inflammation in Retinal Diseases. <i>Antioxidants</i> , 2020, 9, 920.	2.2	27
2004	The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review. <i>Diabetes Therapy</i> , 2020, 11, 2555-2593.	1.2	16
2005	Exposure to Static Magnetic and Electric Fields Treats Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 32, 561-574.e7.	7.2	55
2006	<p><p>The Correlation of Type 2 Diabetes Status with Bone Mineral Density in Middle-Aged Adults</p></p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 3269-3276.	1.1	15
2007	Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 2465-2476.	1.2	15
2008	Predictors for diabetic retinopathy progression—findings from nominal group technique and Evidence review. <i>BMJ Open Ophthalmology</i> , 2020, 5, e000579.	0.8	2
2009	The relationship between advanced glycation end products and gestational diabetes: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0240382.	1.1	14
2010	Chronic Kidney Disease among Diabetes Patients in Ethiopia: A Systematic Review and Meta-Analysis. <i>International Journal of Nephrology</i> , 2020, 2020, 1-15.	0.7	11
2011	Level of glycemic control and its associated factors among type II diabetic patients in debre tabor general hospital, northwest Ethiopia. <i>Metabolism Open</i> , 2020, 8, 100056.	1.4	19
2012	Renal Complication and Glycemic Control in Korean Veterans with Type 2 Diabetes: A 10-Year Retrospective Cohort Study. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-13.	1.0	7
2013	Nutritional interventions for treating foot ulcers in people with diabetes. <i>The Cochrane Library</i> , 2020, 2020, CD011378.	1.5	15
2014	Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2020, 6, 13.	0.4	7
2015	Diabetic Retinopathy Environment-Wide Association Study (EWAS) in NHANES 2005–2008. <i>Journal of Clinical Medicine</i> , 2020, 9, 3643.	1.0	10
2016	Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-12.	1.0	5
2017	<p><p>Association Between Abnormal Glycemic Phenotypes and Microvascular Complications of Type 2 Diabetes Mellitus Outpatients in China</p></p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 4651-4659.	1.1	3
2018	Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 215.	0.6	2

#	ARTICLE	IF	CITATIONS
2019	Regulation of Gluconeogenesis by Aldo-keto-reductase 1a1b in Zebrafish. <i>IScience</i> , 2020, 23, 101763.	1.9	9
2020	Photoreceptor cells and RPE contribute to the development of diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100919.	7.3	86
2021	Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. <i>Health Services Insights</i> , 2020, 13, 117863292092998.	0.6	1
2022	Prescription of Sulphonylureas among Patients with Type 2 Diabetes Mellitus in Italy: Results from the Retrospective, Observational Multicentre Cross-Sectional SUSCIPE (Sulphonyl_UreaS_Correct_Internal_Prescription_Evaluation) Study. <i>Diabetes Therapy</i> , 2020, 11, 2105-2119.	1.2	5
2023	Gender differences in quality of life in adults with long-standing type 1 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 64.	1.2	20
2024	Burden of Diabetes and Prediabetes in Nepal: A Systematic Review and Meta-Analysis. <i>Diabetes Therapy</i> , 2020, 11, 1935-1946.	1.2	39
2025	Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus. <i>Medicine (United States)</i> , 2020, 99, e21236.	0.4	10
2026	Blood Pressure Control among Hypertensive Diabetic Patients on Follow-Up at Chronic Clinic of Nekemte Referral Hospital in West Ethiopia. <i>International Journal of Hypertension</i> , 2020, 2020, 1-8.	0.5	4
2027	Implementation outcomes of a culturally adapted diabetes self-management education intervention for Native Hawaiians and Pacific islanders. <i>BMC Public Health</i> , 2020, 20, 1579.	1.2	7
2028	The Clinical Application of Mealtime Whey Protein for the Treatment of Postprandial Hyperglycaemia for People With Type 2 Diabetes: A Long Whey to Go. <i>Frontiers in Nutrition</i> , 2020, 7, 587843.	1.6	12
2029	Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001624.	1.2	5
2030	&lt;p&gt;Management Strategies for Patients After CABG Surgery in the Outbreak of the COVID-19 Pandemic&lt;/p&gt;. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 1655-1659.	1.2	1
2031	Determinants of glycaemic control among patients with type 2 diabetes: testing a process model based on self-determination theory. <i>Heliyon</i> , 2020, 6, e04993.	1.4	4
2032	A Decision Support System for Diabetes Chronic Care Models Based on General Practitioner Engagement and EHR Data Sharing. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2020, 8, 1-12.	2.2	11
2033	&lt;p&gt;Assessment of Achievement of American Diabetes Association (ADA) Targets in Patients with Type 2 Diabetes Mellitus at a Tertiary Care Centre in Eastern Nepal&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2959-2964.	1.1	3
2034	Dietary protein intake and circulating advanced glycation end product/receptor for advanced glycation end product concentrations in the Health, Aging, and Body Composition Study. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 1558-1565.	2.2	12
2035	Retinal Physiology and Circulation: Effect of Diabetes. , 2020, 10, 933-974.		11
2036	Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study. <i>PLoS Medicine</i> , 2020, 17, e1003316.	3.9	27

#	ARTICLE	IF	CITATIONS
2037	Impact of Intensive Glucose Control in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: 3-Year Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2464.	1.0	2
2038	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. <i>The Cochrane Library</i> , 2020, 2020, CD009966.	1.5	9
2039	Clinical pharmacists' interventions in the management of type 2 diabetes mellitus: a systematic review. <i>Pharmacy Practice</i> , 2020, 18, 2000.	0.8	13
2040	<i>Akkermansia muciniphila</i> is Negatively Correlated with Hemoglobin A1c in Refractory Diabetes. <i>Microorganisms</i> , 2020, 8, 1360.	1.6	31
2041	Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. <i>Diabetes Care</i> , 2020, 43, 2785-2795.	4.3	26
2042	Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 81-89.	0.5	14
2043	Progression of Diabetic Retinopathy and Declining Renal Function in Patients with Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-7.	1.0	12
2044	Performance of Point-of-Care Testing Compared with the Standard Laboratory Diagnostic Test in the Measurement of HbA1c in Indonesian Diabetic and Nondiabetic Subjects. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-6.	1.0	7
2045	No correlation between the variants of exostosin 2 gene and type 2 diabetes in Burkina Faso population. <i>Journal of Public Health in Africa</i> , 2020, 11, 1233.	0.2	0
2046	Assessment of Cardiovascular Risk Factors in Patients with Type 2 Diabetes in Upper Egypt Villages. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 4737-4746.	1.1	7
2047	Down-regulation of hepatic G-6-Pase expression in hyperglycemic rats: Intervention with biogenic gold nanoconjugate. <i>Saudi Journal of Biological Sciences</i> , 2020, 27, 3334-3341.	1.8	4
2048	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. <i>Circulation</i> , 2021, 143, 770-779.	1.6	47
2049	Estimating the attributable risk of vascular disorders in different ranges of fasting plasma glucose and assessing the effectiveness of anti-diabetes agents on risk reduction; questioning the current diagnostic criteria. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1423-1430.	0.8	10
2050	Visit-to-visit variability of glycated albumin was associated with incidence or progression of lower extremity atherosclerotic disease. <i>Cardiovascular Diabetology</i> , 2020, 19, 211.	2.7	4
2051	Can the Consumption of Ultra-Processed Food Be Associated with Anthropometric Indicators of Obesity and Blood Pressure in Children 7 to 10 Years Old?. <i>Foods</i> , 2020, 9, 1567.	1.9	19
2052	Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3409.	1.0	1
2053	Impact of glycemic control over cardiac autonomic neuropathy. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1339-1344.	0.8	4
2054	(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2020, 2020, CD005613.	1.5	25



#	ARTICLE	IF	CITATIONS
2055	Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy. <i>Antioxidants</i> , 2020, 9, 1062.	2.2	23
2056	Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 582826.	1.1	3
2057	Neurovascular Unit Dysfunction and Neurodegenerative Disorders. <i>Frontiers in Neuroscience</i> , 2020, 14, 334.	1.4	120
2058	&lt;p&gt;Nomogram for the Risk of Diabetic Nephropathy or Diabetic Retinopathy Among Patients with Type 2 Diabetes Mellitus Based on Questionnaire and Biochemical Indicators: A Cross-Sectional Study&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1215-1229.	1.1	20
2059	Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas. <i>Diabetes Therapy</i> , 2020, 11, 1251-1269.	1.2	109
2060	What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient. <i>Diabetes Therapy</i> , 2020, 11, 1381-1395.	1.2	4
2061	Genetics of diabetes mellitus and diabetes complications. <i>Nature Reviews Nephrology</i> , 2020, 16, 377-390.	4.1	657
2062	Early-onset type 2 diabetes. <i>Medicine (United States)</i> , 2020, 99, e20189.	0.4	7
2063	Trends in diabetes-related complications in Hong Kong, 2001â€“2016: a retrospective cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 60.	2.7	24
2064	Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1388-1402.	1.1	40
2065	Contemporary Cardiovascular Risk Assessment for Type 2 Diabetes Including Heart Failure as an Outcome: The Fremantle Diabetes Study Phase II. <i>Journal of Clinical Medicine</i> , 2020, 9, 1428.	1.0	7
2066	The association between dietary and skin advanced glycation end products: the Rotterdam Study. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 129-137.	2.2	24
2067	Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 85.	2.7	11
2068	Synergistic Effect of WTC-Particulate Matter and Lysophosphatidic Acid Exposure and the Role of RAGE: In-Vitro and Translational Assessment. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4318.	1.2	5
2069	Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 45.	1.2	10
2070	Metabolic syndrome exacerbates amyloid pathology in a comorbid Alzheimer's mouse model. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165849.	1.8	18
2071	Hypoglycaemia and cardiac arrhythmias in diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882091180.	1.4	25
2072	Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. <i>PLoS ONE</i> , 2020, 15, e0233595.	1.1	36

#	ARTICLE	IF	CITATIONS
2073	Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. <i>Eye</i> , 2020, 34, 1-51.	1.1	104
2074	<p></p>Diabetes-Related Distress and Depression in Saudis with Type 2 Diabetes</p>. <i>Psychology Research and Behavior Management</i> , 2020, Volume 13, 453-458.	1.3	29
2075	Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. <i>Diabetes Therapy</i> , 2020, 11, 1645-1666.	1.2	27
2076	Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis. <i>Diabetes Therapy</i> , 2020, 11, 1745-1755.	1.2	4
2077	Glycemia and Atherosclerotic Cardiovascular Disease: Exploring the Gap Between Risk Marker and Risk Factor. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 100.	1.1	15
2078	Interventions to prevent women from developing gestational diabetes mellitus: an overview of Cochrane Reviews. <i>The Cochrane Library</i> , 2020, 2020, CD012394.	1.5	64
2079	Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation. <i>International Journal of Retina and Vitreous</i> , 2020, 6, 24.	0.9	10
2080	<p></p>The Evolving Treatment of Diabetic Retinopathy</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 653-678.	0.9	134
2081	Prevention of Cognitive Decline in Alzheimer's Disease by Novel Antioxidative Supplements. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1974.	1.8	38
2082	Relationship of ankle-brachial index, vibration perception threshold, and current perception threshold to glycemic variability in type 2 diabetes. <i>Medicine (United States)</i> , 2020, 99, e19374.	0.4	7
2083	for Heterogeneity in the Algorithm for Type 2 Diabetes Management. <i>Current Diabetes Reports</i> , 2020, 20, 14.	1.7	6
2084	Systemic Factors Associated with Treatment Response in Diabetic Macular Edema. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-6.	0.6	14
2085	Level of self-care practice among diabetic patients in Ethiopia: a systematic review and meta-analysis. <i>BMC Public Health</i> , 2020, 20, 309.	1.2	21
2086	How Significant Is Severe Hypoglycemia in Older Adults With Diabetes?. <i>Diabetes Care</i> , 2020, 43, 512-514.	4.3	13
2087	<p></p>Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 333-343.	0.7	11
2088	<p></p>Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 1629-1639.	0.9	1
2089	The prevalence of lipohypertrophy and its associated factors among Saudi patients with type 2 diabetes mellitus. <i>Journal of Taibah University Medical Sciences</i> , 2020, 15, 224-231.	0.5	5
2090	Prevalence, treatment, control of type 2 diabetes and the risk factors among elderly people in Shenzhen: results from the urban Chinese population. <i>BMC Public Health</i> , 2020, 20, 998.	1.2	12

#	ARTICLE	IF	CITATIONS
2091	Identification of pathognomonic purine synthesis biomarkers by metabolomic profiling of adolescents with obesity and type 2 diabetes. <i>PLoS ONE</i> , 2020, 15, e0234970.	1.1	21
2092	Prevalence and determinants of poor glycaemic control: a cross-sectional study among Moroccan type 2 diabetes patients. <i>International Health</i> , 2022, 14, 390-397.	0.8	22
2093	Time in Range, as a Novel Metric of Glycemic Control, Is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-11.	1.0	47
2094	The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China. <i>Cardiovascular Diabetology</i> , 2020, 19, 23.	2.7	53
2095	Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1231-1242.	2.2	13
2096	<p>Khat Chewing and Type 2 Diabetes Mellitus</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 307-312.	1.1	18
2097	Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c<math>\leq 6.5\%</math>) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. <i>Cardiovascular Diabetology</i> , 2020, 19, 21.	2.7	12
2098	Early-onset colorectal cancer: initial clues and current views. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 352-364.	8.2	220
2099	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , 2020, 21, 34.	0.7	19
2100	Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases. <i>Antioxidants</i> , 2020, 9, 142.	2.2	98
2101	The Effect of Diacerein on Type 2 Diabetic Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-9.	1.0	11
2102	HbA1C Variability Is Strongly Associated with Development of Macroalbuminuria in Normal or Microalbuminuria in Patients with Type 2 Diabetes Mellitus: A Six-Year Follow-Up Study. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	13
2103	Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins. <i>JAMA Network Open</i> , 2020, 3, e1918554.	2.8	14
2104	Application of computerized 3D-CT texture analysis of pancreas for the assessment of patients with diabetes. <i>PLoS ONE</i> , 2020, 15, e0227492.	1.1	12
2105	Association of depression and diabetes complications and mortality: a population-based cohort study. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e96.	1.8	54
2106	Profile and factors associated with glycaemic control of patients with type 2 diabetes in Greece: results from the diabetes registry. <i>BMC Endocrine Disorders</i> , 2020, 20, 16.	0.9	5
2107	The antagonism of 6-shogaol in high-glucose-activated NLRP3 inflammasome and consequent calcification of human artery smooth muscle cells. <i>Cell and Bioscience</i> , 2020, 10, 5.	2.1	31
2108	The Threshold of the Severity of Diabetic Retinopathy below Which Intensive Glycemic Control Is Beneficial in Diabetic Patients: Estimation Using Data from Large Randomized Clinical Trials. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-6.	1.0	12

#	ARTICLE	IF	CITATIONS
2109	Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease. <i>JAMA Network Open</i> , 2020, 3, e1919666.	2.8	14
2110	American Society of Retina Specialists Clinical Practice Guidelines: Management of Nonproliferative and Proliferative Diabetic Retinopathy Without Diabetic Macular Edema. <i>Journal of Vitreoretinal Diseases</i> , 2020, 4, 125-135.	0.2	20
2111	The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. <i>Diabetes Therapy</i> , 2020, 11, 509-521.	1.2	8
2112	Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Diabetes Therapy</i> , 2020, 11, 549-560.	1.2	7
2113	New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. <i>Frontiers in Endocrinology</i> , 2019, 10, 929.	1.5	76
2114	Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 2.	1.3	3
2115	Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000807.	1.2	13
2116	Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-12.	1.0	17
2117	Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. <i>Redox Biology</i> , 2020, 32, 101527.	3.9	47
2118	Association of unhealthy dietary behaviors with renal function decline in patients with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000743.	1.2	4
2119	The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia. <i>Journal of Clinical Medicine</i> , 2020, 9, 1091.	1.0	6
2120	Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials. <i>Diabetes Therapy</i> , 2020, 11, 1317-1330.	1.2	4
2121	Demographic and Clinical Factors Associated with Development of Type 2 Diabetes: A Review of the Literature. <i>International Journal of General Medicine</i> , 2020, Volume 13, 121-129.	0.8	42
2122	Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 177-189.	0.7	9
2123	Latest Evidence on Sulfonylureas: What's New?. <i>Diabetes Therapy</i> , 2020, 11, 15-22.	1.2	12
2124	Efficacy and safety of shenqi compound for the treatment of diabetic macroangiopathy. <i>Medicine (United States)</i> , 2020, 99, e19682.	0.4	1
2125	ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000810.	1.2	7
2126	Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II. <i>Cardiovascular Diabetology</i> , 2020, 19, 43.	2.7	16

#	ARTICLE	IF	CITATIONS
2127	Clinical profile at diagnosis with youth-onset type 1 and type 2 diabetes in two pediatric diabetes registries: SEARCH (United States) and YDR (India). <i>Pediatric Diabetes</i> , 2021, 22, 22-30.	1.2	10
2128	Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 244-253.	1.1	25
2129	Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan). <i>Journal of Diabetes Investigation</i> , 2021, 12, 207-216.	1.1	17
2130	Approaches to screening for hyperglycaemia in pregnant women during and after the COVID-19 pandemic. <i>Diabetic Medicine</i> , 2021, 38, e14380.	1.2	30
2131	Association between tear and blood glucose concentrations: Random intercept model adjusted with confounders in tear samples negative for occult blood. <i>Journal of Diabetes Investigation</i> , 2021, 12, 266-276.	1.1	34
2132	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in <sc>SUSTAIN China</sc>: A 30-week, double-blind, phase 3a, randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 404-414.	2.2	45
2133	Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydroglucitol. <i>Journal of Diabetes Investigation</i> , 2021, 12, 940-949.	1.1	18
2134	Identifying patients at increased risk of hypoglycaemia in primary care: Development of a machine learning-based screening tool. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3426.	1.7	7
2135	Postintervention Effects of Varying Treatment Arms on Glycemic Failure and $\beta$ -Cell Function in the TODAY Trial. <i>Diabetes Care</i> , 2021, 44, 75-80.	4.3	8
2136	Metformin treatment and gastrointestinal symptoms in youth: Findings from a large tertiary care referral center. <i>Pediatric Diabetes</i> , 2021, 22, 182-191.	1.2	4
2137	Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic. <i>Diabetic Medicine</i> , 2021, 38, e14433.	1.2	34
2138	Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease. <i>Endocrine Reviews</i> , 2021, 42, 29-55.	8.9	108
2139	A Kinetic Model for Glucose Levels and Hemoglobin A1c Provides a Novel Tool for Individualized Diabetes Management. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 294-302.	1.3	20
2140	Impact of pharmacist-led educational intervention on predictors of diabetic foot at two different hospitals of Malaysia. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021, 13, 108.	0.2	3
2141	Effects of coconut water on blood sugar and retina of rats with diabetes. <i>PeerJ</i> , 2021, 9, e10667.	0.9	1
2142	HbA1c trajectory and cardiovascular outcomes: an analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110263.	1.1	4
2143	Is weight regaining significant post laparoscopic Roux-en-Y gastric bypass surgery? â€œ A 5-year follow-up study on Indian patients. <i>Journal of Minimal Access Surgery</i> , 2021, 17, 159.	0.4	3
2144	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1020-1029.	2.2	19

#	ARTICLE	IF	CITATIONS
2145	Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 699-706.	4.3	31
2146	The Effect of Pyridoxine Hydrochloride Supplementation on Leptin, Adiponectin, Glycemic Indices, and Anthropometric Indices in Obese and Overweight Women. <i>Clinical Nutrition Research</i> , 2021, 10, 230.	0.5	4
2147	Evaluating the Effectiveness of Diabetes Shared Medical Appointments (SMAs) as Implemented in Five Veterans Affairs Health Systems: a Multi-site Cluster Randomized Pragmatic Trial. <i>Journal of General Internal Medicine</i> , 2021, 36, 1648-1655.	1.3	10
2148	Quantitative vibration perception threshold in assessing diabetic polyneuropathy: Should the cutoff value be adjusted for Chinese individuals with type 2 diabetes?. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1663-1670.	1.1	6
2149	Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy. <i>Diabetes Spectrum</i> , 2021, 34, 184-189.	0.4	47
2150	Western Dietary Patterns, Foods, and Risk of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. <i>Advances in Nutrition</i> , 2021, 12, 1353-1364.	2.9	23
2151	Long-Term Weight Loss Strategies for Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1854-1866.	1.8	32
2152	Glutathione S-Transferase (GSTT1 rs17856199) and Nitric Oxide Synthase (NOS2 rs2297518) Genotype Combination as Potential Oxidative Stress-Related Molecular Markers for Type 2 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1385-1403.	1.1	13
2153	The regulatory role of insulin in energy metabolism and leukocyte functions. <i>Journal of Leukocyte Biology</i> , 2021, 111, 197-208.	1.5	16
2154	Effect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 539-545.	1.3	14
2155	Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1855-1863.	1.1	7
2156	Harnessing molecular recognition for localized drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 238-260.	6.6	15
2157	Bacterial processing of glucose modulates <i>C. elegans</i> lifespan and healthspan. <i>Scientific Reports</i> , 2021, 11, 5931.	1.6	15
2158	Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications. <i>Frontiers in Endocrinology</i> , 2021, 12, 636267.	1.5	47
2159	Trial of a New Diabetes Education Model: Closing the Gap in Health Disparity for People with Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 568-574.	1.3	2
2160	Two-Year Treatment With Metformin During Puberty Does Not Preserve $\beta$ -Cell Function in Youth With Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2622-e2632.	1.8	8
2161	Evaluating the quality of care for patients with type 2 diabetes mellitus based on the HbA1c: A national survey in Iran. <i>Heliyon</i> , 2021, 7, e06485.	1.4	6
2162	Assessment for the Correlation Between Diabetic Retinopathy and Metabolic Syndrome: A Cross-Sectional Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1773-1781.	1.1	5

#	ARTICLE	IF	CITATIONS
2163	Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective. <i>Clinical Epigenetics</i> , 2021, 13, 87.	1.8	46
2164	Jumpstarting Health With a 15-Day Whole-Food Plant-Based Program. <i>American Journal of Lifestyle Medicine</i> , 2022, 16, 374-381.	0.8	4
2165	Medication Intake, Perceived Barriers, and Their Correlates Among Adults With Type 1 and Type 2 Diabetes: Results From Diabetes MILES – The Netherlands. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2021, 2, .	0.3	2
2166	The determinants of complication trajectories in American Indians with type 2 diabetes. <i>JCI Insight</i> , 2021, 6, .	2.3	3
2167	Evaluation of Self-Care Practice and Its Associated Factors in Adult Diabetic Patients, Ayder Diabetic Clinic, Mekelle, Ethiopia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 2239-2245.	1.1	3
2168	Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and <sc>HbA1c of more than 10%: A</sc> post hoc analysis of the <sc>EDICT</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1631-1639.	2.2	2
2169	Health Care Providers' Emotional Responses to Their Patients' Hypoglycemic Events: Qualitative Findings From the InHypo-DM Study, Canada. <i>Diabetes Spectrum</i> , 2021, 34, ds200061.	0.4	0
2170	Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1642-1650.	1.1	10
2171	Clinical Application of Time in Range and Other Metrics. <i>Diabetes Spectrum</i> , 2021, 34, 109-118.	0.4	11
2172	Clinical Significance of the Cardio-Ankle Vascular Index in Postmenopausal Women With Hypercholesterolemia. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 276-282.	0.6	1
2173	What Gets Measured Gets Improved – Setting Standards and Accreditation for Quality Improvement for Diabetes Services in Australia. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 193229682110099.	1.3	1
2174	Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes Remission Clinical Trial (DiRECT). <i>Diabetologia</i> , 2021, 64, 1927-1938.	2.9	20
2175	Reexamining the Classification of Older Adults With Diabetes by Comorbidities and Exploring Relationships With Frailty, Disability, and 5-year Mortality. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 2071-2079.	1.7	7
2176	Combination of disease duration – age at diagnosis and hemoglobin A1c – serum C-peptide reactivity ratios predicts patient response to glucose-lowering medication in type 2 diabetes: A retrospective cohort study across Japan (JDDM59). <i>Journal of Diabetes Investigation</i> , 2021, 12, 1967-1977.	1.1	1
2177	American Diabetes Association Framework for Glycemic Control in Older Adults: Implications for Risk of Hospitalization and Mortality. <i>Diabetes Care</i> , 2021, 44, 1524-1531.	4.3	6
2178	A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00259.	1.0	8
2179	Insulin Knowledge, Handling, and Storage among Diabetic Pilgrims during the Hajj Mass Gathering. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-8.	1.0	1
2180	Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	10

#	ARTICLE	IF	CITATIONS
2181	Hyperglucagonemia Does Not Explain the $\beta^2$ -Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. <i>Diabetes Care</i> , 2021, 44, 1961-1969.	4.3	9
2182	Systems Approach to Discovery of Therapeutic Targets for Vein Graft Disease: PPAR $\beta$ Pivotaly Regulates Metabolism, Activation, and Heterogeneity of Macrophages and Lesion Development. <i>Circulation</i> , 2021, 143, 2454-2470.	1.6	21
2183	Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 715-725.	2.4	7
2184	Eye Outcomes in Veteran Affairs Diabetes Trial (VADT) After 17 Years. <i>Diabetes Care</i> , 2021, 44, 2397-2402.	4.3	7
2185	Diabetes and Cardiovascular Complications: The Epidemics Continue. <i>Current Cardiology Reports</i> , 2021, 23, 74.	1.3	6
2186	Advanced Human BBB-on-a-Chip: A New Platform for Alzheimer's Disease Studies. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002285.	3.9	18
2187	Intensity of Glycemic Exposure in Early Adulthood and Target Organ Damage in Middle Age: The CARDIA Study. <i>Frontiers in Physiology</i> , 2021, 12, 614532.	1.3	1
2188	Real-world treatment escalation from metformin monotherapy in youth-onset Type 2 diabetes mellitus: A retrospective cohort study. <i>Pediatric Diabetes</i> , 2021, 22, 861-871.	1.2	6
2189	Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. <i>Diabetes Care</i> , 2021, 44, 1938-1947.	4.3	16
2190	Decision models in type 2 diabetes mellitus: A systematic review. <i>Acta Diabetologica</i> , 2021, 58, 1451-1469.	1.2	13
2191	Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	18
2192	Associations of Type 2 Diabetes Onset Age With Cardiovascular Disease and Mortality: The Kailuan Study. <i>Diabetes Care</i> , 2021, 44, 1426-1432.	4.3	60
2193	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 461-481.	1.8	146
2194	<i>TCF7L2</i> Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2039-2044.	4.3	0
2195	Telehealth delivery of motivational interviewing for diabetes management: A systematic review of randomized controlled trials. <i>Patient Education and Counseling</i> , 2022, 105, 805-820.	1.0	14
2196	Characteristics Associated with Early Worsening of Retinopathy in Patients with Type 2 Diabetes Diagnosed with Retinopathy at Their First Visit: A Retrospective Observational Study. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-9.	1.0	1
2197	Central 5-HTR2C in the Control of Metabolic Homeostasis. <i>Frontiers in Endocrinology</i> , 2021, 12, 694204.	1.5	7
2198	Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3345-3359.	1.1	8



#	ARTICLE	IF	CITATIONS
2199	A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3243-3252.	1.1	3
2200	Association of HbA1c With All-cause Mortality Across Varying Degrees of Glycemic Variability in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3160-3167.	1.8	18
2201	Dietary advanced glycation end-products elicit toxicological effects by disrupting gut microbiome and immune homeostasis. <i>Journal of Immunotoxicology</i> , 2021, 18, 93-104.	0.9	17
2202	The Role of Biofactors in Diabetic Microvascular Complications. <i>Current Diabetes Reviews</i> , 2022, 18, .	0.6	16
2203	Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems. <i>Scientific Reports</i> , 2021, 11, 17373.	1.6	6
2204	Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 714447.	1.5	2
2205	Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2021, 34, 243-247.	0.4	1
2206	Awareness of Diabetic Retinopathy: Insight From the National Health and Nutrition Examination Survey. <i>American Journal of Preventive Medicine</i> , 2021, 61, 900-909.	1.6	10
2207	Cardiovascular Outcomes Trials of Incretin-Based Therapies. <i>Diabetes Spectrum</i> , 2021, 34, 217-224.	0.4	0
2208	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	7.2	87
2209	The effects of insulin therapy on mortality in diabetic patients undergoing percutaneous coronary intervention. <i>Annals of Translational Medicine</i> , 2021, 9, 1294-1294.	0.7	3
2210	The legacy effect in diabetes: are there long-term benefits?. <i>Diabetologia</i> , 2021, 64, 2131-2137.	2.9	18
2211	Lactate and Myocardial Energy Metabolism. <i>Frontiers in Physiology</i> , 2021, 12, 715081.	1.3	26
2212	Disparities in Hemoglobin A1c Testing During the Transition to Adulthood and Association With Diabetes Outcomes in Youth-Onset Type 1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study. <i>Diabetes Care</i> , 2021, 44, 2320-2328.	4.3	2
2213	The substantial burden of non-communicable diseases and HIV-comorbidity amongst adults: Screening results from an integrated HIV testing services clinic for adults in Soweto, South Africa. <i>EClinicalMedicine</i> , 2021, 38, 101015.	3.2	8
2214	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021, 64, 2402-2414.	2.9	6
2215	Further RISE™ing to the Challenge of Type 2 Diabetes in Youth. <i>Diabetes Care</i> , 2021, 44, 1934-1937.	4.3	1
2216	Genetics of Type 2 Diabetes: Opportunities for Precision Medicine. <i>Journal of the American College of Cardiology</i> , 2021, 78, 496-512.	1.2	12

#	ARTICLE	IF	CITATIONS
2217	Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3497-3504.	1.8	3
2218	Differential loss of $\beta$ -cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108948.	1.1	15
2219	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <scp>EMPAâ€REG OUTCOME</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2775-2784.	2.2	12
2220	Benefits of the addition of continuous or flash glucose monitoring versus standard practice using self-monitored blood glucose and haemoglobin A1c in the primary care of diabetes mellitus: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e050027.	0.8	1
2221	The role of Optical Coherence Tomography Angiography to detect early microvascular changes in Diabetic Retinopathy: a systematic review. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1957-1974.	0.8	9
2222	Diabetes Microvascular Disease Diagnosis and Treatment After High-Deductible Health Plan Enrollment. <i>Diabetes Care</i> , 2022, 45, 1754-1761.	4.3	3
2223	A Clinical Conundrum: Intensifying Glycemic Control in the Presence of Advanced Diabetic Retinopathy. <i>Diabetes Care</i> , 2021, 44, 2192-2193.	4.3	7
2224	Hemoglobin A1câ€”Using Epidemiology to Guide Medical Practice: Kelly West Award Lecture 2020. <i>Diabetes Care</i> , 2021, 44, 2197-2204.	4.3	14
2225	Use of Anthropometric Measures of Obesity to Predict Diabetic Retinopathy in Patients with Type 2 Diabetes in China. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4089-4095.	1.1	5
2226	2021 Consensus Pathway of the Taiwanâ€Society of Cardiology on Novelâ€Therapyâ€for Type 2 Diabetes. <i>JACC Asia</i> , 2021, 1, 129-146.	0.5	1
2227	Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial. <i>Endocrine Connections</i> , 2021, 10, 1045-1054.	0.8	5
2228	Habitual intake of dietary advanced glycation end products is not associated with generalized microvascular functionâ€”the Maastricht Study. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 444-455.	2.2	8
2229	Insulin Resistance is Associated with Subclinical Vascular Injury in Patients with a Kidney Disease. <i>Current Cardiology Reviews</i> , 2021, 17, e160721189014.	0.6	0
2230	Pharmacist-led intervention in treatment non-adherence and associated direct costs of management among ambulatory patients with type 2 diabetes in southwestern Nigeria. <i>BMC Health Services Research</i> , 2021, 21, 1000.	0.9	1
2231	The Role of Human-Centered Design in Insulin Pen Innovation and the Future of Insulin Delivery. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 623-627.	1.3	6
2232	A comparative analysis and review of how national guidelines for chronic disease monitoring are made in low- and middle-income compared to high-income countries. <i>Journal of Global Health</i> , 2021, 11, 04055.	1.2	5
2233	Heterogeneity of Treatment Effects Among Patients With Type 2 Diabetes and Elevated Body Mass Index in a Study Comparing Group Medical Visits Focused on Weight Management and Medication Intensification. <i>Medical Care</i> , 2021, Publish Ahead of Print, 1031-1038.	1.1	0
2234	Evaluation of interference from hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by fifteen methods. <i>Clinica Chimica Acta</i> , 2021, 522, 31-35.	0.5	16

#	ARTICLE	IF	CITATIONS
2235	Significance of Glycemic Variability in Diabetes Mellitus. <i>Internal Medicine</i> , 2022, 61, 281-290.	0.3	10
2236	Retinal Protein O-GlcNAcylation and the Ocular Renin Angiotensin System: Signaling Cross-Roads in Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2021, 17, .	0.6	2
2237	Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1231.	1.8	14
2238	Analyzing Birth Cohorts With the National Social Life, Health, and Aging Project. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, S226-S237.	2.4	1
2239	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. <i>Diabetes Therapy</i> , 2020, 11, 33-48.	1.2	17
2240	Evaluation of glycemic control status and its associated factors among diabetes patients on follow-up at referral hospitals of Northwest Ethiopia: A cross-sectional study, 2020. <i>Heliyon</i> , 2020, 6, e05655.	1.4	10
2241	Intensive glycemic control in younger and older U.S. adults with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1299-1304.	1.2	9
2242	“Miscarried helping” in adults with Type 2 diabetes: Helping for Health Inventory” Couples.. <i>Families, Systems and Health</i> , 2017, 35, 409-419.	0.4	8
2243	<i>Nigella sativa</i> stimulates insulin secretion from isolated rat islets and inhibits the digestion and absorption of (CH <sub>2</sub> O) <sub>n</sub> in the gut. <i>Bioscience Reports</i> , 2019, 39, .	1.1	21
2244	Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus. <i>Annals of Surgery</i> , 2003, 238, 467-485.	2.1	1,034
2246	Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). <i>Journal of Diabetes Investigation</i> , 2019, 10, 1272-1283.	1.1	10
2247	Glycated haemoglobin, diabetes, and mortality in men. <i>BMJ: British Medical Journal</i> , 2001, 322, 996-996.	2.4	2
2248	Emergency contraception from pharmacists misses opportunity. <i>BMJ: British Medical Journal</i> , 2001, 322, 1245-1245.	2.4	21
2249	Associations between multimorbidity and glycaemia (HbA1c) in people with type 2 diabetes: cross-sectional study in Australian general practice. <i>BMJ Open</i> , 2020, 10, e039625.	0.8	8
2250	Case-control study of 10 years of comprehensive diabetes care. <i>Western Journal of Medicine</i> , 2000, 172, 85-90.	0.3	44
2251	Achieving further glycemic control in type 2 diabetes mellitus. <i>Western Journal of Medicine</i> , 2000, 173, 175-179.	0.3	9
2252	The target for good glycemic control should be an Hb A1C concentration of less than 0.07. <i>Western Journal of Medicine</i> , 2000, 173, 179-180.	0.3	6
2253	<i>Psoralea corylifolia</i> L. Seed Extract Attenuates Methylglyoxal-Induced Insulin Resistance by Inhibition of Advanced Glycation End Product Formation. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	19

#	ARTICLE	IF	CITATIONS
2254	A comparative evaluation of the analytical performances of Capillary 2 Flex Piercing, Tosoh HLC-723 G8, Premier Hb9210, and Roche Cobas c501 Tina-quant Gen 2 analyzers for HbA1c determination. <i>Biochemia Medica</i> , 2016, 26, 353-364.	1.2	20
2255	Predictors of poor glycaemic control in older patients with type 2 diabetes mellitus. <i>Singapore Medical Journal</i> , 2015, 56, 284-290.	0.3	21
2256	Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon <i>Papio hamadryas</i> . <i>JCI Insight</i> , 2019, 4, .	2.3	15
2257	Reversible retinal vessel closure from VEGF-induced leukocyte plugging. <i>JCI Insight</i> , 2017, 2, .	2.3	44
2258	Peroxisome proliferator-activated receptor $\beta$ ligands and atherosclerosis: ending the heartache. <i>Journal of Clinical Investigation</i> , 2000, 106, 629-631.	3.9	66
2259	A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. <i>Journal of Clinical Investigation</i> , 2001, 107, 853-860.	3.9	135
2260	Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 $\alpha$ and VEGF. <i>Journal of Clinical Investigation</i> , 2002, 109, 805-815.	3.9	115
2261	Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?. <i>Journal of Clinical Investigation</i> , 2003, 112, 986-988.	3.9	60
2262	Why does diabetes increase atherosclerosis? I don't know!. <i>Journal of Clinical Investigation</i> , 2004, 114, 613-615.	3.9	58
2263	Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. <i>Journal of Clinical Investigation</i> , 2004, 114, 877-883.	3.9	91
2264	Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. <i>Journal of Clinical Investigation</i> , 2005, 115, 2434-2443.	3.9	157
2265	Starting insulin therapy in elderly patients. <i>Journal of the Royal Society of Medicine</i> , 2002, 95, 453-455.	1.1	16
2266	An overview of the eye in diabetes. <i>Journal of the Royal Society of Medicine</i> , 2003, 96, 266-272.	1.1	52
2267	Advanced Glycation End Products (AGEs) Induce Apoptosis of Fibroblasts by Activation of NLRP3 Inflammasome via Reactive Oxygen Species (ROS) Signaling Pathway. <i>Medical Science Monitor</i> , 2019, 25, 7499-7508.	0.5	46
2268	Recent advances in the management and understanding of diabetic retinopathy. <i>F1000Research</i> , 2017, 6, 2063.	0.8	17
2269	Why Treatment Fails in Type 2 Diabetes. <i>PLoS Medicine</i> , 2008, 5, e215.	3.9	14
2270	<i>Nigella sativa</i> Improves Glycemic Control and Ameliorates Oxidative Stress in Patients with Type 2 Diabetes Mellitus: Placebo Controlled Participant Blinded Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0113486.	1.1	102
2271	Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study. <i>PLoS ONE</i> , 2015, 10, e0130828.	1.1	16

#	ARTICLE	IF	CITATIONS
2272	The Effect of Comorbidity on Glycemic Control and Systolic Blood Pressure in Type 2 Diabetes: A Cohort Study with 5 Year Follow-Up in Primary Care. PLoS ONE, 2015, 10, e0138662.	1.1	26
2273	Knowledge of A1c Predicts Diabetes Self-Management and A1c Level among Chinese Patients with Type 2 Diabetes. PLoS ONE, 2016, 11, e0150753.	1.1	12
2274	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0153502.	1.1	6
2275	Prevalence, Awareness, Treatment and Control of Diabetes Mellitus in a Chinese Population. PLoS ONE, 2016, 11, e0153791.	1.1	33
2276	Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLoS ONE, 2016, 11, e0154206.	1.1	22
2277	Risk of Diabetes Mellitus on Incidence of Out-of-Hospital Cardiac Arrests: A Case-Control Study. PLoS ONE, 2016, 11, e0154245.	1.1	17
2278	High Glucose Impairs Insulin Signaling in the Glomerulus: An In Vitro and Ex Vivo Approach. PLoS ONE, 2016, 11, e0158873.	1.1	25
2279	Hba1c, Blood Pressure, and Lipid Control in People with Diabetes: Japan Epidemiology Collaboration on Occupational Health Study. PLoS ONE, 2016, 11, e0159071.	1.1	40
2280	The AGE-RAGE Axis and Its Relationship to Markers of Cardiovascular Disease in Newly Diagnosed Diabetic Patients. PLoS ONE, 2016, 11, e0159175.	1.1	27
2281	Association between Sickle Cell Trait and the Prevalence and Severity of Diabetic Retinopathy. PLoS ONE, 2016, 11, e0159215.	1.1	11
2282	Antiglycation and Antioxidant Properties of Momordica charantia. PLoS ONE, 2016, 11, e0159985.	1.1	41
2283	Implementation and Outcomes of a Comprehensive Type 2 Diabetes Program in Rural Guatemala. PLoS ONE, 2016, 11, e0161152.	1.1	11
2284	Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis. PLoS ONE, 2017, 12, e0171315.	1.1	90
2285	The association between various smoking behaviors, cotinine biomarkers and skin autofluorescence, a marker for advanced glycation end product accumulation. PLoS ONE, 2017, 12, e0179330.	1.1	30
2286	Combined poor diabetes control indicators are associated with higher risks of diabetic retinopathy and macular edema than poor glycemic control alone. PLoS ONE, 2017, 12, e0180252.	1.1	26
2287	Bi-stability in type 2 diabetes mellitus multi-organ signalling network. PLoS ONE, 2017, 12, e0181536.	1.1	10
2288	The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II. PLoS ONE, 2018, 13, e0194417.	1.1	6
2289	Impact of Insulin Resistance on Neointimal Tissue Proliferation after 2nd-Generation Drug-Eluting Stent Implantation. Texas Heart Institute Journal, 2015, 42, 327-332.	0.1	11

#	ARTICLE	IF	CITATIONS
2290	Clinical Significance of Skin Autofluorescence in Patients With Type 2 Diabetes Mellitus With Chronic Heart Failure. <i>Cardiology Research</i> , 2018, 9, 83-89.	0.5	8
2291	Determinants of Glycated Hemoglobin in Subjects With Impaired Glucose Tolerance: Subanalysis of the Japan Diabetes Prevention Program. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 360-365.	0.6	4
2292	Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 366-373.	0.6	14
2293	Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 745-753.	0.6	30
2294	Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 802-808.	0.6	5
2295	Clinical Significance of Cardio-Ankle Vascular Index as a Cardiovascular Risk Factor in Elderly Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 330-336.	0.6	11
2296	Type 2 Diabetes and Glycemic Variability: Various Parameters in Clinical Practice. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 737-742.	0.6	18
2297	Inadequate control of diabetes and metabolic indices among diabetic patients: A population based study from the Kerman Coronary Artery Disease Risk Study (KERCADRS). <i>International Journal of Health Policy and Management</i> , 2015, 4, 271-277.	0.5	19
2298	Malignancy incidences by glycemic control among diabetic patients. <i>Endocrine Connections</i> , 2018, 7, 1457-1463.	0.8	4
2299	Development and Validation of a Questionnaire Evaluating Impaired Hypoglycemia Awareness among Adult Filipino Patients with Type 2 Diabetes Mellitus. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2017, 32, 158-164.	0.1	2
2300	Diabetes-Related Attitudes of Health Care Providers in Rural Health Centers in Aklan, Philippines using the Filipino version of Diabetes Attitude Scale (DAS-3). <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2019, 34, 180-187.	0.1	2
2301	Genetic and epigenetic modifications in the pathogenesis of diabetic retinopathy: a molecular link to regulate gene expression. <i>New Frontiers in Ophthalmology (London)</i> , 2016, 2, 192-204.	0.1	16
2302	Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study. <i>Brazilian Journal of Medical and Biological Research</i> , 2020, 53, e8652.	0.7	3
2303	A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. <i>European Endocrinology</i> , 2010, 10, 23.	0.8	11
2304	Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema. <i>European Endocrinology</i> , 2014, 10, 111.	0.8	4
2305	Management of Type 2 Diabetes – Methods for Addition of Prandial to Basal Insulin. <i>European Endocrinology</i> , 2014, 10, 124.	0.8	2
2306	The Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors – Real-world Data. <i>European Endocrinology</i> , 2018, 14, 17.	0.8	26
2307	The Cost-effectiveness of a Flash Glucose Monitoring System for Management of Patients with Type 2 Diabetes Receiving Intensive Insulin Treatment in Sweden. <i>European Endocrinology</i> , 2018, 14, 80.	0.8	16

#	ARTICLE	IF	CITATIONS
2308	Association of vascular endothelial growth factor -634G/C and receptor for advanced glycation end products G82S gene polymorphisms with diabetic retinopathy. <i>International Journal of Ophthalmology</i> , 2016, 9, 1106-11.	0.5	6
2309	What's next after metformin? focus on sulphonylurea: add-on or combination therapy. <i>Pharmacy Practice</i> , 2015, 13, 606-606.	0.8	8
2310	Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies. <i>Oncotarget</i> , 2017, 8, 26448-26459.	0.8	29
2311	Serum cystatin C is associated with large cerebral artery stenosis in acute ischemic stroke. <i>Oncotarget</i> , 2017, 8, 67181-67188.	0.8	16
2312	Association of single-nucleotide polymorphisms in the <i>RAGE</i> gene and its gene- environment interactions with diabetic nephropathy in Chinese patients with type 2 diabetes. <i>Oncotarget</i> , 2017, 8, 96885-96892.	0.8	7
2313	Adherence to Guidelines and its Effects on Hospitalizations with Complications of Type 2 Diabetes. <i>Review of Diabetic Studies</i> , 2004, 1, 29-29.	0.5	33
2314	Type 2 Diabetes – Failure, Blame and Guilt in the Adoption of Insulin Therapy. <i>Review of Diabetic Studies</i> , 2005, 2, 35-35.	0.5	26
2315	The Diterpene Glycoside, Rebaudioside A, Does not Improve Glycemic Control or Affect Blood Pressure After Eight Weeks Treatment in the Goto-Kakizaki Rat. <i>Review of Diabetic Studies</i> , 2005, 2, 84-84.	0.5	22
2316	The Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions. <i>Review of Diabetic Studies</i> , 2006, 3, 208-208.	0.5	10
2317	Improved Monitoring of the Hyperglycemic State in Type 1 Diabetes Patients by Use of the Glycoalbumin/HbA1c Ratio. <i>Review of Diabetic Studies</i> , 2007, 4, 44-44.	0.5	18
2318	3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study. <i>Review of Diabetic Studies</i> , 2007, 4, 89-97.	0.5	11
2319	Alternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic Inflammation. <i>Review of Diabetic Studies</i> , 2014, 11, 231-244.	0.5	27
2320	Type 2 Diabetes Prevention: Implications of Hemoglobin A1c Genetics. <i>Review of Diabetic Studies</i> , 2015, 12, 351-362.	0.5	14
2321	Health-related quality of life associated with diabetic retinopathy in patients at a public primary care service in southern Brazil. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 575-583.	0.3	4
2322	Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?. <i>Annals of Translational Medicine</i> , 2018, 6, 192-192.	0.7	4
2323	Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option?. <i>Annals of Translational Medicine</i> , 2018, 6, S95-S95.	0.7	3
2324	A 7.0% value for glycated haemoglobin is better than a 7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus. <i>Annals of Translational Medicine</i> , 2019, 7, S122-S122.	0.7	3
2325	Prevalence, Patterns and Predictors of Chronic Complications of Diabetes Mellitus at a Large Referral Hospital in Ethiopia: A Prospective Observational Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 4909-4918.	1.1	13

#	ARTICLE	IF	CITATIONS
2326	A critical dialogue: communicating with type 2 diabetes patients about cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2005, 1, 301-307.	1.0	11
2327	Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?. <i>Vascular Health and Risk Management</i> , 2005, 1, 309-316.	1.0	27
2328	Insulin glargine in the treatment of type 1 and type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2006, 2, 59-67.	1.0	33
2329	Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2006, 2, 69-77.	1.0	24
2330	Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. <i>Vascular Health and Risk Management</i> , 2006, 2, 203-212.	1.0	43
2331	Insulin detemir in the treatment of type 1 and type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2006, 2, 277-283.	1.0	16
2332	Insulin resistance and plasma triglyceride level are differently related to cardiac hypertrophy and arterial stiffening in hypertensive subjects. <i>Vascular Health and Risk Management</i> , 2006, 2, 485-490.	1.0	8
2333	Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. <i>Vascular Health and Risk Management</i> , 2006, 2, 507-514.	1.0	18
2334	Neuroretinal Apoptosis as a Vascular Dysfunction in Diabetic Patients. <i>Current Neuropharmacology</i> , 2016, 14, 826-830.	1.4	13
2335	Effects of Resveratrol and other Polyphenols on Sirt1: Relevance to Brain Function During Aging. <i>Current Neuropharmacology</i> , 2018, 16, 126-136.	1.4	90
2336	New Approaches to Providing Individualized Diabetes Care in the 21st Century. <i>Current Diabetes Reviews</i> , 2015, 11, 222-230.	0.6	48
2337	Predicting Current Glycated Hemoglobin Values in Adults: Development of an Algorithm From the Electronic Health Record. <i>JMIR Medical Informatics</i> , 2018, 6, e10780.	1.3	12
2338	Effect of Cognitive Behavioral Therapy for Insomnia on Insomnia Symptoms for Individuals With Type 2 Diabetes: Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019, 8, e14647.	0.5	7
2339	Mapping the Evidence on the Effectiveness of Telemedicine Interventions in Diabetes, Dyslipidemia, and Hypertension: An Umbrella Review of Systematic Reviews and Meta-Analyses. <i>Journal of Medical Internet Research</i> , 2020, 22, e16791.	2.1	141
2340	A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. <i>JMIR Diabetes</i> , 2017, 2, e5.	0.9	120
2341	One Drop   Mobile: An Evaluation of Hemoglobin A1c Improvement Linked to App Engagement. <i>JMIR Diabetes</i> , 2017, 2, e21.	0.9	39
2342	Digital Games for Type 1 and Type 2 Diabetes: Underpinning Theory With Three Illustrative Examples. <i>JMIR Serious Games</i> , 2015, 3, e3.	1.7	49
2343	The Impact of Automated Brief Messages Promoting Lifestyle Changes Delivered Via Mobile Devices to People with Type 2 Diabetes: A Systematic Literature Review and Meta-Analysis of Controlled Trials. <i>Journal of Medical Internet Research</i> , 2016, 18, e86.	2.1	138



#	ARTICLE	IF	CITATIONS
2344	One Drop   Mobile on iPhone and Apple Watch: An Evaluation of HbA1c Improvement Associated With Tracking Self-Care. JMIR MHealth and UHealth, 2017, 5, e179.	1.8	21
2345	Mobile Diabetes Intervention Study of Patient Engagement and Impact on Blood Glucose: Mixed Methods Analysis. JMIR MHealth and UHealth, 2018, 6, e31.	1.8	53
2346	Dietary Advanced Glycation End Products Consumption as a Direct Modulator of Insulin Sensitivity in Overweight Humans: A Study Protocol for a Double-Blind, Randomized, Two Period Cross-Over Trial. JMIR Research Protocols, 2015, 4, e93.	0.5	4
2347	Protective effect of metformin on toxicity of butyric acid and arsenic in isolated liver mitochondria and langerhans islets in male mice: an study. Iranian Journal of Basic Medical Sciences, 2017, 20, 1297-1305.	1.0	18
2348	Polymorphisms of Antioxidant Genes as a Target for Diabetes Management. International Journal of Molecular and Cellular Medicine, 2017, 6, 135-147.	1.1	14
2349	Haptoglobin 1-1 Genotype Modulates the Association of Glycemic Control With Hippocampal Volume in Elderly Individuals With Type 2 Diabetes. Diabetes, 2017, 66, 2927-2932.	0.3	13
2350	HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care, 2021, 44, 290-296.	4.3	49
2351	Type 2 Diabetes in the Elderly: Challenges in a Unique Patient Population. Journal of Geriatric Medicine and Gerontology, 2016, 2, .	0.1	23
2352	Lipotoxicity, Nutrient-Sensing Signals, and Autophagy in Diabetic Nephropathy. JMA Journal, 2020, 3, 87-94.	0.6	10
2353	Cost-effectiveness of Simple Insulin Infusion Devices Compared to Multiple Daily Injections in Uncontrolled Type 2 Diabetics in the United States Based on a Simulation Model. Journal of Health Economics and Outcomes Research, 2018, 6, 84-95.	0.6	8
2354	Upper gastrointestinal function and glycemic control in diabetes mellitus. World Journal of Gastroenterology, 2006, 12, 5611.	1.4	34
2355	Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Experimental and Therapeutic Medicine, 2020, 20, 2396-2400.	0.8	29
2356	Diabcare Asia 2001 - Korea : Country Report on Outcome Data and Analysis. Korean Journal of Internal Medicine, 2005, 20, 48.	0.7	18
2357	The Effect of Early Insulin Therapy on Pancreatic $\beta$ -Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients. Korean Journal of Internal Medicine, 2010, 25, 273.	0.7	27
2358	Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes. Korean Journal of Internal Medicine, 2015, 30, 6.	0.7	33
2359	Blood electrolyte disturbances during severe hypoglycemia in Korean patients with type 2 diabetes. Korean Journal of Internal Medicine, 2015, 30, 648-656.	0.7	6
2360	Treatment of diabetic kidney disease: current and future targets. Korean Journal of Internal Medicine, 2017, 32, 622-630.	0.7	30
2361	Current status of managing diabetes mellitus in Korea. Korean Journal of Internal Medicine, 2016, 31, 845-850.	0.7	35

#	ARTICLE	IF	CITATIONS
2362	Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Korean Journal of Internal Medicine, 2017, 32, 947-958.	0.7	12
2363	Monotherapy in patients with type 2 diabetes mellitus. Korean Journal of Internal Medicine, 2017, 32, 959-966.	0.7	5
2364	Hyperglycemia: a bad signature on the vascular system. Cardiovascular Diagnosis and Therapy, 2015, 5, 403-6.	0.7	17
2365	Management of diabetic renal disease. Annals of Translational Medicine, 2015, 3, 154.	0.7	20
2366	A comparative drug utilisation study of the treatment of diabetes in Malaysia and Australia. Australasian Medical Journal, 2015, 8, 179-188.	0.1	5
2367	Does tight control of systemic factors help in the management of diabetic retinopathy?. Indian Journal of Ophthalmology, 2016, 64, 62.	0.5	19
2368	Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone. Chinese Medical Journal, 2015, 128, 1279-1287.	0.9	3
2369	Yoga- a potential solution for diabetes & metabolic syndrome. Indian Journal of Medical Research, 2015, 141, 753.	0.4	10
2370	Derivation & validation of glycosylated haemoglobin (HbA <sub>1c</sub> ) cut-off value as a diagnostic test for type 2 diabetes in south Indian population. Indian Journal of Medical Research, 2016, 144, 220.	0.4	6
2371	Traumatic injuries in patients with diabetes mellitus. Journal of Emergencies, Trauma and Shock, 2016, 9, 64.	0.3	16
2372	Cinnamon: Mystic powers of a minute ingredient. Pharmacognosy Research (discontinued), 2015, 7, 1.	0.3	74
2373	Updates on the clinical trials in diabetic macular edema. Middle East African Journal of Ophthalmology, 2016, 23, 3.	0.5	19
2374	Comparison of optimal cardiovascular risk factor management in patients with Type 2 diabetes who attended urban medical health center with those attended a tertiary care center: Experiences from Tehran, Iran. International Journal of Preventive Medicine, 2016, 7, 113.	0.2	4
2375	Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian Journal of Endocrinology and Metabolism, 2015, 19, 577.	0.2	77
2376	Hemoglobin E disease and glycosylated hemoglobin. Indian Journal of Endocrinology and Metabolism, 2015, 19, 683.	0.2	9
2377	Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives. Indian Journal of Endocrinology and Metabolism, 2016, 20, 22.	0.2	18
2378	Cardiovascular risk factors, micro and macrovascular complications at diagnosis in patients with young onset type 2 diabetes in India: CINDI 2. Indian Journal of Endocrinology and Metabolism, 2016, 20, 114.	0.2	22
2379	Adherence to diabetes care processes at general practices in the National Capital Region-Delhi, India. Indian Journal of Endocrinology and Metabolism, 2016, 20, 329.	0.2	7

#	ARTICLE	IF	CITATIONS
2380	Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity. Indian Journal of Endocrinology and Metabolism, 2017, 21, 245.	0.2	2
2381	Reported hypoglycemia in Type 2 diabetes mellitus patients: Prevalence and practices-a hospital-based study. Indian Journal of Endocrinology and Metabolism, 2017, 21, 148.	0.2	21
2382	Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement. Indian Journal of Endocrinology and Metabolism, 2017, 21, 210.	0.2	19
2383	Five-year comparison of diabetic control between community diabetic center and primary health-care centers. Journal of Family Medicine and Primary Care, 2016, 5, 641.	0.3	2
2384	Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients. Advanced Biomedical Research, 2018, 7, 96.	0.2	6
2385	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism, 2020, 24, 1.	0.2	85
2386	Diabetic retinopathy awareness and associations with multiple comorbidities: Insights from DIAMOND Study. Indian Journal of Endocrinology and Metabolism, 2018, 22, 30.	0.2	22
2387	Adverse effect profile and effectiveness of sodium glucose co-transporter 2 inhibitors (SGLT2i) - A prospective real-world setting study. Indian Journal of Endocrinology and Metabolism, 2019, 23, 50.	0.2	7
2388	Diabetic macular edema: Evidence-based management. Indian Journal of Ophthalmology, 2018, 66, 1736.	0.5	126
2389	Reason for refusal of insulin therapy among type 2 diabetes mellitus patients in primary care clinic in Bangalore. Journal of Family Medicine and Primary Care, 2020, 9, 854.	0.3	5
2390	The association of diabetes duration and glycemic control with depression in elderly men with type 2 diabetes mellitus. Journal of Research in Medical Sciences, 2019, 24, 17.	0.4	16
2391	Advanced glycation end products and risk of hypertension in Iranian adults: Tehran lipid and glucose study. Journal of Research in Medical Sciences, 2018, 23, 43.	0.4	7
2392	Impact of pharmacist intervention on appropriate insulin pen use in older patients with type 2 diabetes mellitus in a rural area in Iran. Journal of Research in Pharmacy Practice, 2017, 6, 114.	0.2	11
2393	S100A12 and the Airway Smooth Muscle: Beyond Inflammation and Constriction. Journal of Allergy & Therapy, 2012, 01, .	0.1	11
2394	The association between diabetes self-management and microvascular complications in patients with type 2 diabetes. Epidemiology and Health, 2016, 38, e2016004.	0.8	16
2395	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. World Journal of Diabetes, 2019, 10, 291-303.	1.3	14
2396	Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonists' role intreatment; from the past to future. World Journal of Diabetes, 2019, 10, 446-453.	1.3	17
2397	Comparison of awareness of diabetes mellitus type II with treatment's outcome in term of direct cost in a hospital in Saudi Arabia. World Journal of Diabetes, 2019, 10, 463-472.	1.3	8

#	ARTICLE	IF	CITATIONS
2398	Continuous glucose monitoring defined time-in-range is associated with sudomotor dysfunction in type 2 diabetes. <i>World Journal of Diabetes</i> , 2020, 11, 489-500.	1.3	13
2399	Cardiac autonomic neuropathy in patients with diabetes mellitus. <i>World Journal of Diabetes</i> , 2014, 5, 17.	1.3	239
2400	Pathogenesis of diabetic cerebral vascular disease complication. <i>World Journal of Diabetes</i> , 2015, 6, 54.	1.3	25
2401	Toxic stress, inflammation and symptomatology of chronic complications in diabetes. <i>World Journal of Diabetes</i> , 2015, 6, 554.	1.3	29
2402	Alphabet Strategy for diabetes care: A multi-professional, evidence-based, outcome-directed approach to management. <i>World Journal of Diabetes</i> , 2015, 6, 874.	1.3	11
2403	Predictors of hypoglycemia in insulin-treated patients with type 2 diabetes mellitus in Basrah. <i>World Journal of Diabetes</i> , 2016, 7, 470.	1.3	5
2404	Role of lipid-lowering agents in the management of diabetic retinopathy. <i>World Journal of Diabetes</i> , 2017, 8, 1.	1.3	15
2405	Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods. <i>World Journal of Diabetes</i> , 2017, 8, 381.	1.3	14
2406	Adherence to self-care practices, glycemic status and influencing factors in diabetes patients in a tertiary care hospital in Delhi. <i>World Journal of Diabetes</i> , 2018, 9, 72-79.	1.3	32
2407	Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus. <i>World Journal of Stem Cells</i> , 2016, 8, 223.	1.3	10
2408	Treatment Pattern and Factors Associated with Blood Pressure and Fasting Plasma Glucose Control among Patients with Type 2 Diabetes Mellitus in Police Referral Hospital in Ethiopia. <i>Ethiopian Journal of Health Sciences</i> , 2019, 28, 461-472.	0.2	14
2409	Role of ZAC1 in transient neonatal diabetes mellitus and glucose metabolism. <i>World Journal of Biological Chemistry</i> , 2015, 6, 95.	1.7	12
2410	Glycemic Control in Patients with Diabetes across Primary and Tertiary Government Health Sectors in the Emirate of Dubai, United Arab Emirates: A Five-Year Pattern. <i>Oman Medical Journal</i> , 2019, 34, 20-25.	0.3	9
2411	The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. <i>Rambam Maimonides Medical Journal</i> , 2015, 6, e0029.	0.4	3
2412	Methylglyoxal Induces Mitochondrial Dysfunction and Cell Death in Liver. <i>Toxicological Research</i> , 2014, 30, 193-198.	1.1	69
2413	Identifying Factors Associated with Functional Limitation Among Diabetic Patients in Northwest of Iran: Application of the Generalized Additive Model. <i>International Journal of Endocrinology and Metabolism</i> , 2018, 16, e12757.	0.3	6
2414	Prevalence of Lipohypertrophy and Associated Risk Factors in Insulin-Treated Patients With Type 2 Diabetes Mellitus. <i>International Journal of Endocrinology and Metabolism</i> , 2015, 13, e20776.	0.3	36
2415	Cardiovascular Disease Risk Factors Profile in Individuals With Diabetes Compared With Non-Diabetic Subjects in North-East of Iran. <i>Iranian Red Crescent Medical Journal</i> , 2016, 18, e29382.	0.5	7

#	ARTICLE	IF	CITATIONS
2416	A nonparametric methodological analysis of rest-activity rhythm in type 2 diabetes. <i>Sleep Science</i> , 2018, 11, 281-289.	0.4	15
2417	Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus. <i>Annals of Pediatric Endocrinology and Metabolism</i> , 2015, 20, 21.	0.8	8
2418	Intrarenal Oxidative Stress and Augmented Angiotensinogen are Precedent to Renal Injury in Zucker Diabetic Fatty Rats. <i>International Journal of Biological Sciences</i> , 2007, 3, 40-46.	2.6	47
2419	Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining. <i>ELife</i> , 2019, 8, .	2.8	12
2420	Metabolic bariatric surgery and type 2 diabetes mellitus: an endocrinologist's perspective. <i>Journal of Biomedical Research</i> , 2015, 29, 105-11.	0.7	18
2421	Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes. <i>Journal of Biomedical Research</i> , 2019, 33, 1.	0.7	40
2422	The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. <i>Journal of Obesity and Metabolic Syndrome</i> , 2019, 28, 158-166.	1.5	16
2423	Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease. <i>Journal of Obesity and Metabolic Syndrome</i> , 2020, 29, 215-221.	1.5	12
2424	Self-reported frequency, severity of, and awareness of hypoglycemia in type 2 diabetes patients in Turkey. <i>PeerJ</i> , 2016, 4, e2700.	0.9	11
2425	Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study. <i>PeerJ</i> , 2020, 8, e9905.	0.9	1
2426	Thiazolidinediones: A 2010 Perspective. , 2010, 14, 64-72.		40
2427	Implementation and Methodology of a Multidisciplinary Disease-State-Management Program for Comprehensive Diabetes Care. , 2011, 15, 43-8.		18
2428	Renal outcomes and prognostic factors in patients with type-2 diabetes and chronic kidney disease confirmed by renal biopsy. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110523.	1.1	2
2429	Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. <i>Theranostics</i> , 2021, 11, 9376-9396.	4.6	32
2430	Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort. <i>Value in Health</i> , 2022, 25, 435-442.	0.1	4
2431	Personalized diet study of dietary advanced glycation end products (AGEs) and fatty acid desaturase 2 (FADS2) genotypes in obesity. <i>Scientific Reports</i> , 2021, 11, 19725.	1.6	7
2432	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 281-288.	2.2	5
2433	Restriction of Dietary Advanced Glycation End Products Induces a Differential Plasma Metabolome and Lipidome Profile. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000499.	1.5	3

#	ARTICLE	IF	CITATIONS
2434	A novel method for causal structure discovery from EHR data and its application to type-2 diabetes mellitus. <i>Scientific Reports</i> , 2021, 11, 21025.	1.6	6
2435	Longitudinal patterns of urinary incontinence and associated predictors in women with type 1 diabetes. <i>Neurourology and Urodynamics</i> , 2021, , .	0.8	0
2436	The Impact of the Filipino Plate Method versus Standard Nutrition Education on Food Group Proportions and 2-hour Postprandial Blood Glucose for Type 2 Diabetes. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2021, 36, 142-148.	0.1	0
2437	Seeing what you want to see in randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2000, 321, 1078-1078.	2.4	1
2438	Coronary artery disease: Part 2. Treatment. <i>Western Journal of Medicine</i> , 2001, 174, 330-335.	0.3	1
2439	Clinical Evidence Review: Best Practices Diabetes Mellitus Update. , 2006, , .		0
2440	Treating type 2 diabetes. <i>BMJ: British Medical Journal</i> , 1999, 318, 666-666.	2.4	0
2441	Monitoring of International Diabetes Federation-recommended Clinical Diabetes Indicators in a Public Health Centre in Southwest Trinidad. <i>West Indian Medical Journal</i> , 2014, 63, 566-70.	0.4	2
2442	Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression. <i>PLoS ONE</i> , 2014, 9, e113948.	1.1	1
2443	Efficacy, Safety and Treatment Satisfaction of Glimpiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, FC07-10.	0.8	2
2444	Development of the OnTrack Diabetes Program. <i>JMIR Research Protocols</i> , 2015, 4, e24.	0.5	6
2445	Clinical outcomes of a diabetes education program for patients with diabetes mellitus in the Micronesian community in Hawaii. <i>Journal of Research in Pharmacy Practice</i> , 2016, 5, 205.	0.2	5
2446	Diabetic retinopathy care in India: An endocrinology perspective. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 1.	0.2	5
2447	Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy. <i>European Endocrinology</i> , 2016, 12, 31.	0.8	0
2448	Association between estimated blood glucose levels and glycated hemoglobin levels. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 457-460.	0.7	0
2450	Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure. <i>Indian Journal of Endocrinology and Metabolism</i> , 2017, 21, 618.	0.2	2
2451	Evaluation of anti-diabetic activity of AHPL/AYTAB/0513 tablet in streptozotocin induced diabetes in rats. <i>International Journal of Pharmaceutical Investigation</i> , 2017, 7, 25.	0.2	0
2452	Protective Effect of Insulin Treatment on Early Renal Changes in Streptozotocin-Induced Diabetic Rats. <i>Acta Endocrinologica</i> , 2018, 14, 169-174.	0.1	3

#	ARTICLE	IF	CITATIONS
2453	The new basal insulin analog glargine U-300 enables flexible injection schedule. <i>Annals of Translational Medicine</i> , 2018, 6, S1-S1.	0.7	0
2454	Development and Validation of a Diabetic Retinopathy Screening Modality Using a Hand-Held Nonmydriatic Digital Retinal Camera by Physician Graders at a Tertiary-Level Medical Clinic: Protocol for a Validation Study. <i>JMIR Research Protocols</i> , 2018, 7, e10900.	0.5	10
2455	Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 15-20.	0.6	0
2456	Relationships Between Skin Autofluorescence and Cardio-Ankle Vascular Index in Japanese Male Patients With Metabolic Syndrome. <i>Cardiology Research</i> , 2019, 10, 172-180.	0.5	3
2457	Clinical Significance of Low Blood Testosterone Concentration in Men as a Cardiovascular Risk Factor From the Perspective of Blood Rheology. <i>Cardiology Research</i> , 2019, 10, 106-113.	0.5	3
2458	Approach to the treatment of diabetes in the elderly. <i>Sisli Etfal Hastanesi Tip Bulteni</i> , 2019, 53, 96-102.	0.1	3
2459	Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (<i>Diabetes Metab J</i> 2019;43;276-86). <i>Diabetes and Metabolism Journal</i> , 2019, 43, 545.	1.8	1
2460	Clinical Impact of Blood Testosterone Concentration on Cardio-Ankle Vascular Index in Female Patients With Type 2 Diabetes Mellitus. <i>Cardiology Research</i> , 2019, 10, 9-17.	0.5	2
2461	Management and control of type 2 diabetes mellitus in Lebanon: Results from the International Diabetes Management Practices Study Wave 6. <i>World Journal of Diabetes</i> , 2019, 10, 249-259.	1.3	8
2462	Effectiveness and Safety of Hydroxychloroquine compared to Tenueligliptin in uncontrolled T2DM patients as add-on therapy. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2019, 34, 87-91.	0.1	4
2463	Insulin-associated Weight Gain in Type 2 Diabetes and Its Relation with Caloric Intake. <i>Cureus</i> , 2019, 11, e5275.	0.2	0
2464	Using Relational Agents to Promote Family Communication Around Type 1 Diabetes Self-Management in the Diabetes Family Teamwork Online Intervention: Longitudinal Pilot Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e15318.	2.1	17
2465	Association of Diabetes-related Emotional Distress with Diabetes Self-care and Glycemic Control among Adult Patients with Type 2 Diabetes at a Tertiary Hospital in Manila, Philippines. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2019, 34, 189-196.	0.1	5
2466	Superimposition of hypertension on diabetic peripheral neuropathy affects small unmyelinated sensory nerves in the skin and myelinated tibial and sural nerves in rats with alloxan-induced type 1 diabetes. <i>Journal of Toxicologic Pathology</i> , 2020, 33, 161-169.	0.3	1
2468	Risk Factors for Diabetic Peripheral Neuropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. <i>Diabetes Care</i> , 2022, 45, 1065-1072.	4.3	12
2469	Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. <i>Journal of the American Heart Association</i> , 2021, 10, e021230.	1.6	2
2470	Characteristics of Myocardial Perfusion in Type 2 Diabetes Mellitus and Its Association with Left Ventricular Diastolic Dysfunction: A Study of Myocardial Contrast Echocardiography. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7533-7543.	0.8	3
2471	Perceived knowledge on type-2 diabetes of informal caregivers in rural communities of Thai Binh, Vietnam: Implications for health education. <i>Public Health in Practice</i> , 2021, 2, 100210.	0.7	1

#	ARTICLE	IF	CITATIONS
2473	Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 785-801.	1.8	0
2474	Skin Autofluorescence as a Predictor of First Heart Failure Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction. <i>Cardiology Research</i> , 2020, 11, 247-255.	0.5	2
2475	REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy. <i>Journal of Lipid and Atherosclerosis</i> , 2020, 9, 406.	1.1	4
2476	GLP-1 receptor agonist on cardiovascular complications of diabetes mellitus. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 2259-2265.	0.8	2
2477	Pharmacist interventions in improving clinical outcomes in patients with type 2 diabetes mellitus among the underrepresented population: A collaborative ambulatory care pharmacy practice (CAPP) approach. <i>Journal of Research in Pharmacy Practice</i> , 2020, 9, 3.	0.2	4
2478	Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 423-430.	0.6	0
2479	Relationship between self care management with glycemic control in type 2 diabetic patients. <i>International Journal of Preventive Medicine</i> , 2020, 11, 127.	0.2	14
2480	Validation to Brazilian Portuguese of the Self-Care Inventory-revised for adults with type 2 diabetes. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 190-194.	0.3	6
2481	Chronic kidney disease in adults: assessment and management. <i>Clinical Medicine</i> , 2020, 20, 128-132.	0.8	19
2482	Genetic Variation in SOD1 Gene Promoter Ins/Del and Its Influence on Oxidative Stress in Beta Thalassemia Major Patients. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	0
2483	Influence of glycaemic control on macular thickness in diabetic retinopathy. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, , e00308.	1.0	3
2484	Random plasma glucose levels and cause-specific mortality among Chinese adults without known diabetes: an 11-year prospective study of 450,000 people. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002495.	1.2	3
2485	&lt;p&gt;Impact of Diabetes Continuing Education on Primary Healthcare Physiciansâ€™ Knowledge, Attitudes, and Practices&lt;/p&gt;. <i>Advances in Medical Education and Practice</i> , 2020, Volume 11, 781-790.	0.7	1
2486	Glycated Haemoglobin and Outcomes of Percutaneous Coronary Intervention Among Type Two Diabetic Patients in Saudi Arabia. <i>Cureus</i> , 2020, 12, e11278.	0.2	0
2487	Impact of systemic parameters before commencing anti-vascular endothelial growth factor therapy for diabetic macular edema â€“ Pan-Indian survey of retina specialists. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3273.	0.5	0
2488	Severity of diabetic retinopathy and its relationship with age at onset of diabetes mellitus in India: A multicentric study. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3255.	0.5	9
2489	Association between the Plasma-Glycosylated Hemoglobin A1c/High-Density Lipoprotein Cholesterol Ratio and Carotid Atherosclerosis: A Retrospective Study. <i>Journal of Diabetes Research</i> , 2021, 2021, 1-10.	1.0	6
2490	Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis. <i>Advances in Therapy</i> , 2021, , 1.	1.3	2



#	ARTICLE	IF	CITATIONS
2491	Role of the adaptive immune system in diabetic kidney disease. <i>Journal of Diabetes Investigation</i> , 2022, 13, 213-226.	1.1	21
2492	Interpreting global trends in type 2 diabetes complications and mortality. <i>Diabetologia</i> , 2022, 65, 3-13.	2.9	112
2493	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 75, 1420-1428.	3.6	65
2494	Diabetic Retinopathy and Insulin Insufficiency: Beta Cell Replacement as a Strategy to Prevent Blindness. <i>Frontiers in Endocrinology</i> , 2021, 12, 734360.	1.5	0
2495	The association between carbohydrate quality index and anthropometry, blood glucose, lipid profile and blood pressure in people with type 1 diabetes mellitus: a cross-sectional study in Iran. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1349-1358.	0.8	6
2496	Pharmacist Interventions for Medication Adherence: Community Guide Economic Reviews for Cardiovascular Disease. <i>American Journal of Preventive Medicine</i> , 2022, 62, e202-e222.	1.6	6
2497	The role of inflammation and neurodegeneration in diabetic macular edema. <i>Therapeutic Advances in Ophthalmology</i> , 2021, 13, 251584142110559.	0.8	12
2498	Prevalence of diabetic retinopathy in self-reported diabetics among various ethnic groups and associated risk factors in North-East India: A hospital-based study. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3132.	0.5	5
2499	Profile of sight-threatening diabetic retinopathy and its awareness among patients with diabetes mellitus attending a tertiary care center in Kashmir, India. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 3123.	0.5	10
2500	Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 337-346.	0.6	3
2501	An Innovative, Paradigm-Shifting Lifestyle Intervention to Reduce Glucose Excursions With the Use of Continuous Glucose Monitoring to Educate, Motivate, and Activate Adults With Newly Diagnosed Type 2 Diabetes: Pilot Feasibility Study. <i>JMIR Diabetes</i> , 2022, 7, e34465.	0.9	5
2502	Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1997-2012.	0.8	4
2503	Impact of patients' beliefs about insulin on acceptance and adherence to insulin therapy: a qualitative study in primary care. , 2022, 23, 15.		7
2504	Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192110637.	1.0	6
2505	Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression. <i>Glycoconjugate Journal</i> , 2021, 38, 717-734.	1.4	27
2506	Effect of Arterial Stiffness and Carotid Intima-Media Thickness Progression on the Risk of Dysglycemia, Insulin Resistance, and Dyslipidemia: a Temporal Causal Longitudinal Study. <i>Hypertension</i> , 2022, 79, 667-678.	1.3	34
2507	Diabetes Distal Peripheral Neuropathy: Subtypes and Diagnostic and Screening Technologies. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682110353.	1.3	4
2508	Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300ÂU/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study. <i>Diabetes Therapy</i> , 2022, , .	1.2	0

#	ARTICLE	IF	CITATIONS
2509	Exercise is medicine for type 2 diabetes: An interview with Dr. Sheri R. Colberg. <i>Journal of Sport and Health Science</i> , 2022, 11, 179-183.	3.3	3
2510	Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 2022, 24, 109-117.	2.0	4
2511	Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 684-691.	4.3	31
2512	Longitudinal effects of oneâ€leg standing time on neuropathy outcomes in association with glycemic control in nonâ€elderly patients with typeâ€2 diabetes. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1039-1051.	1.1	4
2513	Trends in Glycemic Control Among Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study. <i>Diabetes Care</i> , 2022, 45, 285-294.	4.3	24
2514	Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 578-591.	1.8	3
2515	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	4.3	20
2516	Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. <i>Medicine and Science in Sports and Exercise</i> , 2022, 54, 353-368.	0.2	209
2517	The Benefits of Utilizing Continuous Glucose Monitoring of Diabetes Mellitus in Primary Care: A Systematic Review. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 762-774.	1.3	7
2518	Does AGEâ€RAGE Stress Play a Role in the Development of Coronary Artery Disease in Obesity?. <i>International Journal of Angiology</i> , 2022, 31, 1-9.	0.2	1
2519	Decreased Levels of miR-126 and miR-132 in Plasma and Vitreous Humor of Non-Proliferative Diabetic Retinopathy Among Subjects with Type-2 Diabetes Mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 345-358.	1.1	5
2520	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. <i>Heart Failure Reviews</i> , 2022, , .	1.7	0
2521	Heparan sulfate-dependent RAGE oligomerization is indispensable for pathophysiological functions of RAGE. <i>ELife</i> , 2022, 11, .	2.8	4
2522	Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study. <i>Diabetes Therapy</i> , 2022, 13, 693-708.	1.2	5
2523	Exploring HbA1c variation between Australian diabetes centres: The impact of centre-level and patient-level factors. <i>PLoS ONE</i> , 2022, 17, e0263511.	1.1	2
2524	KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. <i>American Journal of Kidney Diseases</i> , 2022, 79, 457-479.	2.1	18
2525	Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies. <i>Diabetologia</i> , 2022, 65, 587-603.	2.9	15
2526	A 4-week high-AGE diet does not impair glucose metabolism and vascular function in obese individuals. <i>JCI Insight</i> , 2022, 7, .	2.3	14

#	ARTICLE	IF	CITATIONS
2527	Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes. <i>Diabetes Therapy</i> , 2022, 13, 679-690.	1.2	5
2528	A validated analysis pipeline for mass spectrometry-based vitreous proteomics: new insights into proliferative diabetic retinopathy. <i>Clinical Proteomics</i> , 2021, 18, 28.	1.1	4
2529	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S46-S59.	4.3	99
2530	Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. <i>Biomolecules</i> , 2021, 11, 1834.	1.8	47
2531	Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882210816.	1.4	10
2532	Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2404.	1.8	13
2533	The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 32.	1.2	4
2534	Low-grade proteinuria and atherosclerotic cardiovascular disease: A transition study of patients with diabetic kidney disease. <i>PLoS ONE</i> , 2022, 17, e0264568.	1.1	1
2535	Healthy food prescription incentive programme for adults with type 2 diabetes who are experiencing food insecurity: protocol for a randomised controlled trial, modelling and implementation studies. <i>BMJ Open</i> , 2022, 12, e050006.	0.8	5
2536	Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?. <i>Frontiers in Neuroscience</i> , 2022, 16, 824054.	1.4	7
2537	Joint associations of fresh fruit intake and physical activity with glycaemic control among adult patients with diabetes: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e056776.	0.8	0
2538	Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study. <i>PLoS ONE</i> , 2022, 17, e0262831.	1.1	4
2539	Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. <i>BMC Health Services Research</i> , 2022, 22, 217.	0.9	3
2540	SGLT2 inhibitors therapy protects glucotoxicity-induced $\beta$ -cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress. <i>PLoS ONE</i> , 2022, 17, e0258054.	1.1	13
2541	Pediatric Diabetes on the Rise: Trends in Incident Diabetes During the COVID-19 Pandemic. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac024.	0.1	20
2542	Nutrient Regulation of Pancreatic Islet $\beta$ -Cell Secretory Capacity and Insulin Production. <i>Biomolecules</i> , 2022, 12, 335.	1.8	16
2543	Pediatric growth patterns in youth-onset type 2 diabetes mellitus: Implications for physiologically-based pharmacokinetic models. <i>Clinical and Translational Science</i> , 2022, 15, 912-922.	1.5	3
2544	Development and Validation of the Diabetes Pen Experience Measure (DPEM): A New Patient-Reported Outcome Measure. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210793.	1.3	0

#	ARTICLE	IF	CITATIONS
2545	Carpal Tunnel Syndrome and Diabetes—A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1674.	1.0	17
2546	Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , 2022, 12, 424.	1.1	10
2547	Derivation and Validation of a Prediction Model of End-Stage Renal Disease in Patients With Type 2 Diabetes Based on a Systematic Review and Meta-analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 825950.	1.5	8
2548	The Association Between Glycaemic Control, Renal Function and Post-operative Ophthalmic Complications in People With Diabetes Undergoing Cataract Surgery—A Single-Centre Retrospective Analysis. <i>Diabetes Therapy</i> , 2022, 13, 723-732.	1.2	0
2549	Adjuvant Probiotics of <i>Lactobacillus salivarius</i> subsp. <i>salicinius</i> AP-32, <i>L. johnsonii</i> MH-68, and <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2022, 13, 754401.	1.5	28
2550	Stability of extemporaneously prepared sitagliptin phosphate solution. <i>PLoS ONE</i> , 2022, 17, e0262068.	1.1	0
2551	Reversibility of brain glucose kinetics in type 2 diabetes mellitus. <i>Diabetologia</i> , 2022, 65, 895-905.	2.9	3
2552	Individual goal-based plan based on nursing theory for adults with type 2 diabetes and self-care deficits: a study protocol of a randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e053955.	0.8	0
2553	Food-Related Carbonyl Stress in Cardiometabolic and Cancer Risk Linked to Unhealthy Modern Diet. <i>Nutrients</i> , 2022, 14, 1061.	1.7	13
2554	Diabetic retinopathy for the non-ophthalmologist. <i>Clinical Medicine</i> , 2022, 22, 112-116.	0.8	24
2555	Development and validation of a risk prediction model for chronic kidney disease among individuals with type 2 diabetes. <i>Scientific Reports</i> , 2022, 12, 4794.	1.6	9
2556	The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3439.	1.8	28
2557	The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. <i>Advances in Therapy</i> , 2022, 39, 2208-2221.	1.3	13
2558	Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. <i>Diabetes Therapy</i> , 2022, 13, 651-677.	1.2	0
2559	Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis. <i>Diagnostics</i> , 2022, 12, 814.	1.3	1
2560	The Association Between Leucine and Diabetic Retinopathy in Different Genders: A Cross-Sectional Study in Chinese Patients With Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 806807.	1.5	1
2561	Genetic Reduction of Glucose Metabolism Preserves Functional $\beta$ -Cell Mass in KATP-Induced Neonatal Diabetes. <i>Diabetes</i> , 2022, 71, 1233-1245.	0.3	6
2562	Cost-effectiveness of Artificial Intelligence as a Decision-Support System Applied to the Detection and Grading of Melanoma, Dental Caries, and Diabetic Retinopathy. <i>JAMA Network Open</i> , 2022, 5, e220269.	2.8	36

#	ARTICLE	IF	CITATIONS
2563	Self-awareness of HbA1c and its association with glycemic control among patients with type 2 diabetes. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 291-300.	0.5	2
2564	Seasonal variations and the influence of COVID-19 pandemic on hemoglobin A1c, glycoalbumin, and low-density lipoprotein cholesterol. <i>Diabetology International</i> , 2022, 13, 599-605.	0.7	6
2565	D-dimer as a predictor of cardiovascular outcomes in patients with diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 82.	0.7	5
2566	Screening for identification of patients at high risk for diabetes-related foot ulcers: a cross-sectional study. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210878.	0.4	7
2567	Development of an information system and mobile application for the care of type 2 diabetes patients at the primary care level for the health sector in Mexico: study protocol for a randomized controlled, open-label trial. <i>Trials</i> , 2022, 23, 253.	0.7	0
2568	Effect of metformin on microvascular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109821.	1.1	5
2569	Effect of Hemoglobin A1c Trajectories on Future Outcomes in a 10-Year Cohort With Type 2 Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2022, 13, 846823.	1.5	0
2570	Impact of haemoglobin variants on the use of haemoglobin A1c for the diagnosis and monitoring of diabetes: a contextualised review. <i>Irish Journal of Medical Science</i> , 2022, , 1.	0.8	3
2571	The Emerging Role of Continuous Glucose Monitoring in the Management of Diabetic Peripheral Neuropathy: A Narrative Review. <i>Diabetes Therapy</i> , 2022, 13, 931-952.	1.2	4
2572	Reversibility of pancreatic $\beta$ -cells dysfunction after vitamin D and calcium supplementation: a pilot study in a population of obese and prepubescent North-African children. <i>Libyan Journal of Medicine</i> , 2022, 17, 2059896.	0.8	2
2573	Assessment of Anti-VEGFs in Treating Diabetic Macular Edema in Alfaisal Eye Center, Khartoum, Sudan, 2019. <i>Clinical Pharmacology: Advances and Applications</i> , 2022, Volume 14, 37-47.	0.8	0
2574	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
2575	A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8%mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9%mg. <i>Journal of Diabetes Investigation</i> , 2022, , .	1.1	1
2576	Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. <i>Biomolecules</i> , 2022, 12, 542.	1.8	138
2577	The efficacy of <i>Origanum majorana</i> nanocubosomal systems in ameliorating submandibular salivary gland alterations in streptozotocin-induced diabetic rats. <i>Drug Delivery</i> , 2022, 29, 62-74.	2.5	11
2578	Mitochondrial dynamics and diabetic kidney disease: Missing pieces for the puzzle of therapeutic approaches. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 249-273.	1.6	9
2579	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study. <i>Cardiovascular Diabetology</i> , 2021, 20, 241.	2.7	17
2580	Prevalence of and Factors Associated with Diabetic Retinopathy in Patients with Diabetes Mellitus at Siriraj Hospital – Thailand's Largest National Tertiary Referral Center. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4945-4957.	1.1	2

#	ARTICLE	IF	CITATIONS
2581	Prediabetes Burden in Nigeria: A Systematic Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 2021, 9, 762429.	1.3	5
2582	Patient-reported outcome measures for knowledge transfer and behaviour modification interventions in type 2 diabetes—the INDICA study: a multiarm cluster randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e050804.	0.8	9
2584	Urinary NGAL is a Potential Biomarker for Early Renal Injury in Insulin Resistant Obese Non-diabetic Children. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2021, 13, 400-407.	0.4	7
2587	The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer's disease. <i>Neural Regeneration Research</i> , 2022, 17, 2355.	1.6	26
2588	Health care effects and medical benefits of a smartphone-based diabetes self-management application: study protocol for a randomized controlled trial. <i>Trials</i> , 2022, 23, 282.	0.7	3
2589	Treatment of periodontitis for glycaemic control in people with diabetes mellitus. <i>The Cochrane Library</i> , 2022, 2022, CD004714.	1.5	29
2590	Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. <i>Cells</i> , 2022, 11, 1312.	1.8	145
2591	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	0.8	5
2593	Comparative study of the usefulness of a novel insulin therapy in Japanese patients with Type 2 diabetes for concomitant use of an oral antidiabetic agent with twice-daily dosing either of insulin aspart, biphasic insulin aspart-30, or insulin detemir: Two times Insulin injection Combined with oral therapy Efficacy Study (TWICE study)..., 2021, 7, 1-7.		0
2598	Association between family behaviors and self-care activities among type-II diabetes mellitus patients at a teaching hospital in Kathmandu, Nepal. <i>Journal of Education and Health Promotion</i> , 2022, 11, 25.	0.3	1
2599	Evaluation of therapeutic effectiveness of prescribed medications in patients with type 2 diabetes mellitus: Findings from a tertiary care hospital, Lahore, Pakistan. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2017, 9, 121.	0.2	5
2601	The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review. <i>Clinical Medicine</i> , 2022, 22, 257-265.	0.8	1
2602	Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2022, 13, 871660.	1.5	1
2603	Deterioration of glycemic control in youth-onset type 2 diabetes: what are the early and late predictors?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	8
2604	Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 876795.	1.1	1
2605	Sarco/Endoplasmic Reticulum Ca <sup>2+</sup> ATPase 2 Activator Ameliorates Endothelial Dysfunction; Insulin Resistance in Diabetic Mice. <i>Cells</i> , 2022, 11, 1488.	1.8	4
2606	Dietary Advanced Glycation End Products in an Elderly Population with Diabetic Nephropathy: An Exploratory Investigation. <i>Nutrients</i> , 2022, 14, 1818.	1.7	6
2607	Diabetic Retinopathy Is a Predictor of Progression of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. <i>International Journal of Nephrology</i> , 2022, 2022, 1-11.	0.7	8

#	ARTICLE	IF	CITATIONS
2608	Single Nucleotide Polymorphism in the ADIPOQ Gene Modifies Adiponectin Levels and Glycemic Control in Type Two Diabetes Mellitus Patients. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	3
2609	Tight Blood Pressure Control in Chronic Kidney Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 139.	0.8	3
2610	European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. <i>European Stroke Journal</i> , 2022, 7, I-XLI.	2.7	51
2611	Effect of legumes in energy reduced dietary approaches to stop hypertension (DASH) diet on blood pressure among overweight and obese type 2 diabetic patients: a randomized controlled trial. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 72.	1.2	4
2612	Impact of insulin therapy on outcomes of diabetic patients with heart failure: A systematic review and meta-analysis. <i>Diabetes and Vascular Disease Research</i> , 2022, 19, 147916412210931.	0.9	6
2613	Type 2 diabetes in youth: Rationale for use of off-label antidiabetic agents. <i>Pediatric Diabetes</i> , 2022, 23, 615-619.	1.2	2
2614	Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic Î²-Cell Mass and Function. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5104.	1.8	3
2615	Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. <i>Nature Reviews Endocrinology</i> , 2022, 18, 413-432.	4.3	62
2616	The current status of low-density lipoprotein cholesterol for primary prevention of coronary artery disease in late-stage elderly persons with type 2 diabetes mellitus: A retrospective, single-center study. <i>Journal of Diabetes Investigation</i> , 2022, , .	1.1	2
2617	The role of AGEs in pathogenesis of cartilage destruction in osteoarthritis. <i>Bone and Joint Research</i> , 2022, 11, 292-300.	1.3	5
2618	Effect of Diabetes Mellitus on Daily Functioning and Cognition of Alzheimer's Disease Patients Evaluated by DASC-21. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 0, , 76-81.	0.6	0
2619	Single-cell transcriptomic analysis revealing changes in retinal cell subpopulation levels and the pathways involved in diabetic retinopathy. <i>Annals of Translational Medicine</i> , 2022, 10, 562-562.	0.7	4
2620	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. <i>Cardiovascular Diabetology</i> , 2022, 21, 74.	2.7	82
2621	Blood Glucose Meter Buying Behavior of Diabetic Patients: Factors Influencing Purchase. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	0
2622	Long-term prediction models for vision-threatening diabetic retinopathy using medical features from data warehouse. <i>Scientific Reports</i> , 2022, 12, 8476.	1.6	4
2623	Changing the diabetes treatment paradigm from glucose control to cardiorenal protection. <i>Indian Journal of Medical Research</i> , 2021, 154, 655.	0.4	1
2624	Association of continuous glucose monitoring-derived time in range with major amputation risk in diabetic foot osteomyelitis patients undergoing amputation. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882210993.	1.4	3
2625	Hypertension in Patients with Insulin Resistance: Etiopathogenesis and Management in Children. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5814.	1.8	13

#	ARTICLE	IF	CITATIONS
2626	Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. <i>Circulation</i> , 2022, 145, 1632-1641.	1.6	60
2627	Analytical performances of a glycosylated albumin assay that is traceable to standard reference materials and reference range determination. <i>Journal of Clinical Laboratory Analysis</i> , 0, , .	0.9	3
2628	Perspectives on the provision of diabetic retinopathy screening: Survey of eye health care professionals in Haryana. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 2057.	0.5	0
2629	Biochemical mechanism underlying the pathogenesis of diabetic retinopathy and other diabetic complications in humans: the methanol-formaldehyde-formic acid hypothesis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 415-451.	0.9	0
2630	Evolution of the diagnostic value of "the sugar of the blood" hitting the sweet spot to identify alterations in glucose dynamics. <i>Physiological Reviews</i> , 2023, 103, 7-30.	13.1	2
2631	Therapeutic Potential of Phlorotannin-Rich <i>Ecklonia cava</i> Extract on Methylglyoxal-Induced Diabetic Nephropathy in In Vitro Model. <i>Marine Drugs</i> , 2022, 20, 355.	2.2	6
2632	Efficacy and safety of a basal insulin + 2 oral antihyperglycaemic drugs regimen versus a twice daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: the multicentre, open-label, randomised controlled BEYOND trial. <i>Diabetes, Obesity and Metabolism</i> , 0, , .	2.2	2
2633	Guidelines on models of diabetic heart disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 323, H176-H200.	1.5	20
2634	Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	4
2635	One-Year Mean A1c of >7% is Associated with Poor Bone Microarchitecture and Strength in Men with Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2022, 111, 267-278.	1.5	7
2636	Trends and effect of marginalization on diabetes mellitus-related mortality in Mexico from 1990 to 2019. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
2637	Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus. <i>Heliyon</i> , 2022, 8, e09571.	1.4	4
2638	Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1703-1710.	1.1	6
2639	Diabetes: how to manage chronic kidney disease. <i>Drugs in Context</i> , 0, 11, 1-10.	1.0	0
2640	Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema. <i>Cells</i> , 2022, 11, 1950.	1.8	19
2641	Association Between Increased Lipid Profiles and Risk of Diabetic Retinopathy in a Population-Based Case-Control Study. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3433-3446.	1.6	5
2642	Status and Trends of the Association Between Diabetic Nephropathy and Diabetic Retinopathy From 2000 to 2021: Bibliometric and Visual Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
2643	Once-Weekly Exenatide in Youth With Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, 1833-1840.	4.3	28



#	ARTICLE	IF	CITATIONS
2644	Clinical course of adolescents with type 2 diabetes mellitus: A nationwide cohort study in Taiwan. <i>Journal of Diabetes Investigation</i> , 0, , .	1.1	0
2645	Experiment-Based Interventions to Diabetic Retinopathy: Present and Advances. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7005.	1.8	4
2646	Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
2647	Exercise-Induced Browning of White Adipose Tissue and Improving Skeletal Muscle Insulin Sensitivity in Obese/Non-obese Growing Mice: Do Not Neglect Exosomal miR-27a. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	6
2648	Identifying Distinct Risk Thresholds of Glycated Hemoglobin and Systolic Blood Pressure for Rapid Albuminuria Progression in Type 2 Diabetes From NHANES (1999â€“2018). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
2649	The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. <i>Contemporary Clinical Trials Communications</i> , 2022, 28, 100944.	0.5	12
2650	Activation of AMPK/miR-181b Axis Alleviates Endothelial Dysfunction and Vascular Inflammation in Diabetic Mice. <i>Antioxidants</i> , 2022, 11, 1137.	2.2	11
2651	Cardiometabolic Comorbidities in Cancer Survivors. <i>JACC: CardioOncology</i> , 2022, 4, 149-165.	1.7	13
2652	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1472-1488.	1.1	2
2653	Correlation between Diabetic Retinopathy and Diabetic Peripheral Neuropathy in Patients with Type II Diabetes Mellitus. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2022, 14, 658.	0.2	2
2654	Relationships Between Arterial Pressure-Volume Index and Cardiovascular Disease Biomarkers in Patients With Hypertension. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 229-236.	0.6	0
2655	Sex-Specific Associations of Diabetes With Brain Structure and Function in a Geriatric Population. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	7
2656	Assessment of quality of care provided to adults with type 2 diabetes mellitus at public hospitals in Gamo Gofa zone, Southern Ethiopia: Facility based Cross-sectional study. <i>Endocrinology, Diabetes and Metabolism</i> , 0, , .	1.0	1
2657	New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	0
2658	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. <i>Endocrinology and Metabolism</i> , 2022, 37, 415-429.	1.3	3
2659	The 2021â€“2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	3
2660	Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?. <i>Nutrients</i> , 2022, 14, 2675.	1.7	25
2661	Impact of Dietitian-Led Nutrition Therapy of Food Order on 5-Year Glycemic Control in Outpatients with Type 2 Diabetes at Primary Care Clinic: Retrospective Cohort Study. <i>Nutrients</i> , 2022, 14, 2865.	1.7	3

#	ARTICLE	IF	CITATIONS
2662	Risk trajectories of complications in over one thousand newly diagnosed individuals with type 2 diabetes. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
2663	Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8677.	1.2	29
2664	GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7373.	1.8	4
2665	Potential mechanisms underlying the association between type II diabetes mellitus and cognitive dysfunction in rats: a link between miRNA-21 and Resveratrol's neuroprotective action. <i>Metabolic Brain Disease</i> , 2022, 37, 2375-2388.	1.4	5
2666	The Role of Beta Cell Recovery in Type 2 Diabetes Remission. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7435.	1.8	17
2667	Association of hemoglobin A1c time in range with risk for diabetes complications. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002738.	1.2	3
2668	Evaluation of continuous glucose monitoring-derived person-specific <sc>HbA1c</sc> in the presence and absence of complications in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2383-2390.	2.2	3
2669	A simplified prediction model for end-stage kidney disease in patients with diabetes. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2670	Personalized glycemic response led digital therapeutics program improves time in range in a period of 14 days. <i>International Journal of Diabetes in Developing Countries</i> , 0, , .	0.3	4
2671	Pathogenesis of Distal Symmetrical Polyneuropathy in Diabetes. <i>Life</i> , 2022, 12, 1074.	1.1	10
2672	Precariousness, Diabetes Control and Complications in French Guiana. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
2673	Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002806.	1.2	13
2674	HbA1c and FIB-4 as serologic markers for the risk of progression of stage A heart failure. <i>Global Cardiology Science &amp; Practice</i> , 2021, 2021, .	0.3	0
2675	Atherosclerosis risk factor management - what's new for the neurologist?. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 88-93.	0.3	0
2676	New Insights into Treating Early and Advanced Stage Diabetic Retinopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8513.	1.8	11
2677	The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy. <i>Journal of Personalized Medicine</i> , 2022, 12, 1253.	1.1	0
2678	Impact of the Fasting Plasma Glucose Titration Target on the Success of Basal Insulin Titration in Insulin-Naïve Patients with Type 2 Diabetes: A Systematic Analysis. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	1.0	0
2679	Bias or biology? Importance of model interpretation in machine learning studies from electronic health records. <i>JAMIA Open</i> , 2022, 5, .	1.0	4

#	ARTICLE	IF	CITATIONS
2680	The Importance of Continuous Glucose Monitoring-derived Metrics Beyond HbA1c for Optimal Individualized Glycemic Control. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3990-e4003.	1.8	3
2681	Quality of care and prescription patterns among patients with diabetic kidney disease—a large-scale cohort study from Taiwanese clinics. <i>PeerJ</i> , 0, 10, e13636.	0.9	2
2682	Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. <i>Nutrients</i> , 2022, 14, 3086.	1.7	28
2683	The association between advanced glycation end products (AGEs) and ABC (hemoglobin A1C, blood) Tj ETQq1 1 0.784314 rgBT /Over diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	7
2684	Control and complications of diabetes in urban primary care units in Thailand: a cross-sectional study. , 2022, 23, .		0
2685	Prevention and Management Strategies for Diabetic Neuropathy. <i>Life</i> , 2022, 12, 1185.	1.1	15
2686	Prevalence of and risk factors for diabetic retinopathy in residents with different types of abnormal glucose metabolism with or without hypertension: A suburban community-based cross-sectional study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
2687	Developing services to support the delivery of care to people with <sc>early-onset</sc> type 2 diabetes. <i>Diabetic Medicine</i> , 2022, 39, .	1.2	7
2688	The Remarkable Roles of the Receptor for Advanced Glycation End Products (RAGE) and Its Soluble Isoforms in COVID-19: The Importance of RAGE Pathway in the Lung Injuries. <i>Indian Journal of Clinical Biochemistry</i> , 2023, 38, 159-171.	0.9	4
2689	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
2690	Association of Hypoglycemia with Biomarkers of Oxidative Stress and Antioxidants: An Observational Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 1509.	1.0	0
2691	Trends in all-cause mortality and major causes of death between 2007 and 2018 among patients with diabetes in Taiwan. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
2692	The effects of metformin in the treatment of osteoarthritis: Current perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
2693	Characteristics and care of young people with type 2 diabetes included in the national diabetes audit datasets for England. <i>Diabetic Medicine</i> , 2023, 40, .	1.2	5
2694	Impact of Periodontitis on Glycemic Control and Metabolic Status in Diabetes Patients: Current Knowledge on Early Disease Markers and Therapeutic Perspectives. <i>Mediators of Inflammation</i> , 2022, 2022, 1-7.	1.4	8
2695	Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2297-2308.	2.2	14
2696	Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8777.	1.8	6
2697	Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-8.	1.0	0

#	ARTICLE	IF	CITATIONS
2698	Modulation of 1,2-Dicarbonyl Compounds in Postprandial Responses Mediated by Food Bioactive Components and Mediterranean Diet. <i>Antioxidants</i> , 2022, 11, 1513.	2.2	3
2699	Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. <i>Lancet Neurology</i> , The, 2022, 21, 922-936.	4.9	54
2700	Effect of high-sensitivity C-reactive protein on the relationship between haemoglobin A1c and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cohort study. <i>Cardiovascular Diagnosis and Therapy</i> , 2022, 12, 614-625.	0.7	1
2701	Long-Term Changes in HbA1c According to Blood Glucose Control Status During the First 3 Months After Visiting a Tertiary University Hospital. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	4
2702	The Degree of Glycemic Control for the First Three Months Determines the Next Seven Years. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	1
2703	Blood pressure is associated with diabetic retinopathy in type 1 but not in type 2 diabetes. <i>Acta Clinica Croatica</i> , Supplement, 2022, , .	0.1	1
2704	Point-of-care HbA1c Measurements in Oral Cancer and Control Patients in Hungary. <i>In Vivo</i> , 2022, 36, 2248-2254.	0.6	2
2705	Analytical Challenges in Diabetes Management: Towards Glycated Albumin Point-of-Care Detection. <i>Biosensors</i> , 2022, 12, 687.	2.3	7
2706	Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	3
2707	Contribution of Advanced Glycation End Products to PCOS Key Elements: A Narrative Review. <i>Nutrients</i> , 2022, 14, 3578.	1.7	6
2708	Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2022, 37, 641-651.	1.3	7
2709	Enhanced SHP-1 Expression in Podocytopathy Is Associated with Kidney Dysfunction in Patients with Diabetes. <i>Kidney360</i> , 2022, 3, 1710-1719.	0.9	2
2710	Tighter or less tight glycaemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity: A stepped-wedge, cluster-randomised trial. <i>PLoS Medicine</i> , 2022, 19, e1004087.	3.9	10
2711	Glycemia Reduction in Type 2 Diabetes " Microvascular and Cardiovascular Outcomes. <i>New England Journal of Medicine</i> , 2022, 387, 1075-1088.	13.9	62
2712	Ultra-High Temperature Treatment and Storage of Infant Formula Induces Dietary Protein Modifications, Gut Dysfunction, and Inflammation in Preterm Pigs. <i>Molecular Nutrition and Food Research</i> , 2022, 66, .	1.5	6
2713	Involvement of AGE and Its Receptors in the Pathogenesis of Hypertension in Elderly People and Its Treatment. <i>International Journal of Angiology</i> , 0, , .	0.2	0
2714	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2022, 45, 2753-2786.	4.3	435
2715	Time to Treatment Intensification to Reduce Diabetes-Related Complications: A Post Hoc Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 1673.	1.0	2

#	ARTICLE	IF	CITATIONS
2716	Special Issue "The Prevention, Treatment, and Complications of Diabetes Mellitus". Journal of Clinical Medicine, 2022, 11, 5305.	1.0	0
2717	Tumor-Promoting Activity and Proteomic Profiling of Cisplatin/Oxaliplatin-Derived DAMPs in Cholangiocarcinoma Cells. International Journal of Molecular Sciences, 2022, 23, 10540.	1.8	2
2718	Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glyceic control. Annals of Medicine and Surgery, 2022, 81, .	0.5	0
2719	Glycemia Reduction in Type 2 Diabetes " Glycemic Outcomes. New England Journal of Medicine, 2022, 387, 1063-1074.	13.9	69
2720	Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
2721	A potential new pathway for heparin treatment of sepsis-induced lung injury: inhibition of pulmonary endothelial cell pyroptosis by blocking hMGB1-LPS-induced caspase-11 activation. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	12
2722	Heterozygous Loss of KRIT1 in Mice Affects Metabolic Functions of the Liver, Promoting Hepatic Oxidative and Glycative Stress. International Journal of Molecular Sciences, 2022, 23, 11151.	1.8	8
2723	The Amelioration of Detrimental Biochemical Anomalies by Supplementing B, C, and E Vitamins in Subjects with Type 2 Diabetes Mellitus May Reduce the Rate of Development of Diabetic Retinopathy. Journal of Diabetes Research, 2022, 2022, 1-8.	1.0	7
2724	Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease. Chemical Research in Toxicology, 2022, 35, 1720-1746.	1.7	36
2725	Lower bile acids as an independent risk factor for renal outcomes in patients with type 2 diabetes mellitus and biopsy-proven diabetic kidney disease. Frontiers in Endocrinology, 0, 13, .	1.5	3
2726	Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis. BMC Cancer, 2022, 22, .	1.1	2
2727	Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review). Experimental and Therapeutic Medicine, 2022, 24, .	0.8	6
2728	Long-term Outcomes Among Young Adults With Type 2 Diabetes Based on Durability of Glycemic Control: Results From the TODAY Cohort Study. Diabetes Care, 2022, 45, 2689-2697.	4.3	5
2729	The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. International Journal of Molecular Sciences, 2022, 23, 11987.	1.8	7
2730	Long-Term Association between Intensive Medical Treatment and the Incidence of Cardiovascular Outcomes in Patients with Dyslipidemia: an Observational Study. Cardiology and Therapy, 0, , .	1.1	0
2731	Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2. Children, 2022, 9, 1572.	0.6	0
2732	Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider. World Journal of Gastroenterology, 0, 28, 5679-5690.	1.4	0
2733	Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells, 2022, 11, 3362.	1.8	45

#	ARTICLE	IF	CITATIONS
2734	White common bean extract remodels the gut microbiota and ameliorates type 2 diabetes and its complications: A randomized double-blinded placebo-controlled trial. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
2735	New strategies to improve clinical outcomes for diabetic kidney disease. <i>BMC Medicine</i> , 2022, 20, .	2.3	20
2736	Accuracy of the ContourÂ® Next Link 2.4 blood glucose monitoring system in Japanese individuals: a single-center study. <i>Diabetology International</i> , 0, , .	0.7	0
2737	Psychometric and biomedical outcomes of glycated haemoglobin target-setting in adults with type 1 and type 2 diabetes: Protocol for a mixed-methods parallel-group randomised feasibility study. <i>PLoS ONE</i> , 2022, 17, e0275980.	1.1	0
2738	Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	7
2739	Red Blood Cell Lifespan &lt; 74 Days Can Clinically Reduce Hb1Ac Levels in Type 2 Diabetes. <i>Journal of Personalized Medicine</i> , 2022, 12, 1738.	1.1	2
2740	Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease. <i>Nutrients</i> , 2022, 14, 4547.	1.7	7
2741	Dehydrozingerone promotes healing of diabetic foot ulcers: a molecular insight. <i>Journal of Cell Communication and Signaling</i> , 2023, 17, 673-688.	1.8	1
2742	Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 3375-3385.	1.1	0
2743	Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetesâ€”So Why Is Their Uptake So Low?. <i>Clinical Diabetes</i> , 2023, 41, 226-238.	1.2	1
2744	Onceâ€”weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the <sc>UK</sc>: A longâ€”term costâ€”effectiveness analysis based on <sc>SUSTAIN</sc> 11. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 491-500.	2.2	4
2745	The Interplay between Ghrelin and Microglia in Neuroinflammation: Implications for Obesity and Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13432.	1.8	11
2746	Changes in Glycemic Control Following Use of a Spanish-Language, Culturally Adapted Diabetes Program: Retrospective Study. <i>JMIR Formative Research</i> , 2022, 6, e40278.	0.7	2
2747	The Bitter Side of Sugar Consumption: A Mitochondrial Perspective on Diabetes Development. <i>International Journal of Diabetology</i> , 2022, 3, 583-595.	0.9	4
2748	Effects of COVID-19 Pandemic and Lockdown on Monitoring and Treatment Balance of Finnish Coronary Heart Disease and Type 2 Diabetes Patients. <i>Clinical Epidemiology</i> , 0, Volume 14, 1363-1373.	1.5	1
2749	Effect of low dose allopurinol on glycemic control and glycemic variability in patients with type 2 diabetes mellitus: A cross-sectional study. <i>Heliyon</i> , 2022, 8, e11549.	1.4	0
2750	Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities â€” a register-based retrospective cohort study in Finland. , 2022, 23, .		1
2751	Continuous Glucose Monitoring and Other Wearable Devices to Assess Hypoglycemia among Older Adult Outpatients with Diabetes Mellitus. <i>Applied Clinical Informatics</i> , 2023, 14, 037-044.	0.8	2

#	ARTICLE	IF	CITATIONS
2752	Sodium-Glucose Cotransporter-2 Inhibitorsâ€”Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13749.	1.8	6
2753	Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2754	Incident Early- and Later-Onset Type 2 Diabetes and Risk of Early- and Later-Onset Cancer: Prospective Cohort Study. <i>Diabetes Care</i> , 2023, 46, 120-129.	4.3	8
2755	The Efficacy and Frequency of Self-monitoring of Blood Glucose in Non-insulin-Treated T2D Patients: a Systematic Review and Meta-analysis. <i>Journal of General Internal Medicine</i> , 0, , .	1.3	0
2756	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. <i>Methodist DeBaakey Cardiovascular Journal</i> , 2022, 18, 40-53.	0.5	0
2757	Feasibility, acceptability, and effects of a self-stigma reduction pilot program for Japanese individuals with type 2 diabetes. <i>PEC Innovation</i> , 2023, 2, 100112.	0.3	2
2758	Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2759	Fetal pancreas size and maternal serum biomarkers glycated albumin and insulin-regulated aminopeptidase provide no potential for early prediction of gestational diabetes mellitus. <i>Archives of Gynecology and Obstetrics</i> , 2023, 308, 1505-1514.	0.8	2
2760	Fear of hypoglycemia and associated factors in hospitalized patients with type 2 diabetes: a crossâ€”sectional study. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
2761	Sleep and Circadian Rhythm Disturbances in Diabetes: A Narrative Review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 3627-3637.	1.1	8
2762	Blood glucose may be another index to initiate insulin treatment besides glycated hemoglobin A1c after oral antidiabetic medications failure for glycemic control: A realâ€”world survey. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
2763	6. Glycemic Targets: <i>Standards of Care in Diabetesâ€”2023</i>. <i>Diabetes Care</i> , 2023, 46, S97-S110.	4.3	205
2764	4. Comprehensive Medical Evaluation and Assessment of Comorbidities:<i>Standards of Care in Diabetesâ€”2023</i>. <i>Diabetes Care</i> , 2023, 46, s49-s67.2.	4.3	58
2765	Classification of Type 2 Diabetes Incidence Risk and the Health Behavior of the 30â€”50-Year-Old Korean Adults: Latent Class Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16600.	1.2	1
2766	12. Retinopathy, Neuropathy, and Foot Care:<i>Standards of Care in Diabetesâ€”2023</i>. <i>Diabetes Care</i> , 2023, 46, S203-S215.	4.3	56
2767	Role of Advanced Glycation End Products in Intervertebral Disc Degeneration: Mechanism and Therapeutic Potential. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-12.	1.9	6
2768	Fluorescent advanced glycation end products in type 2 diabetes and its association with diabetes duration, hemoglobin A1c, and diabetic complications. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	3
2769	Research Trends in Advanced Glycation End Products and Obesity: Bibliometric Analysis. <i>Nutrients</i> , 2022, 14, 5255.	1.7	2

#	ARTICLE	IF	CITATIONS
2770	Renal outcomes with sodium-glucose cotransporters 2 inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
2771	The Prevalence of Obesity Among Children With Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e2247186.	2.8	15
2772	11. Chronic Kidney Disease and Risk Management: <i>Standards of Care in Diabetesâ€™2023</i>. <i>Diabetes Care</i> , 2023, 46, S191-S202.	4.3	97
2773	Diabetic foot ulcers: Classification, risk factors and management. <i>World Journal of Diabetes</i> , 0, 13, 1049-1065.	1.3	25
2774	A Study on the Protective Effect of sRAGE-MSCs in a Rodent Reperfusion Model of Myocardial Infarction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15630.	1.8	0
2775	Data-Driven Identification of Long-Term Glycemia Clusters and Their Individualized Predictors in Finnish Patients with Type 2 Diabetes. <i>Clinical Epidemiology</i> , 0, Volume 15, 13-29.	1.5	0
2776	Long-Term Risk of Cardiovascular Disease Among Type 2 Diabetes Patients According to Average and Visit-to-Visit Variations of HbA1c Levels During the First 3 Years of Diabetes Diagnosis. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	2
2777	The Role of Inflammation and Therapeutic Concepts in Diabetic Retinopathyâ€™A Short Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1024.	1.8	16
2778	Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 16, 105-115.	1.1	2
2779	Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: aâ€™microsimulation modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 33, 100690.	1.3	1
2780	The Role of Advanced Glycation End Products on Dyslipidemia. <i>Metabolites</i> , 2023, 13, 77.	1.3	8
2781	Improvements in Glycemic Control and Depressive Symptoms among adults with Type 2 Diabetes: A Retrospective Study (Preprint). <i>JMIR Formative Research</i> , 0, , .	0.7	0
2782	The Effect of high temperature on the stability of basal insulin in a pen: a randomized controlled, crossover, equivalence trial. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e003105.	1.2	1
2783	Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity. <i>Pulmonary Therapy</i> , 2023, 9, 71-89.	1.1	4
2784	Patientsâ€™ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. <i>Patient Preference and Adherence</i> , 0, Volume 16, 3415-3428.	0.8	2
2785	Low HbA1c in poorly controlled type 1 diabetes mellitus in a child. <i>Sudanese Journal of Paediatrics</i> , 2022, , 1.	0.6	0
2786	Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight. <i>ESC Heart Failure</i> , 2023, 10, 1242-1249.	1.4	4
2787	Chinese diabetes datasets for data-driven machine learning. <i>Scientific Data</i> , 2023, 10, .	2.4	10



#	ARTICLE	IF	CITATIONS
2788	Temporal trends in, and associations of, early-career general practitioner prescriptions of second-line Type 2 Diabetes medications, 2010–2018. PLoS ONE, 2023, 18, e0280668.	1.1	0
2789	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes and Metabolism Journal, 2023, 47, 10-26.	1.8	4
2790	Risk of fracture in adults with type 2 diabetes in Sweden: A national cohort study. PLoS Medicine, 2023, 20, e1004172.	3.9	6
2791	Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort study. CMAJ Open, 2023, 11, E77-E89.	1.1	1
2792	Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis. Frontiers in Endocrinology, 0, 14, .	1.5	0
2793	Glucokinase Inhibition: A Novel Treatment for Diabetes?. Diabetes, 2023, 72, 170-174.	0.3	0
2794	Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2023, 47, 185-197.	1.8	8
2795	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. International Journal of Heart Failure, 2023, 5, 1.	0.9	2
2796	Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD. Journal of Primary Care and Community Health, 2023, 14, 215013192311535.	1.0	0
2797	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. Biomedicines, 2023, 11, 662.	1.4	3
2798	Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review. Frontiers in Endocrinology, 0, 13, .	1.5	1
2799	Prevalence of diabetic retinopathy in Brazil: a systematic review with meta-analysis. Diabetology and Metabolic Syndrome, 2023, 15, .	1.2	2
2801	Glycemic control and diabetes complications among adult type 2 diabetic patients at public hospitals in Hadiya zone, Southern Ethiopia. PLoS ONE, 2023, 18, e0282962.	1.1	2
2802	Blood pressure control for diabetic retinopathy. The Cochrane Library, 2023, 2023, .	1.5	6
2803	Developing and Validating Models to Predict Progression to Proliferative Diabetic Retinopathy. Ophthalmology Science, 2023, 3, 100276.	1.0	3
2804	Predictive significance of glomerular insulin receptor substrate-1 in patients with diabetic kidney disease. Metabolism Open, 2023, 18, 100240.	1.4	1
2805	Increased Dietary Intake and Serum Levels of Advanced Glycation End Products (Ages) are Associated With Diabetic Macular Edema. Acta Endocrinologica, 2022, 18, 278-287.	0.1	0
2806	Associations Between Mean HbA1c, HbA1c Variability, and Both Mortality and Macrovascular Complications in Patients with Diabetes Mellitus: A Registry-Based Cohort Study. Clinical Epidemiology, 0, Volume 15, 137-149.	1.5	2

#	ARTICLE	IF	CITATIONS
2807	Real-world study of flash glucose monitoring among adults with type 2 diabetes within the Swedish National Diabetes Register. <i>Diabetes and Vascular Disease Research</i> , 2023, 20, 147916412110674.	0.9	1
2808	Continuity of Medication Use by US Adults With Diabetes, 2005-2019. <i>JAMA Network Open</i> , 2023, 6, e2253562.	2.8	3
2809	Sirtuins and redox signaling interplay in neurogenesis, neurodegenerative diseases, and neural cell reprogramming. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	3
2810	Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions. <i>Brain Sciences</i> , 2023, 13, 255.	1.1	5
2811	Diabetic Macular Oedema Guidelines: An Australian Perspective. <i>Journal of Ophthalmology</i> , 2023, 2023, 1-22.	0.6	1
2812	The relationship between well-being and <sc>HbA1c</sc> in adults with type 1 diabetes: A systematic review. <i>Journal of Diabetes</i> , 2023, 15, 152-164.	0.8	4
2813	Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2023, 57, 101868.	3.2	1
2814	CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 15, 97-109.	0.7	0
2815	The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond. <i>Journal of the Indian Institute of Science</i> , 0, , .	0.9	1
2816	Awareness Level of Hypoglycemia Among Diabetes Mellitus Type 2 Patients in Al Qassim Region. <i>Cureus</i> , 2023, , .	0.2	1
2817	Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	15
2818	Cost-Utility Analysis of Deep Learning and Trained Human Graders for Diabetic Retinopathy Screening in a Nationwide Program. <i>Ophthalmology and Therapy</i> , 2023, 12, 1339-1357.	1.0	5
2819	Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis. <i>Metabolism Open</i> , 2023, 17, 100236.	1.4	6
2820	Machine Learning for Predicting Micro- and Macrovascular Complications in Individuals With Prediabetes or Diabetes: Retrospective Cohort Study. <i>Journal of Medical Internet Research</i> , 0, 25, e42181.	2.1	4
2821	Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease. <i>Antioxidants</i> , 2023, 12, 584.	2.2	7
2822	Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4785.	1.8	1
2823	Factors associated with poor glycemic control among adult patients with type 2 diabetes mellitus in Gamo and Gofa zone public hospitals, Southern Ethiopia: A case-control study. <i>PLoS ONE</i> , 2023, 18, e0276678.	1.1	4
2824	AT1 receptor downregulation: A mechanism for improving glucose homeostasis. <i>World Journal of Diabetes</i> , 0, 14, 170-178.	1.3	2

#	ARTICLE	IF	CITATIONS
2825	SGLT2 Inhibitorâ€™Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism. <i>Pharmaceutics</i> , 2023, 15, 965.	2.0	2
2826	Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	3
2827	HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	1
2828	Association between Systemic Factors and Vitreous Fluid Cytokines in Proliferative Diabetic Retinopathy. <i>Journal of Clinical Medicine</i> , 2023, 12, 2354.	1.0	0
2829	Screening for Prediabetes and Diabetes: Clinical Performance and Implications for Health Equity. <i>American Journal of Preventive Medicine</i> , 2023, 64, 814-823.	1.6	6
2830	Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	1
2831	Pre-Ophthalmoscopic Quantitative Biomarkers in Diabetes Mellitus. <i>Translational Vision Science and Technology</i> , 2023, 12, 24.	1.1	2
2832	Impact of Regular Intake of Microalgae on Nutrient Supply and Cardiovascular Risk Factors: Results from the NovAL Intervention Study. <i>Nutrients</i> , 2023, 15, 1645.	1.7	1
2833	RAGE is a critical factor of sex-based differences in age-induced kidney damage. <i>Frontiers in Physiology</i> , 0, 14, .	1.3	0
2834	Insulin resistance and cardiovascular disease. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311645.	0.4	28
2835	Characterizing Diabetes Empowerment and Motivation for Changing Health Behaviors Among People with Type 2 Diabetes: A Cross-Sectional Survey. <i>Diabetes Therapy</i> , 2023, 14, 869-882.	1.2	1
2836	Association of hemoglobin A1c stability with mortality and diabetes complications in older adults with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2023, 11, e003211.	1.2	0
2837	The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6828.	1.8	3
2838	Development and validation of an insulin resistance model for a population without diabetes mellitus and its clinical implication: a prospective cohort study. <i>EClinicalMedicine</i> , 2023, 58, 101934.	3.2	8
2839	Semaglutide-eye-catching results. <i>World Journal of Diabetes</i> , 0, 14, 424-434.	1.3	2
2840	Epidemiology of type 2 diabetes mellitus and treatment utilization patterns among the elderly from the first wave of Longitudinal Aging study in India (2017-18)using a Heckman selection model. <i>BMC Public Health</i> , 2023, 23, .	1.2	5
2841	Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. <i>Life</i> , 2023, 13, 1024.	1.1	1
2842	Glycemia-Induced miRNA Changes: A Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7488.	1.8	2

#	ARTICLE	IF	CITATIONS
2843	Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23
2844	The impact of structured self-monitoring of blood glucose on clinical, behavioral, and psychosocial outcomes among adults with non-insulin-treated type 2 diabetes: a systematic review and meta-analysis. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 0, 4, .	0.3	0
2845	Risk Factors for Recurrent Vitreous Hemorrhage in Type 2 Diabetes Mellitus Patients after Posterior Vitrectomy. <i>Journal of Clinical Medicine</i> , 2023, 12, 2989.	1.0	2
2846	Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies. <i>Nutrients</i> , 2023, 15, 2002.	1.7	3
2847	Risk of non-hypoglycemic agents for hypoglycemia-related hospitalization in patients with type 2 diabetes: a large-scale medical receipt database analysis. <i>BMJ Open Diabetes Research and Care</i> , 2023, 11, e003177.	1.2	1